

Synthesis and characterization of a novel phosphatidylinositol 5-phosphate (PI(5)P) photoaffinity probe

Supplementary Information

Glen Brodie,^{1,2} Ahmed Sayed,^{3,4} Sarah Kreuz,³ Wolfgang Fischle,³ Stuart J. Conway.^{1,2,}*

Author affiliations.

¹Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, U.K.

²Department of Chemistry & Biochemistry, University of California Los Angeles, 607 Charles E. Young Drive East, Los Angeles, California 90095, U.S.A.

³Bioscience Program, Biological and Environmental Science and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955, Kingdom of Saudi Arabia


⁴Chemistry Department, Faculty of Science, Assiut University, Assiut 71516, Egypt

To whom correspondence should be addressed: stuartconway@ucla.edu

TABLE OF CONTENTS

<u>SUPPLEMENTARY FIGURES AND SCHEMES</u>	<u>3</u>
<u>BIOLOGY AND BIOLOGICAL METHODS</u>	<u>8</u>
<u>SYNTHESIS AND CHARACTERIZATION.....</u>	<u>13</u>
<u>NMR SPECTRA AND OTHER DATA</u>	<u>48</u>
<u>REFERENCES</u>	<u>155</u>

Supplementary Figures and Schemes






Figure S1: Determination of the e.e. values of diglycerides **S14** and **S15**. **A** Derivatization of diglycerides. *Reagents and conditions:* i. (+)-MPA or (-)-MPA, DCC, 4-DMAP, CH_2Cl_2 , RT, 6–18 h, 75–83% of **S20**, **S21**, **S22**, or **S23**. **B** ^1H NMR spectra of diastereoisomers revealing the e.e. of **S14** to be ~94% and **S15** to be ~90% using a method described by Seco *et al.*¹ DCC = *N,N'*-dicyclohexylcarbodiimide; 4-DMAP = 4-dimethylaminopyridine; MPA = methoxyphenylacetic acid.





Figure S2: The binding of PI(5)P (1) and PI(5)P-analogues (7) and (8) to recombinant hUHRF1 (200 nM) was analyzed using MST. Fraction bound was plotted as an average of three independent measurements. Error bars correspond to the Std Dev. The K_d values of (7) and (8) could not be determined due to the titration curve not reaching saturation, however, a binding interaction was observed at higher concentrations.



Scheme S2: Alternative reaction conditions for synthesis of alcohol **32**. *Reagents and conditions:* a. Diazirine **27**, DCC, 4-DMAP, CH_2Cl_2 , RT, 18 h, 41% of (+)-**S24**; b. AcOH acid:H₂O (4:1), 50 °C, 2.5 h, 68% of (-)-**32**. Ac = acetyl; DCC = *N,N'*-dicyclohexylcarbodiimide; 4-DMAP = 4-dimethylaminopyridine.




Figure S3: Determination of the e.e. value of diglyceride **32**. (A) Derivatization of diglyceride **32** with MPA. *Reagents and conditions:* (+)-MPA or (–)-MPA, DCC, 4-DMAP, CH₂Cl₂, RT, 6–18 h, 65–82% of **S25** or **S26**. (B) ¹H NMR spectra of each diastereoisomer revealing the e.e. of **32** to be >95% using a method described by Seco *et al.*¹. DCC = *N,N'*-dicyclohexylcarbodiimide; 4-DMAP = 4-dimethylaminopyridine; MPA = methoxyphenylacetic acid




Figure S4: Dynamic light scattering (DLS) data on the distribution of the relative intensity of scattered light by particle size (Stokes diameter) for PI(5)P and probe (9) at a concentration of 50 μM in either deionized water or in MST buffer containing 0.05% Tween-20 at 25 $^{\circ}\text{C}$. MST buffer alone was measured as a control. Unmodified PI(5)P exhibited comparable size distributions under both buffer conditions, with mean hydrodynamic diameters of 37 ± 1.1 nm in water and 48 ± 3.0 nm in MST buffer. In contrast, the diazirine-modified PI(5)P probe (9) formed considerably larger assemblies overall, measuring 270 ± 18 nm in water and 153 ± 35 nm in MST buffer.




Figure S5: SDS-PAGE analysis of total cells lysate prepared from Expi293 cells containing the indicated amounts of doped bacterially expressed recombinant hUHRF1-FLAG after UV-crosslinking of PI(5)P-diazirine (**9**) and labelling with TAMRA-PEG-azide using click chemistry. The gel was analyzed for fluorescence of the TAMRA dye using excitation with light at 546 nm wavelength (**A**) and following Coomassie staining (**B**). UV irr. refers to the lysate/sample being exposed to 365 nm UV light for 30 min, which is necessary for photo-crosslinking of PI(5)P-diazirine (**9**) to bound proteins. The molecular weight markers are indicated. The gel shows that with increased doped hUHRF1, an increase in signal is detected under UV, confirming that the photo-crosslinking and click reaction with diazirine probe (**9**) to hUHRF1 is detected.

Molecular Biology and Biochemistry

Expression and purification of recombinant proteins

C-terminally His6-tagged hUHRF1 was expressed from a pETM-13 plasmid in BL21-DE3 RIL *E. coli* cells cultured in 2xYT medium supplemented with kanamycin (50 µg/mL) and chloramphenicol (34 µg/mL). The culture was grown at 30 °C with shaking at 180 rpm until the culture reached an OD₆₀₀ of 0.5–0.6, after which, protein expression was induced by the addition of IPTG (0.75 mM aqueous), followed by incubation for 3 hours at 25 °C while shaking. C-terminal His6-tagged hTAF3 was expressed from a pET-29b(+) plasmid in a manner similar to hUHRF1 but in the presence of ZnSO₄ (50 µM aqueous), with induction at an OD₆₀₀ of 0.6 using IPTG (300 mM aqueous), followed by incubation overnight at 20 °C.

Bacterial cells were harvested by centrifugation at 7,808 × g for 20 minutes at 4 °C, resuspended in Ni-NTA binding buffer (50 mM Tris-HCl, pH 8.0; 300 mM NaCl; 20 mM imidazole) and lysed using an Avestin Emulsiflex-C5 homogenizer at 4 °C. The lysate was cleared by centrifugation at 30,624 × g for 30 minutes at 4 °C. The resulting supernatant containing either hUHRF1 or hTAF3, was incubated with pre-equilibrated Ni-NTA resin in binding buffer for 1 hour at 4 °C. The resin was subsequently washed three times with washing buffer (50 mM Tris-HCl, pH 8.0; 500 mM NaCl; 30 mM imidazole). Proteins were eluted in elution buffer (50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 500 mM imidazole) and dialyzed overnight at 4 °C against storage buffer [50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 10% (v/v) glycerol, and 1 mM DTT]. Proteins were concentrated using Amicon Ultra centrifugal filter units (Millipore, Billerica, USA) with a 30 kDa cutoff for hUHRF1 and a 10 kDa cutoff for hTAF3, and further purified by size exclusion chromatography using a Superose™ 6 increase 10/300 GL column.

Mammalian expression of hUHRF1

Expi293F™ cells (Thermo Fisher Scientific, Cat. No. A14527) were cultured in Expi293™ Expression Medium (Thermo Fisher Scientific, Cat. No. A1435101) under controlled conditions at 37 °C with 8% CO₂ in a humidified incubator. hUHRF1-FLAG was expressed from a pcDNA3.1+ plasmid, containing a CMV promoter. Cells were transfected using the polyethylenimine reagent (Polyscience, Cat No. 23966-1), following the manufacturer's protocol. Post-transfection, the cells were cultured for 18 to 72 hours to achieve optimal protein expression. Subsequently, cells were harvested by centrifugation at 300 × g for 10 minutes at 4°C. The resulting cell pellet was resuspended in lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl) supplemented with cOmplete™ EDTA-free Protease Inhibitor Cocktail. Cells were lysed by sonication, and the lysate was clarified by centrifugation at 12,000 × g for 15 minutes at 4 °C.

Western blot analysis

Cell lysates (5 mg/ml) were heated for 5 minutes at 95 °C in SDS loading buffer and resolved on 12% acrylamide gels. Proteins were then transferred to nitrocellulose or PVDF membranes, which were subsequently blocked in Tris Buffered Saline with Tween 20 (TBST) containing 5% (w/v) dry milk powder. Anti-hUHRF1 antibodies (sc-373750, Santa Cruz Biotechnology, 1:1000 dilution) and Anti-FLAG antibody (Monoclonal anti-FLAG® BioM2 antibody produced in mouse, Sigma-Aldrich (F1804)) were applied in blocking buffer and incubated overnight. Afterwards, the membranes were washed three times for 10 minutes each with TBST and then incubated with secondary antibodies labeled with HRP in blocking buffer for 1 hour at room temperature. Following another three 10-minute washes with TBST, the membranes were treated with ECL substrate for 2 minutes before visualization.

Microscale thermophoresis

C-terminal His6-tagged hUHRF1 was labelled using the Monolith His-tag labelling kit RED-tris-NTA (Nanotemper #MO-L008) as per the manufacturer's instructions. In summary, MST buffer (20 mM Hepes-NaOH (pH 7.9), 150 mM NaCl, 0.05% (v/v) Tween 20) was prepared. 400 nM of the protein was then incubated with 100 nM of the His-tag labelling dye for 30 minutes at room temperature. Subsequently, the labelled proteins were centrifuged and collected at 15,000 × g for 10 minutes at 4 °C to remove any precipitate. The fluorescently labelled protein was then incubated with a range concentrations of PI(5)P and the diazirine-modified PI(5)P compounds at room temperature for 15 minutes prior to measurement on a Monolith NT.115 instrument (NanoTemper, 80% LED power, 40% MST power).² The data points were fitted using MO.Affinity Analysis v2.3 analysis software, and the dissociation constants were then determined using a single-site model to fit the curve.

Particle Size Measurements

Particle size distribution and mean hydrodynamic diameter were determined using a Malvern Zetasizer Nano ZS (Malvern Instruments, St. Laurent, QC, Canada). Measurements were performed in triplicate using various concentrations of unmodified PI(5)P or the diazirine probe **9**. Dynamic light scattering (DLS) measurements were performed in deionized water and in MST buffer containing 0.05% (v/v) Tween-20.

PI(5)P-diazirine probe crosslinking with hUHRF1 and cell lysate and CuAAC Click reaction

PI(5)P-diazirine probe (50 µM) in DMSO (final conc. 0.5%) was incubated with 0.5 mg/mL hUHRF1 and 2 mg/mL Expi293 cell lysate for 30 min at 4 °C (20 µL reaction volume) in reaction buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 10% glycerol, and 1 mM DTT). The solutions were

irradiated with UV light (365 nm) for 15 min at 4 °C using a UVP Blak-Ray™ B-100A UV Lamp. Meanwhile, the negative control samples were incubated in the dark at 4°C.

The components of the click reaction were prepared as follows: Azide Fluor 545 (100 µM final concentration from a 10 mM DMSO stock solution), CuSO₄ (1 mM final concentration from a 50 mM aqueous stock solution), TCEP-HCl (1 mM final concentration from a 50 mM aqueous stock solution), and TBTA (100 µM final concentration from a 10 mM DMSO stock solution). Subsequently, the click reaction was carried out by the addition of a click mixture with the following volume ratio 1:2:2:1 of Azide Fluor 545: CuSO₄: TCEP: TBTA to the cross-linked samples, and incubated with shaking at 700 rpm for 1 h, in the dark, at room temperature. Then, 4× Laemmli sample buffer premixed with DDT was added to 20 µl of reaction mixture and heated for 5 min at 95 °C. 10 µl was loaded onto 8% SDS-PAGE and gel electrophoresis was performed to separate the proteins. The bottom of the gel was cut to avoid the residual excess of Azide Fluor 545 which could reduce the fluorescence signal of the crosslinked protein. Then, in-gel fluorescence was acquired at 546 nm using a Bio-Rad imager. The gel was further subjected to Coomassie staining followed by a destaining step. The Bio-Rad imager was used to image the Coomassie-stained gel.

For the Biotin-Azide click reaction, the volumes of reagents were scaled up 5-fold while maintaining the same molar ratios as described above. Post-click reaction, 0.5 mL of ice-cold acetone (-20 °C) was added to the mixture. Samples were vortexed and incubated at -20 °C for 30 minutes. The resulting precipitate was collected by centrifugation at 20,000 × g for 10 minutes at 4 °C. The pellet was washed with ice-cold acetone to remove excess Biotin-Azide, followed by sonication in a water bath. Acetone wash and centrifugation steps were repeated twice. The protein pellet was air-dried for 10 minutes at room temperature to remove residual acetone and then resuspended in 50 µL of 1% SDS in PBS, vortexed, and sonicated. The suspension was further diluted with 0.5 mL of affinity purification buffer (50 mM Hepes-NaOH, pH 7.4; 100 mM

NaCl; 1% (v/v) IGEPAL). 50 μ L magnetic streptavidin beads (Streptavidin MagneSphere® Paramagnetic Particles, Promega) pre-equilibrated with affinity purification buffer were added to the solution, and the mixture was incubated overnight at 4 °C on a rotating mixer. The beads were recovered using a magnetic rack and washed three times with wash buffer (50 mM Hepes-NaOH, pH 7.4; 500 mM NaCl; 1% (v/v) IGEPAL). Bound proteins were eluted with 50 μ L of elution buffer (2 mM D-biotin; 1% (v/v) IGEPAL in PBS) for 30 minutes at room temperature, separated by SDS-PAGE (12% gel), transferred to a PVDF membrane, and detected using streptavidin-HRP (Pierce™ High Sensitivity Streptavidin-HRP, 1:1000).³

Anti-FLAG affinity purification

Cell lysate from 293Expi cells overexpressing hUHRF1-FLAG (100 mg total) was incubated with pre-equilibrated Pierce™ Anti-DYKDDDDK Affinity Resin for 2 hours at 4 °C in a buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM DTT, and 10% (v/v) glycerol. The mixture was gently rotated to facilitate binding of the FLAG-tagged protein to the resin. The resin was then washed three times with the same buffer to remove unbound and non-specifically bound proteins. Elution of bound proteins was performed using 0.5 mg/mL 3 \times FLAG peptide in binding buffer, with incubation overnight at 4 °C.

Synthesis and Characterization

Chemistry General Methods

^1H NMR spectra were recorded on Bruker AVIIIHD 400 nanobay (400 MHz), Bruker NEO 600 (600 MHz) with ^1H helium-cooled cryoprobe, or Bruker AVIIIHD 500 (500 MHz) spectrometer in the stated solvents as a reference for the internal deuterium lock. The chemical shift data for each signal are given as δ_{H} in units of parts per million (ppm) relative to tetramethylsilane (TMS) where $\delta_{\text{H}}(\text{TMS}) = 0.00$ ppm. The spectra are calibrated using the solvent peak with the data provided by Fulmer *et al.*⁴ The multiplicity of each signal is indicated by s (singlet); br s (broad singlet); d (doublet); dd (doublet of doublets), ddd (doublet of doublet of doublets), t (triplet), q (quartet), dq (double of quartet) or m (multiplet). The number of protons (n) for a given resonance signal is indicated by nH. Where appropriate, coupling constants (J) are quoted in Hz and are recorded to the nearest 0.1 Hz. Identical proton coupling constants (J) are averaged in each spectrum and reported to the nearest 0.1 Hz. The coupling constants are determined by analysis using Bruker TopSpin version 4.1.3 software. ^1H spectra were assigned using 2D NMR experiments including COSY, HMBC, HSQC, HMBC, and ^1H - ^{31}P HMBC, as required. ^{31}P NMR spectra were recorded on a Bruker AVIIIHD 400 nanobay (162 MHz), or Bruker NEO 600 (243 MHz) spectrometer in the stated solvents as a reference for the internal deuterium lock, using a broadband proton decoupling pulse sequence. The chemical shift for each signal is given as δ_{P} in units of parts per million (ppm) relative to 85% phosphoric acid as an external reference where $\delta_{\text{P}}(\text{H}_3\text{PO}_4) = 0.00$ ppm. Signals are singlets unless otherwise stated. ^{31}P spectra were assigned using ^1H - ^{31}P NMR experiments as necessary. ^{13}C NMR spectra were recorded on a Bruker AVIIIHD 400 nanobay (101 MHz), Bruker NEO 600 (151 MHz) spectrometer in the stated solvents, with broadband proton decoupling and an internal deuterium lock. The chemical shift data for each signal are given as δ_{C} in units of parts per million (ppm) relative to tetramethylsilane (TMS) where $\delta_{\text{C}}(\text{TMS}) = 0.00$ ppm. The spectra are calibrated using the solvent peak with the data provided by Fulmer

*et al.*⁴ The shift values of resonances are quoted to 1 decimal place unless peaks have similar chemical shifts, in which case 2 decimal places are used. Where appropriate, the multiplicity of each signal is indicated by d (doublet), t (triplet) or m (multiplet). Coupling constants (*J*) are quoted in Hz and are recorded to the nearest 0.1 Hz. These were determined using Bruker TopSpin version 4.1.

When two diastereoisomers or regioisomers are present in the sample, A and B denote each of the two diastereoisomers without distinguishing between them. A is arbitrarily assigned to the diastereoisomer with the highest ppm shift and B to the diastereoisomer with the lowest ppm shift, in ¹H NMR, ¹³C NMR and ³¹P NMR spectra.

Low resolution electrospray ionization spectra were acquired on a Waters LCT Premier spectrometer or Agilent 6120 Quadrupole spectrometer. High resolution mass spectra were recorded on either a Bruker MicroTOF spectrometer, operating in positive or negative mode, or Waters Micromass LCT from solutions of MeOH, MeCN or H₂O. *m/z* values are reported in Daltons and followed by their percentage abundance in parentheses.

Specific optical rotations were measured using a Schmidt + Haensch UniPol L2000 polarimeter, in cells with a path length of 1 dm, using a sodium lamp at 589 nm. The concentration (*c*) is expressed in g/100 mL (equivalent to g/0.1 dm³) Specific rotations are denoted $[\alpha]_D^T$ and are given in implied units of 10⁻¹degcm²g⁻¹ at the temperature stated.

Melting points were determined using a Gallenkamp MF370 and are uncorrected. The solvents of crystallization are shown in parentheses. Infrared (IR) spectra were obtained from neat samples, either as liquids or solids using a diamond ATR module. The spectra were recorded on a Bruker Tensor 27 spectrometer. Absorption maxima are reported in wavenumbers (cm⁻¹).

Thin layer chromatography (TLC) was carried out on normal phase Merck silica gel 60 F254 aluminum-supported chromatography sheets. Visualization was by absorption of UV light (λ_{\max} 254 nm) or by development from an aqueous solution of potassium permanganate. Reaction progress was monitored at appropriate times either by TLC or by ^{31}P NMR. Normal phase silica gel flash column chromatography was performed either manually using VWR Prolabo silica gel 60 (240–400 mesh) under a positive pressure of nitrogen or using a Biotage Selekt System with pre-packaged normal phase Biotage Sfar columns.

Chemicals were purchased from Apollo Scientific, Merck UK, Alfa Aesar UK, Fisher Scientific UK, and Fluorochem. All reagents were purified, when necessary, by standard techniques. Et_3N , DIPEA, DIPA were dried by stirring over CaH_2 followed by distillation. These were stored under Ar and over 3 Å molecular sieves. PCl_3 was heated under reflux to expel dissolved HCl, then distilled and stored under Ar. Anhydrous solvents were obtained under the following conditions: THF, MeCN, DMF, Et_2O , toluene, MTBE and CH_2Cl_2 were dried by passing through a column of activated basic alumina, and then then further dried over 3 Å molecular sieves. Anhydrous MeOH was purchased from Sigma Aldrich UK in SureSeal™ bottles and used without further purification. All other solvents were used as supplied (analytical or HPLC grade) without purification.


Where appropriate and if not otherwise stated, all non-aqueous reactions were performed in a flame dried flask under an inert atmosphere. Hexane refers to a mixture of hexane isomers and petroleum ether refers to the fraction of light petroleum ether boiling within the range of 40–60 °C. Brine refers to a saturated aqueous solution of sodium chloride. *In vacuo* refers to the removal of solvents under reduced pressure using a Büchi™ rotary evaporator in a water bath at 40 °C, unless otherwise stated. Vacuum transfer refers to the removal of solvents on a manifold linked to a high vacuum pump at RT. Lyophilization refers to the removal of H_2O and MeCN from aqueous solutions by freeze drying using a CHRIST Alpha 2-4 LSC basic lyophilizer. Celite® refers to Celite® 545 filter aid, treated with sodium carbonate, flux-calcined 23 which was

purchased from Merck. Glass microfiber filter refers to Whatman® borosilicate glass microfiber filters, Grade GF/B.

Compound purity was determined by analytical high-performance liquid chromatography (HPLC) on a PerkinElmer Flexar system with a Binary LC Pump and UV/VIS LC Detector using a normal phase HyperSil GOLD™ Silica column (5 µm, 4.6 × 150 mm) with heptane (A) and IPA (B) as eluents. Gradient methods of 19 minutes were employed with a constant flow rate, and detection at 254 or 220 nm where an isocratic method was employed. Samples were injected by dissolving in the relevant solvent system. The method was A = Heptane; B = IPA; 2.0 mL.min⁻¹; 245, 220, or 280 nm, 90% A, 10% B, isocratic 18 min, with 1 min pre-equilibration before injection. Absolute configuration of alcohols **32**, **S14** and **S15** were determined using both enantiomers of α-methoxyphenylacetic acid (MPA) as a chiral derivatizing agent *via* esterification as described by Seco *et al.* and Joffrin *et al.*^{1,5}


Synthetic Protocols, Characterization data, and Compound Assignments

myo-Inositol 1,3,5-orthoformate **11**



To a solution of *myo*-inositol **10** (5.00 g, 27.8 mmol, 1.0 eq) in DMF (50 mL) were added triethylorthoformate (8.24 g, 55.6 mmol, 2.0 eq) and PTSA·H₂O (211 mg, 1.11 mmol, 0.04 eq). The reaction mixture was stirred at 110 °C for 18 h and then allowed to cool to RT. The solution was neutralized by the addition of solid NaHCO₃ (10 g) and filtered to remove excess NaHCO₃ and sodium tosylate. The volatile components were removed *in vacuo* and residual DMF was removed using toluene as an azeotrope. The resulting solid was then crystallized from hot MeOH following cooling to -20 °C for 1 h. The resulting colorless crystalline solid was isolated by filtration, washed with CHCl₃ (25 mL), and dried to give *myo*-inositol-1,3,5-orthoformate **11** (4.82 g, 84%): *R*_f 0.40 (MeCN:EtOAc, 8:2); m.p. 255–260 °C (dec.); ¹H NMR (400 MHz; D₆-DMSO) δ_H 5.52–5.38 (2H, m, C(4)OH and C(6)OH), 5.45 (1H, d, *J* 1.4, H-7), 5.30 (1H, br s, C(2)OH), 4.28 (2H, dd, *J* 4.0, 4.0, H-1 and H-3), 4.09–4.05 (1H, m, H-5), 4.02–3.99 (1H, m, H-2), 3.97–3.93 (2H, m, H-4 and H-6); LRMS *m/z* (ESI⁺) 191.0 ([M+H]⁺ 100%). These data are in good agreement with the literature values.⁵


4,6-Di-O-(4-methoxybenzyl)-*myo*-inositol 1,3,5-orthoformate **12**



To a solution of orthoformate **11** (5.00 g, 26.3 mmol, 1.0 eq) in anhydrous DMF (200 mL) was added NaH 60% dispersion in mineral oil (2.21 g, 25.2 mmol, 2.1 eq) as a single batch. The solution was stirred for 1.5 h, while being heated to 50 °C. The solution was then cooled to RT and PMBCl (7.13 mL, 52.6 mmol, 2.0 eq) was added dropwise over 10 min. The reaction was stirred for a further 18 h, after which the reaction was quenched with H₂O, and then concentrated *in vacuo*. Residual DMF was removed using toluene as an azeotrope. The residue was then dissolved in MeCN and extracted with petroleum ether to remove any mineral

oil present. The MeCN layer was then concentrated *in vacuo*. The residue was then dissolved in EtOAc (100 mL) and partitioned with H₂O (100 mL). The EtOAc phase was removed, and the remaining aqueous fraction was extracted with EtOAc (3 × 100 mL). The combined organic phases were then washed (brine), dried (Na₂SO₄), filtered, and concentrated *in vacuo*, before being dissolved in the minimum amount of warm EtOAc. The solution was then allowed to cool where orthoformate **12** formed as a colorless crystalline powder (3.39 g, 30%), which was retrieved *via* filtration and required no further purification. The process was repeated twice to recover the maximum amount of material. *R_f* 0.50 (petroleum ether:EtOAc, 5:5); m.p. 110–112 °C (EtOAc), [lit.⁵ 105–107 °C (hexane:EtOAc)]; ¹H NMR (400 MHz, CDCl₃) δ_H 7.22–7.15 (4 H, m, H-11, H-13, H-19, H-20), 6.85–6.79 (4 H, m, H-10, H-14, H-18, H-22), 5.45 (1 H, d, *J* 1.0, H-7), 4.58 (2 H, d, *J* 11.1, H-8', H-16'), 4.50 (2 H, d, *J* 11.1, H-8'', H-16''), 4.42–4.39 (2 H, m, 2 × inositol CH), 4.34 (2 H, t, *J* 3.7, inositol CH), 4.21–4.17 (3 H, m, 3 × inositol CH), 3.80 (6 H, s, H-15, H-23), 2.99 (1 H, d, *J* 11.5, C(2)OH); LRMS (ESI⁺) 453 ([M+Na]⁺, 100%). These data are in good agreement with the literature values.⁵


4,6-Di-O-(4-methoxybenzyl)-*myo*-inositol **13**



To a solution of the orthoformate **12** (2.00 g, 4.65 mmol, 1.0 eq) in MeOH:H₂O (132 mL, 10:1 v/v) was added a few drops of 2 M HCl until a pH of 2–3 was achieved. The reaction was stirred at 45 °C for 1 h after which TLC analysis showed potential minor deprotection of the PMB groups. The reaction was then cooled to 40 °C and allowed to stir for a further 3 h where TLC showed most of the starting material had been consumed. The reaction was then cooled to RT and neutralized with sat. aqueous NaHCO₃ until a pH of approximately 7 was reached. The mixture was then concentrated *in vacuo* and the resulting solid was taken up in EtOAc. The remaining solid was removed by filtration and the solution was then passed through a column of


silica gel, eluting with 100% EtOAc to give tetraol **13** (1.56 g, 80%) as a colorless solid. R_f 0.30 (EtOAc); m.p. 134–136 °C (EtOAc), [lit.⁵ 144–145 °C (EtOAc)]; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ_{H} 7.34–7.28 (4 H, m, H-10, H-12, H-18, H-20), 6.93–6.88 (4 H, m, H-9, H-13, H-17, H-21), 4.83 (2 H, d, J 11.1, H-7', H-15'), 4.77 (2 H, d, J 11.1, H-7'', H-15''), 4.16–4.12 (1 H, m, inositol CH), 3.81 (6 H, s, H-14, H-22), 3.67–3.60 (2 H, m, 2 \times inositol CH), 3.56–3.47 (3 H, m, 3 \times inositol CH), 2.55 (1 H, d, J 1.3, -OH), 2.46 (1 H, d, J 2.1, -OH), 2.42 (2 H, d, J 4.9, 2 \times -OH). These data are in good agreement with the literature values.⁵

(+)-1D-1-O-Acetyl-4,6-di-O-(4-methoxybenzyl)-myo-inositol **14**




The immobilized Lipozyme® TL-IM (2.00 g) was added to a solution of 4,6-di-O-benzyl-*myo*-inositol **13** (1.20 g, 2.85 mmol, 1.0 eq) in vinyl acetate (250 mL) and hexane (250 mL). After stirring at 45 °C for 18 h the reaction mixture was filtered through a pad of Celite®, washed with hexane (3 \times 20 mL) and the combined filtrates were concentrated *in vacuo* to give (–)-**14** (1.30 g, 99%, >99% e.e. other enantiomer not observed) as a colorless amorphous solid, requiring no further purification: R_f 0.61 (EtOAc); $[\alpha]_D^{25} +24.4$ (c 1.0, CHCl_3). [lit.⁵ $[\alpha]_D^{25} +24.0$ (c 1.0, CH_3Cl)]; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ_{H} 7.33–7.28 (2 H, m, H-9 and H-13), 7.25–7.21 (2 H, m, H-17 and H-21), 6.92–6.86 (4 H, m, H-10, H-12, H-18 and H-20), 4.91 (1 H, d, J 11.1, H-7'), 4.85 (1 H, dd, J 10.1, 2.7, H-1), 4.74 (1 H, d, J 11.1, H-15'), 4.69–4.62 (2 H, m, H-7'' and H-15''), 4.20 (1 H, dd, J 2.7, 2.7, H-2), 3.89 (1 H, dd, J 10.0, 9.9, H-6), 3.80 (6 H, s, H-14 and H-22), 3.71–3.62 (1 H, m, H-4), 3.61–3.53 (2 H, m, H-3 and H-5), 2.52–2.39 (3 H, m, 3 \times -OH), 2.12 (3 H, s, H-24). These data are in good agreement with the literature values.⁵

1,1-Dimethoxycyclopentane **15**



To a solution of cyclopentanone (6.31 mL, 71.3 mmol, 1.0 eq) in hexane (48 mL) were added K-10 montmorillonite clay (10.8 g) and trimethylorthoformate (17.9 mL, 159 mmol, 2.3 eq). The suspension was stirred rapidly for 18 h at RT. The dark brown reaction mixture was then filtered through a pad of Celite® and washed with hexane (2 × 10 mL) and Et₂O (2 × 10 mL). The combined filtrates were concentrated *in vacuo* to give 1,1-dimethoxycyclopentane **15** (7.08 g, 88%) as a colorless oil with sufficient purity for use in the next step: *R_f* 0.51 (petroleum ether:EtOAc, 8:2); ¹H NMR (400 MHz; CDCl₃) δ_H 3.21 (6H, s, C(2)OCH₃), 1.80–1.71 (4H, m, H-3 and H-1), 1.69–1.61 (4H, m, H-4 and H-5); These data are in good agreement with the literature values.⁵


(-)-1D-1-O-Acetyl-2,3-O-cyclopentylidene-4,6-di-O-(4-methoxybenzyl)-myo-inositol **16**



To a solution of (+)-1D-1-O-acetyl-4,6-di-O-(4-methoxybenzyl)-myo-inositol **14** (1.00 g, 2.16 mmol, 1.0 eq) and 1,1-dimethoxycyclopentane **15** (4.22 g, 32.4 mmol, 15 eq) in CH₂Cl₂ (6 mL) was added PTSA·H₂O (31 mg, 0.17 mmol, 0.08 eq). The resulting solution was stirred at RT for 8 h, after which time TLC analysis confirmed complete consumption of starting material. The solution was then quenched with a few drops of Et₃N (until pH 7 was achieved) and concentrated *in vacuo*. The residue obtained was purified using flash column chromatography over silica gel with a Biotage system (petroleum ether:EtOAc, 10:0 to 7:3) to give alcohol **16** (870 mg, 76%) as a pale-yellow oil: *R_f* 0.63 (petroleum ether:EtOAc, 1:1); [α]_D²⁵ -24.4 (c 1.0, CHCl₃), [lit.⁵ [α]_D²⁵ -25.3 (c 1.0, CHCl₃)]; ¹H NMR (600 MHz, CDCl₃) δ_H 7.33–7.28 (2 H, m, H-9 and H-13), 7.27–7.23 (2 H, m, H-17 and H-21), 6.91–6.84 (4 H, m, H-10, H-12, H-18, and H-20), 5.15 (1 H, dd, *J* 8.3, 3.8, H-1), 4.84 (1 H, d, *J* 11.2, H-7'), 4.72 (1 H, d, *J* 11.2, H-15'), 4.68 (1 H, d, *J* 11.2, H-15''), 4.63 (1 H, d, *J* 11.2, H-7''), 4.31 (1 H, dd, *J* 5.5, 3.8, H-2), 4.14 (1 H, dd, *J* 5.9, 5.9, H-3), 3.80 (3 H, s, H-14 or H-22), 3.80 (3

H, s, H-14 or H-22), 3.77 (1 H, dd, J 7.9, 7.9, H-6), 3.63–3.57 (2 H, m, H-4 and H-5), 2.62 (1 H, s, -OH), 2.11 (3 H, s, H-24), 1.98–1.85 (2 H, m, H-26 or H-29), 1.76–1.62 (6 H, m, H-26 or H-29, H-27 and H-28); LRMS m/z (ESI⁺) 551.2 ([M+Na]⁺, 100%). These data are in good agreement with the literature values.⁵


(1,5-Dihydro-2,4,3-benzodioxaphosphepin-3-yl)diethylamine 17



To a two-neck round bottomed flask equipped with a stirrer bar, was added anhydrous Et₂O and freshly distilled PCl₃ (2.54 mL, 29.1 mmol, 1.0 eq) under an atmosphere of argon. The solution was cooled to -78 °C, after which a solution of freshly distilled anhydrous diethylamine (6.03 mL, 58.2 mmol 2.0 eq) in anhydrous Et₂O (232 mL) was added dropwise *via* cannula. The reaction mixture was stirred for 1.5 h before being allowed to reach RT and then stirred for an additional 16 h. The resulting precipitate was removed by Schlenk filtration, and the filtrate collected in a two-neck round bottomed flask equipped with a stirrer bar. The filtered solid was washed with anhydrous Et₂O (3 × 50 mL) and the filtrate was then cooled to -78 °C under an atmosphere of argon. A solution of Et₃N (8.11 mL, 58.3 mmol, 2.0 eq) and 1,2-benzenedimethanol (4.02 g, 29.1 mmol, 1.0 eq) in a mixture of anhydrous THF (40 mL) and anhydrous Et₂O (160 mL) was cooled to -78 °C and then added dropwise *via* cannula to the stirred filtrate. After complete addition of the 1,2-benzenedimethanol solution, the reaction was allowed to proceed for 1.5 h, before being allowed to reach RT. The reaction mixture was then stirred for a further 16 h. The resulting precipitate was removed using Schlenk filtration, and the filtered solid was washed with anhydrous Et₂O (3 × 50 mL). The filtrate was then concentrated *in vacuo* to give (1,5-dihydro-2,4,3-benzodioxaphosphepin-3-yl)diethylamine **17** as a colorless oil (5.26 g, 76%). Analysis by ³¹P NMR showed that the product was ~87% pure. This unstable phosphoramidite was therefore used in subsequent steps without further purification or characterization. The product was stored under Ar at -20 °C and was checked by ³¹P NMR before

each use: $^1\text{H NMR}$ (400 MHz; CDCl_3) δ_{H} 7.31–7.16 (4H, m, H-6 to H-9), 5.18 (2H, dd, J 13.8, 7.0, H-4 and H-11), 4.91 (2H, dd, J 19.4, 13.8, H-4' and H-11'), 3.19 (4H, dq, J 9.9, 7.0, H-2 and H-3), 1.11 (6H, t, J 7.0, C(2) CH_3 and C(3) CH_3); $^{31}\text{P NMR}$ (162 MHz, CDCl_3) δ_{P} 145.3 (P-1); These data are in good agreement with the literature values.⁵


1D-1-O-Acetate-2,3-O-cyclopentylidene-4,6-di-O-(4-methoxybenzyl)-5-O-(2-oxo-5,6-benzo-1,3,2-dioxaphosphep-2-yl)-myo-inositol (-)-18



To phosphoramidite **17** (770 mg, 3.22 mmol, 2.0 eq) in anhydrous CH_2Cl_2 (8 mL) was added 1*H*-tetrazole (7.16 mL, 3.22 mmol, 2.0 eq, 0.45 M in MeCN). After stirring at RT for 10 min, a solution of alcohol **(-)-16** (850 mg, 1.61 mmol, 1.0 eq) in anhydrous CH_2Cl_2 (2 mL) was added dropwise. The cloudy reaction mixture was allowed to stir for 16 h, after which the reaction mixture was cooled to $-78\text{ }^\circ\text{C}$ and *m*CPBA (722 mg, 3.22 mmol, 2.0 eq, 77%) was added in a single portion. The reaction mixture was stirred at $-78\text{ }^\circ\text{C}$ and then gradually warmed to RT and stirred for a further 3 h. The reaction was then quenched with an aqueous solution of $\text{Na}_2\text{S}_2\text{O}_3$ (10% w/v, 20 mL) and the aqueous layer was extracted with CH_2Cl_2 (3 \times 20 mL). The combined organic layers were washed with brine (60 mL), dried over Na_2SO_4 , filtered, and concentrated *in vacuo*. Purification using column chromatography over silica gel (petroleum ether:EtOAc, 10:0 to 6:4) afforded **(-)-18** (1.06 g, 92%) as a colorless foam: R_f 0.34 (petroleum ether:EtOAc, 1:1); $[\alpha]_D^{25}$ -2.9 (c 1.0, CHCl_3); ν_{max} (thin film)/ cm^{-1} 2398, 1744, 1613, 1514, 1247, 1017; $^1\text{H NMR}$ (600 MHz, CDCl_3) δ_{H} 7.34–7.31 (4 H, m, H-9, H-13, H-33, H-36), 7.29–7.26 (2 H, m, H-17, H-21), 7.21–7.17 (2 H, m, H-34 and H-35), 6.87–6.81 (4 H, m, H-10, H-12, H-18, H-20), 5.23 (1 H, dd, J 8.5, 3.6, H-1), 5.18 (1 H, dd, J 15.8, 13.9, H-31' or H-38'), 5.12 (1 H, dd, J 16.4, 13.9, H-31' or H-38'), 5.09–5.00 (2 H, m, H-37'' and H-38''), 4.77 (1 H, d, J 10.8, H-15'), 4.76 (1 H, d, J 11.1, H-7'), 4.68 (1 H, d, J 11.2, H-7''), 4.63–4.58 (2 H, m, H-5, H-15''), 4.38 (1 H, dd, J 6.3, 3.6, H-2), 4.20 (1 H,

dd, J 6.0, 6.0, H-3), 4.02 (1 H, dd, J 8.5, 6.8, H-6), 3.89 (1 H, dd, J 7.5, 6.0, H-4), 3.79 (6 H, s, H-14 and H-22), 2.08 (3 H, s, H-24), 1.98–1.85 (2 H, m, H-26', H-29'), 1.73–1.61 (6 H, m, H-26'', H-27, H-28, H-29''); ^{31}P NMR (243 MHz, CDCl_3) δ_{P} -0.7 (P-30); ^{13}C NMR (151 MHz, CDCl_3) δ_{C} 170.1 (C-23), 159.35, 159.34 (C-11 and C-19), 135.49, 135.45 (C-32 and C-37), 130.33, 130.23 (C-8 and C-16), 129.82 (C-9 and C-13), 129.63 (C-17, C-21), 129.07, 129.04 (C-33 and C-36), 128.8 (C-34 and C-35), 120.1 (C-25), 113.85, 113.76 (C-10, C-12, C-18, C-20), 80.8 (d, J 6.5, C-5), 78.9 (d, J 3.3, C-4), 77.7 (d, J 4.4, C-6), 77.6 (C-3), 68.5 (d, J 2.2, C-31 or C-38), 68.4 (d, J 2.7, C-31 or C-38), 74.0 (C-15), 73.7 (C-2), 72.9 (C-7), 70.5 (C-1), 68.45 (d, J 2.2, C-31 or C-38), 68.41 (d, J 2.7, C-31 or C-38), 55.4 (C-14 and C-22), 36.9, 36.7, 24.1, 23.5 (C-26, C-27, C-28 and C-29), 21.2 (C-24); HRMS m/z (ESI $^{+}$) found 711.2551 [M+H] $^{+}$ ($\text{C}_{37}\text{H}_{44}\text{O}_{12}\text{P}$ requires 711.2565 [M+H] $^{+}$).


1*D*-2,3-*O*-Cyclopentylidene-4,6-di-*O*-(4-methoxybenzyl)-5-*O*-(2-oxo-5,6-benzo-1,3,2-dioxaphosphep-2-yl)-*myo*-inositol (+)-19



To a solution of (-)-18 (600 mg, 0.884 mmol, 1.0 eq) in MeOH (80 mL) was added ground K_2CO_3 (233 mg, 1.68 mmol, 2.0 eq). The reaction mixture was stirred at RT for 1 h, after which TLC confirmed the reaction had gone to completion. The solution was neutralized with 1 M HCl (pH 7) and the volatiles partially removed *in vacuo*. H_2O (30 mL) was added to the resulting residue and the aqueous layer was extracted with EtOAc (4 \times 10 mL). The combined organic fractions were washed with brine (40 mL), dried over Na_2SO_4 , filtered, and concentrated *in vacuo*. The resulting residue was purified by column chromatography over silica gel (petroleum ether:EtOAc, 10:0 to 3:7) and afforded alcohol (+)-19 (462 mg, 82%) as a colorless solid: R_f 0.34 (petroleum ether/EtOAc, 1:1); $[\alpha]_D^{25}$ +0.5 (c 2.0, CHCl_3); m.p. 125–127 $^{\circ}\text{C}$ (MeCN); ν_{max} (thin film)/ cm^{-1} 2938, 1613, 1514, 1249, 1016; ^1H NMR (600 MHz, CDCl_3) δ_{H}

7.35–7.28 (6 H, m, H-9, H-13, H-17, H-21, H-31, H-34), 7.24–7.15 (2 H, m, H-32, H-33), 6.88–6.85 (2 H, m, H-10, H-12 or H-18, H-20), 6.83–6.80 (2 H, m, H-10, H-12 or H-18, H-20), 5.22–5.03 (4 H, m, H-29 and H-36), 4.87 (1 H, d, J 10.8, H-7' or H-15'), 4.77 (1 H, d, J 11.2, H-7' or H-15'), 4.66 (1 H, d, J 11.2, H-7'' or H-15''), 4.63–4.58 (2 H, m, H-5 and H-7'' or H-15''), 4.35 (1 H, dd, J 6.5, 3.1, H-2), 4.20 (1 H, dd, J 6.5, 6.5, H-3), 3.99–3.93 (3 H, m, H-1, H-4, H-6), 3.79 (3 H, s, H-14 or H-22), 3.78 (3 H, s, H-14 or H-22), 2.49 (1 H, d, J 3.1, C(1)OH), 1.99–1.88 (2 H, m, C-24' and C-27''), 1.79–1.64 (6 H, m, H-24'', H-25, H-26, H-27''); ^{31}P NMR (243 MHz, CDCl_3) δ_{P} -0.7 (P-28); ^{13}C NMR (151 MHz, CDCl_3) δ_{C} 159.5, 159.3 (C-11 and C-19), 135.6, 135.5 (C-30 and C-35), 130.4, 130.3 (C-8 and C-16), 130.0 (C-9 and C-13), 129.7 (C-17 and C-21), 129.1 (d, J 7.1, C-32 or C-33), 128.9 (d, J 6.5, C-32 or C-33), 119.9 (C-23), 114.0, 113.7 (C-10, C-12, C-18 and C-20), 81.1 (d, J 6.5, C-5), 79.7 (d, J 3.8, H-4 or H-6), 79.6 (d, J 3.8, H-4 or H-6), 77.6 (C-3), 75.1 (C-2), 73.9, 72.9 (C-7, C-15), 68.8 (C-1), 68.5 (d, J 6.5, C-29 or C-36), 68.4 (d, J 6.0, C-29 or C-36), 55.41, 55.39 (C-14 and C-22), 36.6, 24.1, 23.4 (C-24, C-25, C-26, and C-27); LRMS (ESI^+) 691 ($[\text{M}+\text{Na}]^+$, 100%); HRMS m/z (ESI^+) found 669.2479 $[\text{M}+\text{H}]^+$ ($\text{C}_{35}\text{H}_{41}\text{O}_{11}\text{P}$ requires 669.2459 $[\text{M}+\text{H}]^+$).


1-Tetrahydropyranyloxy-11-bromoundecane **21**



To a solution of 1-bromo-11-hydroxyundecane **20** (20.0 g, 79.6 mmol, 1 eq) in dichloromethane (250 mL) was added 3,4-dihydro-2*H*-pyran (30.1 g, 368 mmol, 4.5 eq) and pyridinium *p*-toluene sulfonate (1.20 g, 4.78 mmol, 0.06 eq). The resulting solution was stirred for 18 h at RT. The reaction was then quenched by the addition of solid sodium hydrogen carbonate (1 g) and dried by vigorously stirring the solution with MgSO_4 . The mixture was then filtered through a large plug of silica gel, which was subsequently washed with petroleum ether. The


combined organic filtrates were then concentrated *in vacuo* to give 1-tetrahydropyranyloxy-11-bromoundecane **21** as a colorless oil (26.4 g, 99%): R_f 0.73 (petroleum ether:EtOAc, 9:1); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ_{H} 4.57 (dd, J 4.5, 2.7, 1H, H-12), 3.92–3.81 (m, 1H, H-16'), 3.72 (dt, J 9.6, 6.9, 1H, H-13'), 3.56–3.44 (m, 1H, H-16''), 3.44–3.32 (m, 3H, H-1, H-13''), 1.93–1.22 (m, 24H, H-2 to H-11, H-14, H-15); LRMS m/z (ESI⁺) 357.162 ($[\text{M}+\text{Na}]^+$, 100%); These data are in good agreement with the literature values.⁶

13-**{(Tetrahydropyran-2'-yl)oxy}tridecan-1-yne 22**

 A solution of lithium acetylide (ethylenediamine complex 90%, 3.62 g, 39.4 mmol, 1.32 eq) in anhydrous DMSO (20 mL) was added dropwise to a solution of 1-tetrahydropyranyloxy-11-bromoundecane **21** in anhydrous DMSO (50 mL) under an atmosphere of argon. The reaction was stirred for 16 h, after which the reaction was quenched with distilled H_2O (40 mL) until effervescence ceased. The mixture was then extracted with Et_2O (4 × 40 mL), the combined organic extracts were dried over Na_2SO_4 and were then concentrated *in vacuo*. The residue was purified by column chromatography over silica gel (petroleum ether: Et_2O , 10:0 to 9:1) resulting in **22** as a colorless oil (5.45 g, 65%): R_f 0.52 (petroleum ether: Et_2O , 9:1); ν_{max} (thin film)/ cm^{-1} 3312, 2929, 2855, 2118, 1034, 631; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ_{H} 4.57 (1H, dd, J 4.4, 2.7, H-14), 3.87 (1H, m, H-18'), 3.72 (1H, dt, J 9.6, 6.8, H-1'), 3.53–3.46 (1H, m, H-18''), 3.38 (1H, dt, J 9.6, 6.8, H-1''), 2.17 (2H, td, J 7.1, 2.7, H-11), 1.93 (1H, t, J 2.7, H-13), 1.88–1.23 (m, 24H, H-2 to H-10, H-15 to H-17); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ_{C} 99.0 (C-14), 84.9 (C-12), 68.2 (C-13), 67.8 (C-1), 62.5 (C-18), 31.0 (C-15), 29.9, 29.70, 29.68, 29.62, 29.2, 28.9, 28.7, 26.4, 25.7 (C-2 to C-10, C-16, C-17) 19.9 (C-15), 18.5


(C-11); LRMS m/z (ESI⁺) 303.189 ([M+Na]⁺, 100%); HRMS m/z (ESI⁺) found 303.2299 [M+Na]⁺ (C₁₈H₃₂O₂Na requires 303.2295 [M+Na]⁺).

Tridec-12-yn-1-ol **23**



To a solution of THP-protected alcohol **22** (5.00 g, 17.8 mmol, 1 eq) in ethanol (89 mL), was added HCl_(aq) (2 M, 0.89 mL). The mixture was heated under reflux for 16 h, after which the reaction was diluted with distilled H₂O (100 mL). The aqueous solution was then extracted with Et₂O (3 × 100 mL). The combined extracts were then dried over Na₂SO₄ and were then concentrated under a stream of nitrogen resulting in tridec-12-yn-1-ol **23** as a colorless solid (3.35 g, 96%): R_f 0.43 (petroleum ether:EtOAc, 8:2); m.p. 28–30 °C (Et₂O) [lit.⁷ 30–32 °C]; ¹H NMR (400 MHz, CDCl₃) δ_H 3.64 (2H, t, J 6.6, H-1), 2.18 (2H, td, J 7.1, 2.7, H-11), 1.93 (1H, t, J 2.7, H-13), 1.62–1.47 (4H, m, H-10, H-2), 1.45–1.24 (14H, m, H-3 to H-9). These data are in good agreement with the literature values.^{7,8}


Tridec-12-ynal **24**



Anhydrous DMSO (11.6 mL) in CH₂Cl₂ (30 mL) was added dropwise over 10 min to a stirred solution of oxalyl chloride (7 mL) in CH₂Cl₂ (150 mL) at –78 °C, under an atmosphere of argon. After 30 min, tridec-12-yn-1-ol **23** (7.24 g, 40.7 mmol, 1 eq) in CH₂Cl₂ (60 mL) was added dropwise *via* cannula over 30 min. Following 1 h of stirring, 35 mL of Et₃N was added, and the reaction was allowed to stir for a further 1.5 h at –78 °C. The reaction was then allowed to reach RT and stirred for a further 3 h. The reaction mixture was then washed with 5% aqueous HCl (200 mL), saturated NaHCO_{3(aq)} (300 mL) and finally brine (300 mL), before being dried over Na₂SO₄, and then concentrated *in vacuo* to afford

tridec-12-ynal **24** as a brown oil (5.23 g, 66%): R_f 0.67 (petroleum ether:EtOAc, 9:1); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ_{H} 9.76 (1H, t, J 1.9, H-1), 2.41 (2H, td, J 7.4, 1.9, H-2), 2.18 (2H, td, J 7.1, 2.7, H-11), 1.93 (1H, t, J 2.7, H-13), 1.67–1.58 (2H, m, H-10 or H-3), 1.56–1.47 (2H, m, H-10 or H-3), 1.43–1.24 (12H, m, H-4 to H-9). These data are in good agreement with the literature values.⁸


Ethyl 4-oxohexadec-15-ynoate **25**



Tridec-12-ynal **24** (6.66 g, 34.3 mmol, 1.0 eq) and ethyl acrylate (8.00 mL, 73.5 mmol, 2.1 eq) in 1,4-dioxane (75 mL) was added dropwise *via* cannula over 2 h to a suspension of 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (1.30 g, 4.80 mmol, 0.14 eq) in Et_3N (3.35 mL, 24.0 mmol, 0.7 eq) and 1,4-dioxane (75 mL) at 80 °C under an atmosphere of argon and the reaction was stirred for 56 h. The reaction mixture was then concentrated *in vacuo* and the resultant residue was redissolved in CH_2Cl_2 (250 mL), which was washed in succession with 10% $\text{H}_2\text{SO}_{4(\text{aq})}$ (250 mL), saturated NaHCO_3 (250 mL), and then brine (250 mL). The organic mixture was then dried over Na_2SO_4 , filtered, and concentrated *in vacuo*. Purification using silica gel column chromatography (petroleum ether:EtOAc, 100:0 to 93:7) resulted in **25** (3.85 g, 41%) with an unknown impurity that could not feasibly be separated on large scale. The bulk of the material was used without further purification; however, a small amount was further purified using column chromatography over a slow gradient and large volume of silica gel (petroleum ether:EtOAc, 100:0 to 95:5) for analysis: R_f 0.76 (petroleum ether:EtOAc, 8:2); m.p. 34–35 °C (petroleum ether:EtOAc); ν_{max} (thin film)/ cm^{-1} 3297, 2927, 1735, 1716, 1186, 631; $^1\text{H NMR}$ (600 MHz, CDCl_3) δ_{H} 4.12 (2 H, q, J 7.2, H-17), 2.71 (2 H, t, J 6.6, H-3), 2.57 (2 H, t, J 6.6, H-2), 2.43 (2 H, t, J 7.5, H-5), 2.17 (2 H, td, J 7.2, 2.6, H-14), 1.93 (1 H, t, J 2.6, H-16), 1.61–1.55 (2 H, m, H-6), 1.54–1.49 (2 H, m, H-13), 1.41–1.34 (2 H, m, H-12), 1.31–1.26 (10 H, m, H-7 to H-11), 1.25 (3 H, t, J 7.2, H-18); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ_{C} 209.3 (C-4), 173.0 (C-1), 84.9 (C-15), 68.2 (C-16), 60.7 (C-17), 43.0 (C-5), 37.2 (C-3), 29.6, 29.51, 29.50, 29.3, 29.2 (C-11 to C-7), 28.9 (C-12), 28.6 (C-13), 28.2 (C-2), 23.9 (C-


6), 18.5 (C-14), 14.3 (C-18); HRMS m/z (ESI⁺) found 295.2265 [M+H]⁺ (C₁₈H₃₁O₃ requires 295.2268 [M+H]⁺).

4-Oxohehexadec-15-ynoic acid **26**




To a solution of ethyl 4-oxohehexadec-15-ynoate **25** (3.18 g, 10.8 mmol, 1.0 eq) in methanol (82 mL), was added LiOH (1.29 g, 54.0 mmol, 5.0 eq) and H₂O (0.97 mL, 54 mmol, 5.0 eq). The mixture was stirred at RT for 16 h before the solution was half-concentrated *in vacuo* and then acidified to a pH of 3 using aqueous HCl (1 M). The resulting solution was then extracted with dichloromethane and the combined organic layers were then dried over anhydrous Na₂SO₄. The solution was then concentrated *in vacuo* and crystallized under a stream of nitrogen which resulted in 4-oxohehexadec-15-ynoic acid **26** as a colorless crystalline solid (2.85 g, 99%): R_f 0.21 (petroleum ether:EtOAc:AcOH, 80:19:1); m.p. 75–80 °C (CH₂Cl₂); ν_{\max} (thin film)/cm⁻¹ 3284, 2851, 1702, 906, 729, 647; ¹H NMR (600 MHz, CDCl₃) δ_H 2.71 (2 H, t, J 6.5, H-3), 2.63 (2 H, t, J 6.5, H-2), 2.44 (2 H, t, J 7.4, H-5), 2.17 (2 H, td, J 7.1, 2.6, H-14), 1.93 (1 H, t, J 2.6, H-16), 1.61–1.55 (2 H, m, H-6), 1.55–1.48 (2 H, m, H-13), 1.41–1.34 (2 H, m, H-12), 1.32–1.24 (10 H, m, H-11 to H-7); ¹³C NMR (151 MHz, CDCl₃) δ_C 209.1 (C-4), 178.1 (C-1), 84.9 (C-15), 68.2 (C-16), 42.9 (C-5), 36.9 (C-3), 29.5, 29.5, 29.5, 29.3, 29.2 (C-7 to C-11), 28.9 (C-12), 28.6 (C-13), 27.8 (C-2), 23.9 (C-6), 18.5 (C-14); LRMS m/z 531.309 ([2M-H]⁻, 100%); HRMS m/z (ESI⁺) found 267.1955 [M+H]⁺ (C₁₆H₂₇O₃ requires 267.1955 [M+H]⁺).

3-[3-(Dodec-11-yn-1-yl)diazirin-3-yl]propanoic acid **27**



A dried round bottom flask containing acid **26** (1.00 g, 3.25 mmol, 1.0 eq) under an atmosphere of argon was cooled to 0 °C and was charged with 7 M NH₃ in methanol (60 mL). The resulting solution was stirred at 0 °C for 3 h before hydroxylamine-*O*-sulfonic acid (594 mg, 5.25 mmol, 1.4 eq) was added as a single batch. The resulting solution was stirred at 0 °C for 1 h and was then allowed to warm to room temperature over 16 h. The resulting suspension was evaporated to dryness *in vacuo* and resuspended in anhydrous methanol (30 mL). The solid by-product was filtered off through a PTFE syringe filter and the filtrate was collected in a dry RBF, equipped with a stir bar under argon. The solution was cooled to 0 °C and anhydrous diisopropylethylamine (2 mL) was added, followed by iodine (portion-wise), until a dark brown colour persisted for more than 30 min — indicating total oxidation of the diaziridine intermediate. The solution was then partially concentrated before being diluted with EtOAc (60 mL) and washed with 1 M HCl (60 mL, 10% (w/v), Na₂S₂O₄ (60 mL portions until clarified) and brine (60 mL). Volatiles were removed *in vacuo* and the resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc, 100:0 to 88:12 with 0.1% acetic acid), resulting in diazirine **27** as a colorless waxy amorphous solid (467 mg, 52%): *R_f* 0.48 (petroleum ether:EtOAc:AcOH, 79:20:1); *ν*_{max} (thin film)/cm⁻¹ 3288, 2852, 1694, 1462, 932; ¹H NMR (600 MHz, CDCl₃) δ_H 2.20–2.12 (4 H, m, H-2, H-14), 1.93 (1 H, t, *J* 2.6, H-16), 1.73 (2 H, t, *J* 7.8, H-3), 1.52 (2 H, p, *J* 7.2, H-13), 1.38 (4 H, m, H-12, H-5), 1.32–1.18 (10 H, m, H-7 to H-11), 1.10–1.04 (2 H, m, H-6); ¹³C NMR (151 MHz, CDCl₃) δ_C 177.9 (C-1), 84.9 (C-15), 68.2 (C-16), 32.8 (C-5), 29.54, 29.52, 29.47, 29.3, 29.2 (C-7 to C-11), 28.9 (C-12), 28.6 (C-13), 28.4 (C-2), 28.20 (C-4), 28.17 (C-3), 23.9 (C-6), 18.5 (C-14); HRMS *m/z* (ESI⁻) found 277.1919 [M-H]⁻ (C₁₆H₂₅O₂N₂ requires 277.1911 [M-H]⁻).

(-)-(S)-(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl palmitate (-)-29



N,N'-Dicyclohexylcarbodiimide (6.24 g, 30.2 mmol,

2.0 eq) was added to a stirred solution of (*R*)-(-)-2,3-

isopropylidene-*sn*-glycerol (-)-**28** (2.00 g, 15.1 mmol,

1.0 eq), palmitic acid (3.88 g, 15.1 mmol, 1.0 eq) and 4-DMAP (0.11 g, 0.91 mmol, 0.06 eq) in

CH₂Cl₂ (45 mL) and was stirred for 16 h. The mixture was then diluted with hexane (20 mL),

filtered through Celite® and washed with hexane (3 × 10 mL). The combined filtrates were

concentrated *in vacuo*. The residue obtained was purified by column chromatography over silica

gel (petroleum ether:EtOAc, 95:5) to yield (-)-**29** (4.33 g, 77%) as a colorless solid: *R_f* 0.18

(petroleum ether:EtOAc, 20:1); m.p. 29–30 °C (heptane:EtOAc), [lit.⁹ 32.0–32.5 °C,

pentane:EtOAc]; [α]_D²⁵ -8.4 (c 1.0, hexane), [lit.⁹ [α]_D²⁰ -7.91 (c 3.14, hexane)]; ¹H NMR (400 MHz,

CDCl₃) δ_H 4.35–4.28 (1H, m, H-2), 4.16 (1H, dd, *J* 11.5, 4.7, H-1'), 4.10 (1H, d, *J* 6.2, H-3'), 4.09–


4.05 (1H, m, H-1''), 3.74 (1H, dd, *J* 8.4, 6.2, H-3''), 2.34 (2H, t, *J* 7.6, H-6), 1.67–1.57 (2H, m, H-

7), 1.44 (3H, s, C(4)CH₃), 1.37 (3H, s, C(4)CH₃), 1.33–1.23 (29H, m, H-8 to H-19), 0.92–0.84 (3H,

m, H-20); LRMS *m/z* (ESI⁺) 393.350 ([M+Na]⁺, 100%); These data are in good agreement with

the literature values.⁹

(+)-(*R*)-2-Hydroxy-3-((triethylsilyl)oxy)propyl palmitate **30**



Acetonide (-)-**29** (2.04 g, 5.50 mmol, 1.0 eq)

was dissolved in anhydrous dichloroethane (40

mL) under an atmosphere of argon. DIPEA

(1.92 mL, 11.0 mmol, 2 eq) was added followed by TESOTf (1.49 mL, 6.60 mmol, 1.2 eq) and the

mixture was stirred at reflux for 24 h. Additional TESOTf (0.50 mL, 2.20 mmol, 0.4 eq) was then


added due to presence of remaining starting material, and the mixture was stirred for a further 24

h. The reaction was cooled to RT, diluted with petroleum ether and washed with 0.1 M aqueous

HCl. The aqueous fraction was extracted with petroleum ether (3 × 10 mL). The combined organic

fractions were then washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was then dissolved in a mixture of THF (42 mL) and 10% aqueous Na₂CO₃ (18 mL), before I₂ (2.09 g, 8.25 mmol, 1.5 eq) was added. The reaction was stirred for 2 h and then quenched with 10% aqueous Na₂S₂O₃ (100 mL). The solution was extracted with Et₂O (3 × 100 mL), and the combined Et₂O fractions were washed with brine (300 mL), dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The resulting residue was then purified by silica gel column chromatography (cyclohexane:EtOAc, 100:0 to 90:10) giving alcohol **(+)-30** as a yellow oil (438 mg, 18%): *R_f* 0.17 (petroleum ether:EtOAc, 95:5); $[\alpha]_D^{25} +1.4$ (c 4.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ_H 4.16 (1 H, dd, *J* 11.5, 5.0, H-1'), 4.11 (1 H, dd, *J* 11.5, 5.9, H-1''), 3.92–3.84 (1 H, m, H-2), 3.67 (1 H, dd, *J* 10.1, 4.6, H-3'), 3.60 (1 H, dd, *J* 10.1, 5.7, H-3''), 2.54 (1 H, d, *J* 5.3, C(2)OH), 2.34 (2 H, t, *J* 7.5, H-5), 1.62 (2 H, p, *J* 7.5, H-6), 1.35–1.23 (24 H, m, H-7 to H-18), 0.96 (9 H, t, *J* 7.9, H-21, H-23, H-25), 0.88 (3 H, t, *J* 6.7, H-19), 0.62 (6 H, q, *J* 7.9, H-20, H-22, H-24); LRMS (ESI⁺) 467.3 ([M+Na]⁺, 100%), 911.5 ([2M+Na]⁺, 100%); These data are in good agreement with the literature values.¹⁰


(+)-(R)-2-((3-(3-(Dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-(triethylsilyl)oxy)propyl palmitate **31**



To a solution of alcohol **(+)-30** (240 mg, 0.540 mmol, 1.0 eq) in anhydrous CH₂Cl₂ (2 mL) was added DCC (223 mg, 1.08 mmol, 2.0 eq), 4-DMAP (4 mg, 0.03 mmol, 0.06 eq) and diazirine **50** (150 mg, 1.08 mmol, 1.0 eq). The solution was stirred at RT for 18 h, after which the reaction mixture was diluted with hexane (10 mL). The suspension was filtered through a PTFE syringe filter, and the filtrate was concentrated *in vacuo* at RT. The resulting residue was purified by column chromatography over silica gel (petroleum ether:Et₂O, 10:0 to 9:1) which yielded **(+)-31** (324 mg, 85%) as a colorless oil:

R_f 0.44 (hexane:Et₂O, 90:10); $[\alpha]_D^{25} +8.8$ (c 1.0, CHCl₃); ν_{\max} (thin film)/cm⁻¹ 3313, 2925, 2854, 1744, 1459, 1167, 1115; ¹H NMR (600 MHz, CDCl₃) δ_H 5.08–5.04 (1 H, m, H-2), 4.35 (1 H, dd, J 11.9, 3.6, H-1'), 4.16 (1 H, dd, J 11.9, 6.1, H-1''), 3.75–3.68 (2 H, m, H-3), 2.30 (1 H, t, J 7.5, H-5), 2.17 (2 H, td, J 7.2, 2.6, H-33), 2.13–2.09 (2 H, m, H-21), 1.93 (1 H, t, J 2.6, H-35), 1.72 (1 H, t, J 7.8, H-22), 1.60 (2 H, p, J 7.4, H-6), 1.52 (1 H, p, J 7.2, H-32), 1.41–1.34 (4 H, m, H-31, H-29), 1.34–1.18 (34 H, m, H-7 to H-18 and H-24 to H-28), 1.11–1.03 (2 H, m, H-30), 0.94 (9 H, t, J 7.9, H-37, H-39, H-41), 0.88 (3 H, t, J 7.0, H-19), 0.59 (6 H, q, J 7.9, H-36, H-38, H-40); ¹³C NMR (151 MHz, CDCl₃) δ_C 173.6 (C-4), 171.8 (C-20), 84.9 (C-34), 72.4 (C-2), 68.2 (C-35), 62.4 (C-1), 61.2 (C-3), 34.3 (C-5), 32.9 (C-24), 32.1, 29.8, 29.8, 29.8, 29.6, 29.6, 29.6, 29.5, 29.4, 29.3, 29.3, 29.2, 28.9, 28.8, 28.6, 28.4 (C-7 to C-17, C-21 to C-22, C-26 to C-32), 28.3 (C-23), 25.1 (C-6), 24.0 (C-25), 22.8 (C-18), 18.5 (C-33), 14.3 (C-19), 6.8 (C-37, C-39, C-41), 4.4 (C-36, C-38, C-40); HRMS m/z (ESI⁺) found 727.5410 [M+Na]⁺ (C₄₁H₇₆O₅N₂SiNa requires 727.5416 [M+Na]⁺).

(-)-(S)-2-((3-(3-(Dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-hydroxypropyl palmitate **32**



Method 1: Aqueous acetic acid (AcOH:H₂O 4:1 v/v, 2 mL) was added to protected diglyceride **S24** (374 mg, 0.419 mmol, 1.0 eq) and stirred vigorously. MeCN was


then added dropwise in an attempt to homogenize the solution. The mixture was then stirred at 50 °C for 3.5 h, after which TLC showed remaining starting material. The solution was concentrated *in vacuo* and the resulting residue was redissolved in acetic acid (2 mL) and a few drops of H₂O was added. The solution was stirred for a further 30 min after which the mixture was cooled to RT and concentrated *in vacuo*. The resulting residue was then purified *via* column chromatography over silica gel (petroleum ether:EtOAc, 100:0 to 76:24) giving alcohol **32** as a colorless waxy solid (167 mg, 68%): R_f 0.23 (petroleum ether:EtOAc, 8:2); $[\alpha]_D^{25} -3.3$ (c 1.0,

CHCl₃); ν_{\max} (thin film)/cm⁻¹ 3313, 2981, 2925, 2854, 1742, 1463, 1381, 1251, 1165, 955; ¹H NMR (600 MHz, CDCl₃) δ_{H} 5.09 (1 H, p, *J* 4.9, H-2), 4.32 (1 H, dd, *J* 12.0, 4.5, H-1'), 4.23 (1 H, dd, *J* 12.0, 5.6, H-1''), 3.80–3.70 (2 H, m, H-3), 2.32 (2 H, t, *J* 7.5, H-5), 2.20–2.12 (4 H, m, H-33 and H-21), 1.93 (1 H, t, *J* 2.6, H-35), 1.82–1.71 (2 H, m, H-22), 1.65–1.58 (2 H, m, H-6), 1.52 (2 H, p, *J* 7.2, H-32), 1.42–1.34 (4 H, m, H-30 and H-31), 1.34–1.19 (34 H, m, H-28 to H-24 and H-18 to H-7), 1.12–1.04 (2 H, m, H-29), 0.88 (3 H, t, *J* 7.0, H-19); ¹³C NMR (151 MHz, CDCl₃) δ_{C} 173.9 (C-4), 172.0 (C-20), 84.9 (C-34), 72.9 (C-2), 68.2 (C-35), 62.0 (C-1), 61.6 (C-3), 34.2 (C-5), 32.8 (C-31), 32.1 (C-17), 29.85, 29.83, 29.81, 29.77, 29.62, 29.55, 29.54, 29.51, 29.49, 29.41, 29.29, 29.27, 29.21, 29.20 (C-24 to C-30, C-7 to C-16), 28.9 (C-21), 28.6 (C-32), 28.4 (C-23), 28.3 (C-22), 25.0 (C-6), 23.9 (C-29), 22.8 (C-18), 18.5 (C-33), 14.3 (C-19); LRMS *m/z* (ESI⁻) 635.5 (M+FA-H, 100%); HRMS *m/z* (ESI⁺) found 613.4553 [M+Na]⁺ (C₃₅H₆₂O₅N₂Na) requires 613.4551 [M+Na]⁺.

Method 2: Silane **31** (200 mg, 0.284 mmol, 1.0 eq) was dissolved in a mixture of anhydrous MeOH (2.1 mL) and anhydrous CH₂Cl₂ (0.7 mL). A substoichiometric amount of FeCl₃ (2 mg, 0.01 mmol, 0.05 eq) was added and the reaction mixture, which was stirred for 3 h until TLC analysis confirmed complete consumption of the starting material. The solution was diluted with Et₂O (20 mL), washed with H₂O (20 mL), and the aqueous component was extracted further with Et₂O (3 × 20 mL). The combined Et₂O extracts were then washed with brine, dried over Na₂SO₄, filtered, and concentrated *in vacuo*, resulting in alcohol **32** (156 mg, 93%, >95% e.e.) as a colorless waxy solid requiring no further purification. No transesterification by-product was observed by ¹H NMR, suggesting the reaction did not affect the enantiopurity of the product. $[\alpha]_{\text{D}}^{25}$ -3.5 (c 1.0, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ_{H} 5.09 (1 H, p, *J* 5.0, H-2), 4.32 (1 H, dd, *J* 12.0, 4.5, H-1'), 4.23 (1 H, dd, *J* 12.0, 5.6, H-1''), 3.80–3.70 (2 H, m, H-3), 2.32 (2 H, t, *J* 7.6, H-5), 2.17 (3 H, td, *J* 7.1, 2.5), H-33), 2.15 (2 H, t, *J* 7.4, H-21), 1.93 (1 H, t, *J* 2.6, H-35), 1.82–1.71 (2 H, m, H-22), 1.61 (2 H, p, *J* 7.4, H-6), 1.52 (2 H, p, *J* 7.2, H-32), 1.41–1.35 (4 H, m, H-30, H-31), 1.32–1.19 (34 H, m,

H-7 to H-18 and H-24 to H-28), 1.10–1.03 (2 H, m, H-29), 0.88 (3 H, t, J 7.0, H-19); ^{13}C NMR (151 MHz, CDCl_3) δ_{C} 173.9 (C-4), 172.0 (C-20), 84.9 (C-34), 72.9 (C-2), 68.2 (C-35), 62.0 (C-1), 61.6 (C-3), 34.2 (C-5), 32.8 (C-31), 32.1 (C-17), 29.85, 29.83, 29.81, 29.77, 29.62, 29.55, 29.54, 29.51, 29.49, 29.41, 29.29, 29.27, 29.21, 29.20 (C-30 to C-24, C-16 to C-7), 28.9 (C-21), 28.6 (C-32), 28.4 (C-23), 28.3 (C-22), 25.0 (C-6), 23.9 (C-29), 22.8 (C-18), 18.5 (C-33), 14.3 (C-19). All other characterization data matched those reported above. The e.e. of (–)-**32** was calculated by ^1H NMR using a chiral auxiliary (see **Figure S3**).

(2R)-3-(((Benzyloxy)(diisopropylamino)phosphaneyloxy)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyloxy)propyl) palmitate **34**




To a solution of benzyloxy-bis(*N,N*-diisopropylamino) phosphine **33** (172 mg, 0.507 mmol, 3.0 eq) in anhydrous

dichloromethane (1 mL) was added 1*H*-tetrazole (1.13 mL, 0.507 mmol, 3.0 eq, 0.45 M in MeCN). The solution was stirred for 15 min, after which alcohol **32** (100 mg, 0.169 mmol, 1.0 eq) was added as a single batch. The reaction mixture was stirred at RT for 18 h, diluted with CH_2Cl_2 (10 mL), and then quenched by the addition of saturated aqueous NaHCO_3 (3 mL). The organic phase was extracted with CH_2Cl_2 (3 \times 3 mL). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4 , filtered, and then concentrated *in vacuo*. The residue obtained was purified by column chromatography over silica gel (hexane:EtOAc:Et₃N, 90:5:5) to give phosphoramidite **34** (135 mg, 96%) as a colorless viscous oil, containing a mixture of two diastereoisomers. Due to its unstable nature, this phosphoramidite was used without further characterization: R_f 0.73 (petroleum ether:EtOAc:Et₃N, 90:5:5); $[\alpha]_D^{25} +5.3$ (c 1.0, CHCl_3); ν_{max} (thin film)/ cm^{-1} 3312, 2926, 2854, 2118, 1743, 1497, 1364, 1184, 976; ^1H NMR (400 MHz, CDCl_3) δ_{H} 7.39–7.26 (10 H, m, H-41 to H-45 Diast. A and B), 5.21–5.14 (2 H, m, H-2 Diast. A and B), 4.82–4.61 (4 H, m, H-1 Diast. A and B), 4.36 (1 H, dd, J 8.5, 3.7, H-3' Diast. A), 4.32 (1 H, dd, J 8.5,

3.7, H-3' Diast. B), 4.21–4.12 (2 H, m, H-3'' Diast. A and B), 3.83–3.54 (8 H, m, H-37, H-38, H-39. Diast A and B), 2.29 (4 H, t, J 7.6, H-5 Diast. A and B), 2.18 (2 H, td, J 7.2, 2.7, H-33 Diast. A and B), 2.12–2.06 (2 H, m, H-21 Diast. A and B), 1.93 (2 H, t, J 2.7, H-35), 1.73–1.68 (4 H, m, H-22 Diast. A and B), 1.65–1.56 (4 H, m, H-6 Diast. A and B), 1.56–1.47 (4 H, m, H-32 Diast. A and B), 1.43–1.15 (100H, m, H-31, H-30, H-28 to H-24 and H-18 to H-7, 2 × C(37)CH₃, 2 × C(38)CH₃, Diast. A and B), 1.10–1.00 (4 H, m, H-29 Diast. A and B), 0.88 (6 H, t, J 6.6, H-19 Diast. A and B); ³¹P NMR (162 MHz, CDCl₃) δ_P 148.9 (P-36 Diast. A), 148.7 (P-36 Diast. B); HRMS m/z (ESI⁺) found 828.6007 [M+H]⁺ (C₄₈H₈₃O₆N₃P) requires 828.6014 [M+H]⁺.

(+)-(2R)-3-(((Benzyloxy)(((3aR,4R,5S,6R,7S,7aR)-4,6-bis((4-methoxybenzyl)oxy)-5-((3-oxido-1,5-dihydrobenzo[e][1,3,2]dioxaphosphepin-3-yl)oxy)hexahydrospiro[benzo[d][1,3]dioxole-2,1'-cyclopentan]-7-yl)oxy)phosphoryl)oxy)-2-(((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)propyl palmitate (+)-35




To a solution of phosphoramidite **34** (150 mg, 0.181 mmol, 1.0 eq) in anhydrous CH₂Cl₂ (1.8 mL) was added 1*H*-tetrazole (402 μL, 0.181 mmol, 1.0 eq, 0.45 M in MeCN). After 10 min, inositol **(+)-19** (120 mg, 0.181 mmol, 1.0 eq) was added as a single batch to the cloudy reaction mixture, and the mixture was stirred at

RT for a further 18 h. The reaction mixture was then cooled to –78 °C and *m*CPBA (41 mg, 0.181 mmol, 1.0 eq, 77%) was added in one portion. The reaction mixture was stirred for 1 h, warmed to RT, stirred for a further 3 h, and then quenched by the addition of an aqueous solution of Na₂S₂O₃ (10% w/v, 5 mL). After stirring for 15 min, the aqueous phase was extracted with CH₂Cl₂ (4 × 5 mL) and the combined organic layers were washed with brine (15 mL), dried over Na₂SO₄, filtered, and then concentrated *in vacuo*. Purification by column chromatography over silica gel (petroleum ether:EtOAc, 10:0, 5:5) yielded protected PI(5)P **(+)-35** (147 mg, 57%) as a colorless, gummy oil containing a mixture of two diastereoisomers: *R_f* 0.51 (petroleum

ether:EtOAc, 5:5); $[\alpha]_D^{25} +2.4$ (c 0.7, CHCl₃); ν_{\max} (thin film)/cm⁻¹ 2927, 2854, 2360, 2341, 1744, 1515, 1250, 1015, 763; ¹H NMR (600 MHz, CDCl₃) δ_H 7.38 – 6.75 (34 H, m, H-9, H-10, H-12, H-13, H-17, H-18, H-20, H-21, H-31 to H-34, H-40 to H-44 Diast. A and B), 5.19–4.98 (13 H, m, H-38 Diast. A, H-38' Diast. B, H-29, H-36, H-46 Diast. A and B), 4.94 (1 H, dd, *J* 11.8, 7.6, H-38'' Diast. B), 4.78 (2 H, dd, *J* 10.5, 4.1, H-15' Diast. A and B), 4.73 (2 H, dd, *J* 11.3, 4.0, H-7' Diast. A and B), 4.70–4.65 (3 H, m, H-7'' Diast. A, H-1 Diast. A and B), 4.66–4.59 (5 H, m, H-7'' Diast. B, H-15'', H-5 Diast. A and B), 4.48 (2 H, dd, *J* 6.4, 3.7, H-2 Diast. A and B), 4.26 (1 H, dd, *J* 12.1, 4.0, H-47' Diast. A), 4.19 (1 H, dd, *J* 6.1, 6.1, H-3 Diast. A), 4.18 (1 H, dd, *J* 6.1, 6.1, H-3 Diast. B), 4.17–4.12 (2 H, m, H-45', H-47'' Diast. A), 4.12–3.97 (6 H, m, H-6, H-45'' Diast. A, H-45', H-45'', H-47' Diast. B), 3.94–3.85 (3 H, m, H-47'' Diast. B, H-4 Diast. A and B), 3.78 (3 H, s, PMB -OCH₃ Diast. A), 3.77 (6 H, s, PMB -OCH₃ Diast. A and B), 3.75 (3 H, s, PMB -OCH₃ Diast. B.), 2.27 (2 H, t, *J* 7.6, H-65 Diast. A), 2.25 (2 H, t, *J* 7.6, H-65 Diast. B), 2.17 (4 H, td, *J* 7.2, 2.6, H-61 Diast. A and B), 2.07 (2 H, td, *J* 7.9, 3.1, H-49 Diast. A), 2.02–1.98 (2 H, m, H-49 Diast. B), 1.98–1.85 (6 H, m, H-63, H-24', H-27' Diast. A and B), 1.74–1.61 (16 H, m, H-24'', H-27'', H-25, H-26, H-50 Diast. A and B), 1.59–1.54 (4 H, m, H-66 Diast. A and B), 1.51 (4 H, p, *J* 7.2, H-60 Diast. A and B), 1.41–1.15 (76 H, m, H-52 to H-57, H-59, H-67 to H-78 Diast. A and B), 1.07–0.98 (4 H, m, H-58 Diast. A and B), 0.88 (6 H, t, *J* 7.0, H-79 Diast. A and B); ³¹P NMR (243 MHz, CDCl₃) δ_P -0.64 (P-28 Diast. A), -0.67 (P-28 Diast. B), -1.85 (P-37 Diast. A), -1.97 (P-37 Diast. B); ¹³C NMR (151 MHz, CDCl₃) δ_C 173.33, 173.27 (C-64 Diast. A and B), 171.53, 171.48 (C-48 Diast. A and B), 159.38, 159.37, 159.32 (C-11, C-19 Diast. A and B), 135.9 – 135.7 (m, C-39 Diast. A and B), 135.48, 135.46, 135.39 (C-8, C-16, C-30, C-35), 130.1 (d, *J* 2.7), 129.84 (d, *J* 2.2), 129.76, 129.69, 129.11, 129.10, 129.07, 128.89, 128.87, 128.84, 128.83, 128.73, 128.72, 128.67, 128.60, 128.0, 127.8 (Aromatic C-10, C-12, C-18, C-20, C-31, C-32, C-33, C-34, C-40, C-41, C-42, C-43, C-44 Diast. A and B), 120.1 (C-23 Diast. A and B), 113.80, 113.79, 113.77 (C-9, C-13, C-17, C-21 Diast. A and B), 84.9 (C-62 Diast. A and B), 80.50 (C-5 Diast. A), 80.47 (C-5 Diast. B), 78.62

(d, *J* 2.7, C-4, Diast. A), 78.56 (d, *J* 2.7, C-4 Diast. B), 78.2–78.0 (m, C-6 Diast. A), 78.0–77.8 (m, C-6 Diast. B), 77.2 (C-3 Diast. A and B by HSQC), 75.35 (C-1 Diast. A), 75.31 (C-1 Diast. B), 74.24 (C-2 Diast. A), 74.17 (C-2 Diast. B), 74.0 (d, *J* 2.7, C-15 Diast. A), 72.8 (d, *J* 4.4, C-15 Diast. B), 70.04 (d, *J* 3.3, C-46 Diast. A), 69.98 (d, *J* 3.8, C-46 Diast. B), 69.6 (t, *J* 5.7, C-38 Diast. A and B), 68.5–68.4 (m, C-29 and C-36 Diast. A and B), 68.2 (C-63 Diast. A and B), 65.7 (d, *J* 5.4, C-45 Diast. A), 65.4 (d, *J* 5.5, C-45 Diast. B), 61.7 (C-47 Diast. A), 61.6 (C-47 Diast. B), 55.39, 55.36, 55.35 (C-14, C-22 Diast. A and B), 36.57, 36.56, 36.39, 36.36 (C-24, C-27 Diast. A and B), 34.11 (C-65 Diast. A), 34.07 (C-65 Diast. B), 32.81, 32.77, 32.1, 29.85, 29.82, 29.82, 29.81, 29.79, 29.65, 29.64, 29.56, 29.51, 29.4, 29.31, 29.29, 29.2 (C-52 to C-57, C-67 to C-76 Diast. A and B), 28.9 (C-59 Diast. A and B), 28.62 (C-60 Diast. A and B), 28.57 (C-49 Diast. A), 28.54 (C-49 Diast. B), 28.21 (C-50 Diast. A), 28.20 (C-50 Diast. B), 28.17 (C-51 Diast. A and B), 24.97 (C-66 Diast. A), 24.95 (C-66 Diast. B), 24.03 (C-58 Diast. A), 24.00 (C-58 Diast. B), 23.9 (C-59 Diast. A and B), 23.4 (C-25 or C-26 Diast. A and B), 22.8 (C-77 or C-78 Diast. A and B), 18.5 (C-61 Diast. A and B), 14.3 (C-79 Diast. A and B); HRMS *m/z* (ESI⁺) found 1411.7101 [M+H]⁺ (C₇₇H₁₀₉O₁₈N₂P₂ requires 1411.7145 [M+H]⁺). NP-HPLC *t_R* = 11.28 min (Diast. A), 12.20 (Diast. B.), 99.55% @ 280 nm, 98.74% @ 254 nm.

Ammonium (1*S*,2*R*,3*R*,4*R*,5*R*,6*R*)-3-(((*R*)-2-((3-(3-(dodec-11-yn-1-yl)-3*H*-diazirin-3-yl)propanoyl)oxy)-3-(palmitoyloxy)propoxy)oxidophosphoryl)oxy)-2,4,5,6-tetrahydroxycyclohexyl phosphate, PI(5)P-DIAZ, 9




To a solution of protected PI(5)P (+)-**35** (15 mg, 0.011 mmol, 1.0 eq) in anhydrous toluene (1 mL) was added TMSBr (44 μ L, 0.33 mmol, 30 eq). The solution was stirred at RT for 2 h after which TLC confirmed complete

consumption of the starting material. The reaction mixture was cooled to 0 °C and concentrated *in vacuo*. The resulting residue was redissolved in anhydrous toluene (1 mL) and concentrated again *in vacuo*. This was repeated three times to remove residual TMSBr, being careful to keep the flask under inert and dry conditions. The residue was then dissolved in MeOH (1 mL), stirred at 0 °C for 1 h and was then concentrated *in vacuo* (2–3 mbar) at 0 °C to avoid bumping. The residue obtained was dissolved in the minimal amount of MeOH:CH₂Cl₂ (1:1 v/v) and purified by column chromatography over silica gel (CHCl₃:MeOH:2.2 M NH₄OH, 9:7:2). The combined fractions were partially concentrated *in vacuo* at 0 °C, then milli Q H₂O (30 mL) was added. Lyophilization yielded PI(5)P DIAZ **9** (6 mg, 56%) as a colorless, fluffy powder. The compound was stored at –80 °C as the assumed *tris*-ammonium salt: *R_f* 0.53 (CHCl₃:MeOH:2.2 M NH₄OH, 9:7:2); ν_{\max} (solid)/cm⁻¹ 3317, 2918, 2850, 1742, 1727, 1199, 1048, 947, 727; ¹H NMR (600 MHz, MeOD:CDCl₃:D₂O, 4:3:1) δ_{H} 5.28–5.22 (1 H, m, H-10), 4.42–4.40 (1 H, m, H-11' by HSQC), 4.20 (1 H, dd, *J* 12.3, 7.4, H-11''), 4.17 (1 H, dd, *J* 2.7, 2.7, H-2), 4.07–4.00 (2 H, m, H-9), 3.98–3.93 (1 H, m, H-1), 3.90–3.81 (2 H, m, H-5, H-6), 3.78 (1 H, dd, *J* 9.3, 9.3 H-4), 3.50 (1 H, dd, *J* 9.7, 2.8, H-3), 2.33 (2 H, t, *J* 7.6, H-29), 2.23–2.09 (4 H, m, H-13, H-25), 2.05 (1 H, t, *J* 2.6, H-27), 1.80–1.73 (1 H, m, H-14'), 1.71–1.64 (1 H, m, H-14''), 1.62–1.55 (2 H, m, H-30), 1.50 (2 H, p, *J* 7.2, H-24), 1.42–1.35 (4 H, m, H-21, H-23), 1.35–1.18 (34 H, m, H-16 to H-20, H-31 to H-42), 1.09–1.01 (2 H, m, H-22), 0.87 (3 H, t, *J* 7.0, H-43); ³¹P NMR (243 MHz, MeOD:CDCl₃:D₂O, 4:3:1) δ_{P} 1.6 (P-7), –0.2 (P-8); ¹³C NMR (151 MHz, MeOD:CDCl₃:D₂O, 4:3:1) δ_{C} 175.3 (C-28), 173.3 (C-12), 85.4 (C-26), 80.2 (d, *J* 5.4, C-5), 77.0 (d, *J* 6.0, C-1), 72.8 (d, *J* 2.2, C-4), 72.0 (C-2), 71.92 (C-6), 71.87 (C-10), 71.7 (C-3), 69.0 (C-27), 64.4 (d, *J* 4.4, C-9), 63.6 (C-11), 34.8 (C-29), 33.3 (C-23), 32.6, 30.37, 30.32, 30.2, 30.13, 30.10, 30.0, 29.89, 29.88, 29.76, 29.4 (C-16 to C-21, C-31 to C-41), 29.2 (C-13, C-24), 28.9 (C-15), 28.8 (C-14), 25.6 (C-30), 24.5 (C-22), 23.3 (C-42), 18.9 (C-25), 14.5 (C-43); LRMS *m/z* (ESI⁻) 911.3 [M–H]⁻, 455.4 [M–H]⁻; HRMS *m/z* (ESI⁻) found 911.4425 [M–H]⁻ (C₄₁H₇₃O₁₆N₂P₂ requires 911.441 [M–H]⁻).


* $[\alpha]_D$ measurements could not be reliably obtained due to micelle formation.

4,6-Di-O-benzyl-*myo*-inositol 1,3,5-orthoformate **S1**



LiH (998 mg, 126 mmol, 4.0 eq) was gradually added to a solution of *myo*-inositol-1,3,5-orthoformate **11** (6.00 g, 31.5 mmol, 1.0 eq) in anhydrous DMF (90 mL), and the resulting solution was stirred at RT for 30 min. Benzyl bromide (8.58 mL, 72.2 mmol, 2.3 eq) was then added dropwise and the solution was stirred for a further 72 h. The reaction was quenched with H₂O (90 mL), and the volatile components were removed *in vacuo*. Residual DMF was removed using toluene as an azeotrope. The resultant yellow paste was dissolved in EtOAc (250 mL) and washed with H₂O (2 × 100 mL). The organic layer was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The remaining residue was dissolved in the minimum volume of hot EtOAc and then cooled to –30 °C to yield 4,6-di-O-benzyl-*myo*-inositol 1,3,5-orthoformate **S1** (7.29 g, 63%) as a colorless solid: *R*_f 0.48 (petroleum ether:EtOAc, 1:1); m.p. 117–119 °C (EtOAc) [lit.⁵ 123–124 °C (EtOAc)]; ¹H NMR (400 MHz; CDCl₃) δ_H 7.31–7.24 (10H, m, H-10 to H-14 and H-17 to H-21), 5.47 (1H, d, *J* 1.0, H-7), 4.67 (2H, d, *J* 11.6, H-8 and H-15), 4.59 (2H, d, *J* 11.6, H-8' and H-15'), 4.48–4.45 (1H, m, H-2), 4.37 (2H, dd, *J* 3.8, 3.8, H-4 and H-6), 4.25–4.18 (3H, m, H-1, H-3 and H-5), 3.00 (1H, d, *J* 11.6, C(2)OH); LRMS *m/z* (ESI⁺) 370.75 ([M+H]⁺ 100%). These data are in good agreement with the literature values.^{5,11}


4,6-Di-O-benzyl-*myo*-inositol **S2**



The protected orthoformate **S1** (3.00 g, 8.10 mmol, 1.0 eq) was dissolved in MeOH (8.1 mL) and PTSA·H₂O (1.54 g, 8.10 mmol, 1.0 eq) was added. The solution was heated to 50 °C and stirred for 50 min. The reaction was then


quenched with Et₃N (1.12 mL, 8.10 mmol, 1.0 eq) and then concentrated *in vacuo*. The residue was purified by column chromatography over silica gel (EtOAc) to yield 4,6-di-*O*-benzyl-*myo*-inositol **S2** as a colorless, fluffy solid (2.82 g, 97%): *R*_f 0.40 (EtOAc); m.p. 130–132 °C (EtOAc), [lit.¹² 138.5–139 °C (hexane:CH₂Cl₂)]; ¹H NMR (400 MHz; CDCl₃) δ_H 7.41–7.29 (10H, m, H-9 to H-13 and H-16 to H-20), 4.91 (2H, d, *J* 11.4, H-7 and H-14), 4.85 (2H, d, *J* 11.4, H-7' and H-14'), 4.15 (1H, dd, *J* 2.9, 2.9, H-5), 3.67 (2H, dd, *J* 9.3, 9.3, H-4 and H-6), 3.59–3.52 (3H, m, H-1, H-2 and H-3), 2.20 (4H, br s, C(1)OH, C(2)OH, C(3)OH and C(5)OH); LRMS *m/z* (ESI⁺) 383.0 ([M+Na]⁺, 100%). These data are in good agreement with the literature values.⁵

(-)-1*D*-1-*O*-Acetyl-4,6-di-*O*-benzyl-*myo*-inositol (-)-**S3**



The immobilized Lipozyme® TL-IM (3.00 g) was added to a solution of 4,6-di-*O*-benzyl-*myo*-inositol **S2** (1.00 g, 2.77 mmol, 1.0 eq) in vinyl acetate (250 mL) and hexane (250 mL). After stirring at 45 °C for 18 h the reaction mixture was filtered through a pad of Celite®, washed with hexane (3 × 20 mL) and the combined filtrates were concentrated *in vacuo* to give (-)-**S3** (1.06 g, 95%, >99% e.e. (other enantiomer not observed) as a colorless solid. The product was deemed to be pure enough, requiring no further purification: *R*_f 0.78 (EtOAc); [α]_D²⁵ -34.4 (c 1.0, MeOH) [lit.⁵ [α]_D²⁵ -39.3 (c 1.0, MeOH)]; m.p. 92–95 °C (EtOAc) [lit. 96–97 °C (EtOAc)]; ¹H NMR (400 MHz; CDCl₃) δ_H 7.40–7.27 (10H, m, H-16 to H-20 and H-9 to H-13), 4.98 (1H, d, *J* 11.4, H-7), 4.86 (1H, dd, *J* 10.2, 2.8, H-1), 4.80 (1H, d, *J* 11.6, H-14), 4.75 (1H, d, *J* 11.6, H-7'), 4.74 (1H, d, *J* 11.6, H-14'), 4.19 (1H, dd, *J* 2.8, 2.8, H-2), 3.92 (1H, dd, *J* 10.2, 9.1, H-6), 3.70 (1H, dd, *J* 9.3, 9.3, H-4), 3.65–3.55 (2H, m, H-5 and H-3), 2.64 (4H, br s, C(5)OH, C(3)OH, C(2)OH), 2.08 (3H, s, H-22); *m/z* LRMS (ESI⁺) found 425.2 ([M+Na]⁺, 100%). These data are in good agreement with the literature values.⁵


(-)-1D-1-O-Acetyl-2,3-O-cyclopentylidene-4,6-di-O-benzyl-*myo*-inositol (-)-S4



To a clear solution of (-)-1D-1-O-acetyl-4,6-di-O-benzyl-*myo*-inositol **S3** (800 mg, 1.99 mmol, 1.0 eq) and 1,1-dimethoxycyclopentane (4.55 mL, 33.2 mmol, 17 eq) in CH₂Cl₂ (5.0 mL) was added PTSA·H₂O (30 mg, 0.16 mmol, 0.080 eq). The resulting solution was stirred at RT for 18 h.

The solution was then quenched with Et₃N (0.020 mL, 0.16 mmol, 0.08 eq) and concentrated *in vacuo*. The residue obtained was purified by column chromatography over silica gel (petroleum ether:EtOAc, 9:1 to 5:5) to give (-)-**S4** (899 mg, 96%) as a pale yellow oil: *R*_f 0.59 (petroleum ether:EtOAc, 9:1 to 5:5); $[\alpha]_D^{25}$ -30.1 (c 1.0, CHCl₃), [lit.⁵ $[\alpha]_D^{25}$ 23.2 (c 1.0, CHCl₃)]; ¹H NMR (400 MHz; CDCl₃) δ_H 7.41–7.25 (10H, m, H-9 to H-13 and H-16 to H-20), 5.18 (1H, dd, *J* 8.4, 3.7, H-1), 4.92 (1H, d, *J* 11.6, H-7), 4.82 (1H, d, *J* 11.6, H-14), 4.75 (1H, d, *J* 11.6, H-14'), 4.71 (1H, d, *J* 11.6, H-7'), 4.33 (1H, dd, *J* 5.6, 3.7, H-2), 4.19–4.15 (1H, m, H-3), 3.84–3.76 (1H, m, H-6), 3.68–3.59 (2H, m, H-5 and H-4), 2.65 (1H, s, C(5)OH), 2.08 (3H, s, H-22), 1.99–1.83 (2H, m, H-24', H-27'), 1.79–1.62 (6H, m, H-25, H-26 and H-24'' and H-27''). These data are in good agreement with the literature values.⁵

(-)-1D-1-O-Acetate-2,3-O-cyclopentylidene-4,6-di-O-benzyl-5-O-(2-oxo-5,6-benzo-1,3,2-dioxaphosphep-2-yl)-*myo*-inositol (-)-S5




To a solution of alcohol (-)-**S4** (400 mg, 0.854 mmol, 1.0 eq) and *N,N*-diethyl-1,5-dihydrobenzo[*e*][1,3,2]dioxaphosphepin-3-amine **17** (613 mg, 2.56 mmol, 3.0 eq) in CH₂Cl₂ (15 mL) was added 1*H*-tetrazole (5.70 mL, 2.56 mmol, 3.0 eq, 0.45 M in MeCN). After stirring at RT for 1 h, the cloudy reaction mixture was cooled to -78

°C and *m*CPBA (574 mg, 2.56 mmol, 3.0 eq, 77%) was added in a single portion. The reaction mixture was gradually warmed to RT over 20 min, stirred for 1 h and then finally quenched with

an aqueous solution of Na₂S₂O₃ (10% w/v, 10 mL). The aqueous layer was extracted with CH₂Cl₂ (4 × 10 mL) and the combined organic layers were washed with an aqueous solution of Na₂S₂O₃ (10% w/v, 3 × 10 mL), brine (30 mL) and then dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Purification by column chromatography over silica gel (petroleum ether:EtOAc, 9:1 to 5:5) afforded **(-)-S5** (512 mg, 93%) as an amorphous, colorless foam: *R_f* 0.13 (petroleum ether:Et₂O, 4:6); $[\alpha]_D^{25}$ -5.9 (c 1.0, CHCl₃), [lit.⁵ $[\alpha]_D^{25}$ -8.1 (c 1.0, CHCl₃)]; ¹H NMR (400 MHz; CDCl₃) δ_H 7.44–7.39 (2H, m, H-9 and H-13), 7.37–7.24 (10H, m, H-10 to H-12, H-16 to H-20, H-32 and H-33), 7.20–7.13 (2H, m, H-31 and H-34), 5.25 (1H, dd, *J* 8.7, 3.6, H-1), 5.22–4.93 (4H, m, H-29 and H-36), 4.86 (1H, d *J* 11.3, H-14), 4.85 (1H, d *J* 11.6, H-7), 4.76 (1H, dd *J* 11.6, H-7'), 4.69 (1H, dd, *J* 11.3, H-14'), 4.67–4.60 (1H, m, H-5), 4.39 (1H, dd, *J* 6.2, 3.6, H-2), 4.23 (1H, dd, *J* 6.2, 6.2, H-3), 4.04 (1H, dd, *J* 8.7, 7.0, H-6), 3.89 (1H, dd, *J* 7.9, 6.0, H-4), 2.05 (3H, s, H-22), 1.99–1.83 (2H, m, H-24 and H-27), 1.75–1.61 (6H, m, H-24', H-25, H-26 and H-27'); ³¹P NMR (162 MHz, CDCl₃) δ_P -0.24; LRMS *m/z* (ESI⁺) 650.7 ([M+H]⁺, 100%). These data are in good agreement with the literature values.⁵


(+)-1D-2,3-O-Cyclopentylidene-4,6-di-O-benzyl-5-O-(2-oxo-5,6-benzo-1,3,2-dioxosphep-2-yl)-myo-inositol (+)-S6



To a solution of acetate **(-)-S5** (660 mg, 1.08 mmol, 1.0 eq) in MeOH (92 mL) was added ground K₂CO₃ (298 mg, 2.16 mmol, 2.0 eq). The reaction mixture was stirred at RT for 1 h. The solvent was then partially removed *in vacuo* at RT and H₂O (30 mL) was added to the resulting residue. The aqueous layer was extracted with EtOAc (4 × 10 mL) and the combined organic layers were washed with brine (40 mL), and then dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Purification using column chromatography over silica gel (petroleum ether:EtOAc, 9:1 to 5:5) afforded alcohol **(+)-S6** (474 mg, 72%) as an amorphous

solid: R_f 0.59 (petroleum ether:EtOAc, 2:8); $[\alpha]_D^{25} +1.6$ (c 1.0, CHCl₃), [lit.⁵ $[\alpha]_D^{25} +3.1$ (c 2.0, CHCl₃)]; ¹H NMR (400 MHz, CD₂Cl₂) δ_H 7.62–7.00 (14H, m, H-9 to H-13, H-16 to H-20, H-29 to H-32), 5.18–5.07 (3H, m, H-27 or H-34, H-27' and H-34'), 5.00 (1H, dd, J 17.8, 13.7, H-27 or H-34), 4.88 (1H, d, J 11.1, H-7 or H-14), 4.87 (1H, d, J 11.4, H-7 or H-14), 4.73 (2H, d, J 11.4, H-7' or H-14'), 4.60–4.50 (1H, m, H-5), 4.33 (1H, dd, J 6.5, 3.7, H-2), 4.23 (1H, dd, J 6.5, 6.5, H-3), 4.04–3.89 (3H, m, H-1, H-5, H-6), 2.55 (1H, d, J 4.1, C(1)OH), 2.00–1.91 (2H, m, H-22 or H-25), 1.82–1.63 (6H, m, H-23, H-24 and H-22 or H-25). ³¹P NMR (162 MHz, CD₂Cl₂) δ_P -1.0; LRMS m/z (ESI⁺) 609.285 ([M+H]⁺, 100%). These data are in good agreement with the literature values.⁵


(-)-[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]methyl octanoate (-)-S7



N,N'-Dicyclohexylcarbodiimide (6.14 g, 30.3 mmol, 2.0 eq) was added to a stirred solution of (*R*)-(-)-2,3-isopropylidene-*sn*-glycerol (-)-**28** (2.00 g, 15.1 mmol, 1.0 eq), octanoic acid (3.09 mL, 15.1 mmol, 1.0 eq) and 4-DMAP (0.11 g, 0.91 mmol, 0.06 eq) in CH₂Cl₂ (45 mL), and was stirred for 16 h. The mixture was then diluted with hexane (20 mL), filtered through Celite® and washed with hexane (3 × 10 mL). The combined filtrates were concentrated *in vacuo* and the residue obtained was purified by column chromatography over silica gel (petroleum ether:EtOAc, 20:1) to yield (-)-**S7** (3.55 g, 91%) as a colorless oil: R_f 0.18 (petroleum ether:EtOAc, 20:1); $[\alpha]_D^{25} -12.0$ (c 1.0, hexane); ν_{\max} (thin film)/cm⁻¹ 2987, 2956, 2930, 2858, 1741, 1457, 1371, 1255, 1215, 1161, 1087, 1057, 843; ¹H NMR (400 MHz, CDCl₃) δ_H 4.36–4.25 (1H, m, H-2), 4.16 (1H, dd, J 11.5, 4.7, H-1), 4.13–4.03 (2H, m, H-1' and H-3), 3.74 (1H, dd, J 8.4, 6.2, H-3'), 2.34 (2H, t, J 7.6, H-6), 1.68–1.57 (2H, m, H-7), 1.43 (3H, s, C(4)CH₃), 1.37 (3H, s, C(4)CH₃), 1.34–1.24 (8H, m, H-8 to H-11), 0.90–0.85 (3H, m, H-12). ¹³C NMR (101 MHz, CDCl₃) δ_C 173.8 (C-5), 110.0 (C-4), 73.8 (C-2), 66.5 (C-3), 64.7 (C-1), 34.3 (C-6), 31.8 (C-10), 29.2, 29.0 (C-8 and C-9), 26.8 (C(4)-CH₃), 25.6 (C(4)-CH₃), 25.0 (C-7), 22.7 (C-11), 14.2 (C-12); LRMS m/z (ESI⁺) 281.198 ([M+Na]⁺, 100%); HRMS m/z (ESI⁺) found


281.1724 [M+Na]⁺ (C₁₄H₂₆O₄Na requires 281.1723 [M+Na]⁺). These data are in good agreement with the literature values.

(+)-(2S)-2,3-Dihydroxypropyl hexadecanoate (+)-S8



To acetone (**-**)-**29** (3.00 g, 8.10 mmol, 1.0 eq), was added 30 mL of a mixture of acetic acid and distilled H₂O (4:1). The reaction mixture was stirred and heated to 50 °C for 2 h. Following complete consumption of the starting material as observed *via* TLC, the reaction mixture was transferred to a conical flask and diluted with distilled H₂O (100 mL). Any solid formed was dissolved *via* the addition of CH₂Cl₂ and vigorous swirling. Solid K₂CO₃ was then slowly added to the resultant biphasic solution with swirling until effervescence ceased. The aqueous layer was then extracted with CH₂Cl₂ (3 × 150 mL) and the combined organic extracts were washed with brine (150 mL), dried over Na₂SO₄, and concentrated *in vacuo*. The resultant colorless solid was then subject to crystallization from EtOAc and heptane to give 2,3-dihydroxypropyl hexadecanoate (**+**)-**S8** as white shiny crystals (2.43 g, 91%): *R*_f 0.31 (petroleum ether:EtOAc, 1:1) m.p. 59–63 °C (hexane:EtOAc), [Lit.⁹ 68.5–69.5 °C (pentane:EtOAc)]; [α]_D²⁵+2.8 (c 3.4, pyridine) [lit.⁵ [α]_D²⁵+3.9 (c 2.9, pyridine)], [lit.⁹[α]_D²³+4.14 (c 2.53, pyridine)]; δ_H (400 MHz, CDCl₃) 4.21 (1H, dd, *J* 11.6, 4.6, H-1), 4.15 (1H, dd, *J* 11.7, 6.1, H-1'), 3.98–3.89 (1H, m, H-2), 3.75–3.66 (1H, m, H-3), 3.60 (1H, dd, *J* 11.4, 5.7, H-3'), 2.49–2.42 (1H, br s, C(2)OH), 2.35 (2H, t, *J* 7.6, H-5), 2.01 (1H, br s, C(3)OH), 1.68–1.58 (2H, m, H-6), 1.36–1.22 (24H, m, H-7 to H-18) 0.91–0.84 (3H, t, *J* 6.7, H-19); LRMS *m/z* (ESI⁺) 353.309 ([M+Na]⁺, 100%); These data are in good agreement with the literature values.⁹


(+)-(2S)-2,3-Dihydroxypropyl octanoate (+)-S9



To acetonide **(-)-S7** (3.00 g, 11.6 mmol, 1.0 eq), was added 30 mL of a mixture of acetic acid and distilled H₂O (4:1). The reaction mixture

was stirred and heated to 50 °C for 2 h. Following complete consumption of the starting material as observed *via* TLC, the reaction mixture was transferred to a conical flask and diluted with distilled H₂O (100 mL). Any solid formed was dissolved *via* the addition of CH₂Cl₂ and vigorous swirling. Solid K₂CO₃ was then slowly added to the resultant biphasic solution with swirling until effervescence ceased. The aqueous layer was then extracted with CH₂Cl₂ (3 × 150 mL) and the combined organic extracts were washed with brine (150 mL), dried over Na₂SO₄, and concentrated *in vacuo* to give diol **(+)-S9** (2.51 g, 99%) as a colorless oil with no need for further purification: *R*_f 0.25 (petroleum ether:EtOAc, 1:1); $[\alpha]_D^{25} +0.45$ (c 3.1, pyridine); ν_{\max} (thin film)/cm⁻¹ 2956, 2926, 2857, 1737, 1169, 1109, 1049; ¹H NMR (400 MHz, CDCl₃) δ_H 4.20 (1H, dd, *J* 11.7, 4.7, H-1), 4.15 (1H, dd, *J* 11.7, 6.1, H-1'), 3.97–3.89 (1H, m, H-2), 3.70 (1H, dd, *J* 11.5, 4.0, H-3), 3.60 (1H, dd, *J* 11.5, 5.8, H-3'), 2.57 (1H, s, C(2)OH), 2.35 (2H, t, *J* 7.6, H-5), 2.14 (1H, s, C(3)OH), 1.69–1.57 (2H, m, H-6), 1.36–1.22 (8H, m, H-7 to H-10), 0.92–0.84 (3H, m, H-11); ¹³C NMR (101 MHz, CDCl₃) δ_C 174.5 (C-4), 70.4 (C-2), 65.3 (C-1), 63.5 (C-3), 34.3 (C-5), 31.8, 29.2, 29.0, 25.1, 22.7 (C-6 to C-10), 14.2 (C-11); LRMS *m/z* (ESI⁺) 241.0 ([M+Na]⁺, 100%); HRMS *m/z* (ESI⁺) found 241.1411 [M+Na]⁺ (C₁₁H₂₂O₄Na requires 241.1410 [M+Na]⁺).

(+)-(2S)-3-[Bis(4-methoxyphenyl)(phenyl)methoxy]-2-hydroxypropyl hexadecanoate (+)-S10




To a solution of diol **(+)-S8** (1.50 g, 4.54 mmol, 1.0 eq) in anhydrous pyridine (45 mL) was added 4,4'-dimethoxytrityl chloride (1.85 g, 5.45 mmol, 1.2 eq) in one

portion. After 50 min stirring at RT, the yellow solution was concentrated *in vacuo* at RT. The

residue obtained was purified by column chromatography over silica gel (petroleum ether:EtOAc, 95:5 to 80:20) to give **(+)-S10** (2.24 g, 78%) as a green-tinted oil: R_f 0.54 (petroleum ether:EtOAc, 8:2); $[\alpha]_D^{25} +2.4$ (c 1.0, CHCl₃); ν_{\max} (thin film)/cm⁻¹ 2924, 2853, 1737, 1608, 1509, 1251, 1177, 1036, 829; ¹H NMR(400 MHz, CDCl₃) δ_H 7.44–7.39 (2H, m, H-22 and H-26), 7.34–7.26 (6H, m, H-23, H-25, H-H-28, H-32, H-35, H-39), 7.25–7.16 (1H, m, H-24), 6.86–6.80 (4H, m, H-29, H-31, H-36, H-38), 4.21 (1H, dd, J 11.5, 4.4, H-1), 4.16 (1H, dd, J 11.5, 6.1, H-1'), 4.03–3.94 (1H, m, H-2), 3.79 (6H, s, H-33 and H-40), 3.25–3.17 (2H, m, H-3), 2.40 (1H, d, J 5.2, C(2)OH), 2.29 (2H, t, J 7.6, H-5), 1.63–1.53 (2H, m, H-6), 1.35–1.21 (24H, m, H-7 to H-18), 0.92–0.84 (3H, m, H-19). ¹³C NMR (101 MHz, CDCl₃) δ_C 174.1 (C-4), 158.7 (C-30 and C-37), 144.7 (C-21), 135.9 (C-27 and C-34), 130.2 (C-28, C-32, C-35 and C-39), 128.2 (C-22 and C-26), 128.0 (C-23 and C-25), 127.0 (C-24), 113.3 (C-29, C-31, C-36 and C-38), 86.4 (C-20), 69.5 (C-2), 65.9 (C-1), 64.2 (C-3), 55.4 (C-33 and C-40), 34.3 (C-5), 32.1 (C-17), 29.84, 29.80, 29.79, 29.6, 29.5, 29.4, 29.3 (C-7 to C-16), 25.0 (C-6), 22.8 (C-18), 14.3 (C-19); LRMS m/z (ESI⁺) 655.473 ([M+Na]⁺, 100%); HRMS m/z (ESI⁺) found 655.3965 [M+Na]⁺ (C₄₀H₅₆O₆Na requires 655.3969 [M+Na]⁺).


(+)-(2S)-3-[Bis(4-methoxyphenyl)(phenyl)methoxy]-2-hydroxypropyl octanoate (+)-S11



To a solution of diol **(+)-S9** (1.50 g, 6.87 mmol, 1.0 eq) in anhydrous pyridine (69 mL) was added 4,4'-dimethoxytrityl chloride (2.79 g, 8.24 mmol, 1.2 eq) in one portion. After 50 min stirring at RT, the yellow solution was concentrated *in vacuo* at RT. The residue obtained was purified by column chromatography over silica gel (petroleum ether:EtOAc, 10:0 to 8:2) to give alcohol **(+)-S11** (2.83 g, 79%) as a green-tinted oil: R_f 0.54 (petroleum ether:EtOAc, 8:2); $[\alpha]_D^{25} +3.1$ (c 1.0, CHCl₃); ν_{\max} (thin film)/cm⁻¹ 2929, 2857, 1736, 1608, 1509, 1250, 1176, 1035, 829; ¹H NMR (400 MHz, CDCl₃) δ_H 7.44–7.39 (2H, m, H-14, H-16), 7.34–7.26 (6H, m, H-15, H-17, H-20, H-25, H-28, H-32), 7.24–7.19

(1H, m, H-16), 6.86–6.80 (4H, m, H-22, H-24, H-29, H-31), 4.21 (1H, dd, J 11.5, 4.4, H-1), 4.16 (1H, dd, J 12.1, 5.6, H-1'), 4.02–3.94 (1H, m, H-2), 3.79 (6H, s, H-26, H-33), 3.22 (1H, dd, J 9.6, 5.0, H-3), 3.19 (1H, dd, J 9.6, 5.6, H-3'), 2.42 (1H, d, J 5.2, C(2)OH), 2.29 (2H, t, J 7.6, H-5), 1.64–1.53 (2H, m, H-6), 1.35–1.22 (8H, m, H-7 to H-10), 0.88 (3H, t, J 6.8, H-11); ^{13}C NMR (101 MHz, CDCl_3) δ_{C} 174.1 (C-4), 158.7 (C-23, C-30), 144.7 (C-13), 135.9 (C-19, C-27), 130.2 (C-20, C-25, C-28, C-32), 128.2 (C-14, C-18), 128.0 (C-15, C-17), 127.0 (C-16), 113.3 (C-22, C-24, C-29, C-31), 86.4 (C-12), 69.5 (C-2), 65.9 (C-1), 64.2 (C-3), 55.4 (C-26, C-33), 34.3 (C-5), 31.8, 29.2, 29.0 (C-7 to C-9), 25.0 (C-6), 22.7 (C-10), 14.2 (C-11); LRMS m/z (ESI $^+$) 543.348 ([M+Na] $^+$, 100%); HRMS m/z (ESI $^+$) found 543.2714 [M+Na] $^+$ ($\text{C}_{32}\text{H}_{40}\text{O}_6\text{Na}$ requires 543.2717 [M+Na] $^+$).


(+)-(2S)-3-[Bis(4-methoxyphenyl)(phenyl)methoxy]-2-(octanoyloxy)propyl hexadecanoate (+)-S12



To a solution of alcohol **(+)-S10** (1.00 g, 1.58 mmol, 1.0 eq) in CH_2Cl_2 (20 mL) was added DCC (392 mg, 1.90 mmol, 1.2 eq), 4-DMAP (12 mg, 0.10 mmol, 0.06 eq) and octanoic acid (0.25 mL, 1.6 mmol, 1.0 eq). The solution was stirred at RT for 18 h, after which the reaction mixture was diluted with hexane (20 mL). The suspension was filtered through celite, and the celite was subsequently washed with hexane (3×10 mL). The combined filtrates were concentrated *in vacuo* at RT. The resulting residue was purified by column chromatography over silica gel (petroleum ether:EtOAc, 100:0, to 92:8) which yielded **(+)-S12** (1.01 g, 84%) as a colorless oil: R_f 0.50 (petroleum ether:EtOAc 9:1); $[\alpha]_D^{25} +14.6$ (c 1.0, CHCl_3); ν_{max} (thin film)/ cm^{-1} 2925, 2854, 1742, 1608, 1509, 1251, 1176, 1037, 829; ^1H NMR(400 MHz, CDCl_3) δ_{H} 7.45–7.39 (2H, m, H-22 and H-26), 7.34–7.24 (6H, m, H-23, H-25, H-28, H-32, H-35, H-39), 7.24–7.18 (1H, m, H-24), 6.86–6.79 (4H, m, H-29, H-31, H-36, H-38), 5.30–5.22 (1H, m, H-2), 4.34 (1H, dd, J

11.9, 3.7, H-1), 4.23 (1H, dd, J 11.9, 6.7, H-1'), 3.79 (6H, s, H-33, H-40), 3.23 (1H, d, J 1.6, H-3), 3.22 (1H, d, J 1.9, H-3'), 2.33 (2H, td, J 7.4, 1.0, H-5), 2.24 (2H, td, J 8.0, 7.1, H-42), 1.69–1.49 (4H, m, H-6, H-43), 1.39–1.20 (32H, m, H-7 to H-18 and H-44 to H-47), 0.89 (2H, t, H-48), 0.88 (3H, t, H-19). ^{13}C NMR (101 MHz, CDCl_3) δ_{C} 173.5, 173.2 (C-4, C-41), 158.7 (C-30 and C-37), 144.7 (C-21), 135.89, 135.86 (C-27, C-34), 130.14, 130.11 (C-28, C-32, C-35, C-39), 128.22, 127.94 (C-22, C-23, C-25, C-26), 127.0 (C-24), 113.3 (C-29, C-31, C-35, C-39), 86.2 (C-20), 70.6 (C-2), 63.1 (C-1), 62.2 (C-3), 55.3 (C-33, C-40), 34.6, 34.3 (C-5, C-42), 32.1, 31.8 (C-17, C-46), 29.83, 29.79, 29.62, 29.49, 29.47, 29.3, 29.2, 29.1 (C-7 to C-16 and C-44 and C-45), 25.1, 25.0 (C-6, C-43), 22.8, 22.8, (C-18, C-47), 14.3, 14.2 (C-19, C-48); LRMS m/z (ESI $^+$) 781.591 ([M+Na] $^+$, 100%); HRMS m/z (ESI $^+$) found 781.5010 [M+Na] $^+$ ($\text{C}_{48}\text{H}_{70}\text{O}_7\text{Na}$ requires 781.5014 [M+Na] $^+$).


(+)-(2S)-1-[Bis(4-methoxyphenyl)(phenyl)methoxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (+)-S13



To a solution of alcohol **(+)-S11** (1.00 g, 1.92 mmol, 1.0 eq) in CH_2Cl_2 (20 mL) was added DCC (475 mg, 2.30 mmol, 1.2 eq), 4-DMAP (14 mg, 0.12 mmol, 0.06 eq) and palmitic acid (492 mg, 1.92 mmol, 1.0 eq). The solution was stirred at RT for 18 h, after which the reaction mixture was diluted with hexane (20 mL). The suspension was filtered through celite, and the celite subsequently washed with hexane (3×10 mL). The combined filtrates were concentrated *in vacuo* at RT. The resulting residue was purified by column chromatography over silica gel (petroleum ether:EtOAc, 10:0 to 9:1) which yielded **(+)-S13** (1.00 g, 69%) as a colorless oil: R_f 0.50 (petroleum ether:EtOAc, 9:1); $[\alpha]_D^{25} +12.9$ (c 1.0, CHCl_3); ν_{max} (thin film)/ cm^{-1} 2925, 2854, 1742, 1608, 1509, 1251, 1176, 1037, 829; ^1H NMR (400 MHz, CDCl_3) δ_{H} 7.44–7.39 (2H, m, H-30, H-34), 7.29 (6H, m, H-31, H-33, H-36, H-40, H-43, H-47), 7.23–7.17 (1H, m, H-32), 6.85–

6.79 (4H, m, H-37, H-39, H-44, H-46), 5.29–5.22 (1H, m, H-2), 4.34 (1H, dd, J 11.8, 3.7, H-1), 4.23 (1H, dd, J 11.8, 6.7, H-1'), 3.79 (6H, s, H-41, H-48), 3.24 (1H, dd, J 10.0, 4.9, H-3), 3.21 (1H, dd, J 10.0, 5.1, H-3'), 2.36–2.30 (2H, m, H-5 or H-13), 2.26–2.21 (2H, m, H-5 or H-13), 1.68–1.50 (4H, m, H-6, H-14), 1.36–1.22 (32H, m, H-7 to H-10, and H-15 to H-26), 0.91–0.86 (6H, m, H-11 and H-27); ^{13}C NMR (101 MHz, CDCl_3) δ_{C} 173.5, 173.2 (C-4, C-12), 158.6 (C-38 and C-35), 144.7 (C-29), 135.89, 135.86 (C-35, C-42), 130.13, 130.12, (C-36, C-40, C-43, C-47), 128.2, 127.9 (C-37, C-39, C-43, C-47), 127.0 (C-32), 113.3 (C-38, C-40, C-45, C-47), 86.2 (C-28), 70.6 (C-2), 63.1 (C-1), 62.2 (C-3), 55.3 (C-41, C-48), 34.6, 34.3 (C-5, C-13), 32.1, 31.8 (C-9, C-25), 29.83, 29.78, 29.6, 29.49, 29.47, 29.3, 29.2, 29.1 (C-7, C-8, C-15 to C-24), 25.1, 25.0 (C-6, C-14), 22.8, 22.7 (C-10, C-26), 14.3, 14.2 (C-11, C-27); LRMS m/z (ESI $^+$) 781.604 ([M+Na] $^+$, 100%); HRMS m/z (ESI $^+$) found 781.5009 [M+Na] $^+$ ($\text{C}_{48}\text{H}_{70}\text{O}_7\text{Na}$ requires 781.5014 [M+Na] $^+$).

(-)-(2S)-3-Hydroxy-2-(octanoyloxy)propyl hexadecanoate (-)-S14




Aqueous acetic acid (AcOH:H₂O, 4:1 v/v, 5 mL) was added to **(+)-S12** (800 mg, 1.05 mmol, 1.0 eq) and stirred vigorously. CH₂Cl₂ was then added dropwise

until the biphasic mixture homogenized and became bright orange. The mixture was then stirred further at 50 °C for 2 h. Complete consumption of the starting material was monitored *via* TLC. The solution was then cooled to RT and concentrated *in vacuo*. The resulting residue was then purified *via* column chromatography over silica gel (petroleum ether:EtOAc, 100:0 to 84:16) yielding alcohol **(-)-S14** (387 mg, 81%, ~94% e.e.) which crystalized under a stream of nitrogen from EtOAc to form a colorless solid: R_f 0.34 (petroleum ether:EtOAc, 9:1); $[\alpha]_D^{25}$ -4.5 (c 1.0, CHCl_3); m.p. 27–28 °C (EtOAc); ν_{max} (thin film)/ cm^{-1} 2924, 2854, 1742, 1466, 1164, 1108, 1052, 723; ^1H NMR (400 MHz, CDCl_3) δ_{H} 5.08 (1H, m, H-2), 4.32 (1H, dd, J 12.0, 4.5, H-1), 4.24 (1H, dd, J 12.0, 5.6, H-1'), 3.75–3.71 (2H, m), 2.35 (2H, t, J 7.5, H-5), 2.32 (2H, t, J 7.5, H-21), 2.01

(1H, t, *J* 6.5, C(3)OH), 1.68–1.57 (4H, m, H-6, H-22), 1.37–1.20 (32H, m, H-7 to H-18 and H-23 to H-26), 0.92–0.84 (6H, m, H-19, H-27); ¹³C NMR (101 MHz, CDCl₃) δ_C 173.9, 173.6 (C-4, C-20), 72.3 (C-2), 62.1 (C-3), 61.8 (C-1), 34.4, 34.3 (C-5, C-21), 32.1, 31.8 (C-17, C-25), 29.85, 29.81, 29.77, 29.6, 29.5, 29.4, 29.3, 29.2 (C-7 to C-16, C-23, C-24), 25.1, 25.0 (C-6, C-22), 22.8, 22.7 (C-18, C-26), 14.3, 14.2 (C-19, C-27); LRMS *m/z* (ESI⁺) 479.443 ([M+Na]⁺, 100%); HRMS *m/z* (ESI⁺) found 479.3708 [M+Na]⁺ (C₂₇H₅₂O₅Na requires 479.3707 [M+Na]⁺); The e.e. of (–)-**S14** was calculated by ¹H NMR using a chiral auxiliary (see **Figure S1**).


(2S)-1-Hydroxy-3-(octanoyloxy)propan-2-yl hexadecanoate (–)-**S15**



Aqueous acetic acid (AcOH:H₂O, 4:1 v/v, 5 mL) was added to (+)-**S13** (800 mg, 1.05 mmol, 1.0 eq) and stirred vigorously. CH₂Cl₂ was then added dropwise until the biphasic mixture homogenized and became bright orange. The mixture was then stirred further at 50 °C for 2 h. Complete consumption of the starting material was monitored *via* TLC. The solution was then cooled to RT and concentrated in *vacuo*. The resulting residue was then purified *via* column chromatography over silica gel (petroleum ether:EtOAc, 100:0, 84:16) yielding alcohol (–)-**S15** (389 mg, 81%, ~90% e.e.) which crystallized under a stream of nitrogen from EtOAc to form a colorless solid: *R*_f 0.37 (petroleum ether:EtOAc, 9:1); [α]_D²⁵ –3.8 (c 1.0, CHCl₃); m.p. 26–28 °C (EtOAc); ν_{max} (thin film)/cm^{–1} 2924, 2854, 1742, 1466, 1164, 1109, 1051, 723; ¹H NMR (400 MHz, CDCl₃) δ_H 5.11–5.05 (1H, m, H-2), 4.32 (1H, dd, *J* 12.0, 4.5, H-1), 4.24 (1H, dd, *J* 12.0, 5.7, H-1'), 3.75–3.71 (2H, m, H-3), 2.37–2.29 (4H, m, H-5, H-13), 2.02 (1H, t, *J* 6.5, C(3)OH), 1.68–1.57 (4H, m, C-6, C-14), 1.37–1.21 (34H, m, H-7 to H-10 and H-15 to H-26), 0.92–0.85 (6H, m, H-11, H-27); ¹³C NMR (101 MHz, CDCl₃) δ_C 173.9, 173.6 (C-4, C-12), 72.3 (C-2), 62.1 (C-3), 61.7 (C-1), 34.5, 34.3 (C-5, C-13), 32.1, 31.8 (C-9, C-25), 29.84, 29.80, 29.77, 29.6, 29.5, 29.4, 29.24, 29.22, 29.1 (C-7, C-8, C-15 to C-24), 25.1, 25.0 (C-6, C-14), 22.8, 22.7 (C-10, C-26), 14.3, 14.2

(C-11, C-27); LRMS m/z (ESI⁺) 935.83 ([2M+Na]⁺, 100%); HRMS m/z (ESI⁺) found 479.3706 [M+Na]⁺ (C₂₇H₅₂O₅Na requires 479.3707 [M+Na]⁺); The e.e. of (–)-**S15** was calculated by ¹H NMR using a chiral auxiliary (see **Figure S1**).


(+)-(2R)-3-((Benzyloxy)[di(propan-2-yl)amino]phosphanyl)oxy-2-(octanoyloxy)propyl hexadecanoate (+)-S16



To a solution of benzyloxy-bis(*N,N*-diisopropylamino) phosphine **33** (558 mg, 1.65 mmol, 3.0 eq) in anhydrous CH₂Cl₂ (6 mL) was added 1*H*-tetrazole (3.70 mL, 1.65 mmol, 3.0 eq, 0.45 M in MeCN). The solution was stirred for 10 min, after which, alcohol (–)-**S14** (250 mg, 0.547 mmol, 1.0 eq) was added in a single batch. The reaction mixture was stirred at RT for 18 h, then diluted with CH₂Cl₂ (10 mL), and was then quenched by the addition of a saturated aqueous solution of NaHCO₃ (10 mL). The organic phase was extracted with CH₂Cl₂ (3 × 10 mL). The combined organic layers were washed with brine (20 mL), dried over MgSO₄, filtered, and then concentrated *in vacuo*. The residue obtained was purified by column chromatography over silica gel (hexane:EtOAc:Et₃N, 85:10:5) to give phosphoramidite (+)-**S16** (415 mg, >99%) as a colorless viscous oil, containing a mixture of two diastereoisomers. Due to its unstable nature, this phosphoramidite was synthesized fresh before each use and was used without further characterization: *R*_f 0.75 (petroleum ether:EtOAc:Et₃N, 85:10:5); [α]_D²⁵ +7.9 (c 1.0, CHCl₃); ν_{max} (thin film)/cm⁻¹ 2962, 2925, 2854, 1743, 1457, 976; ¹H NMR (400 MHz, CDCl₃) δ_H 7.40–7.22 (10H, m, H-33, H-34, H-35, H-36, H-37, Diast. A and B), 5.23–5.14 (2H, m, H-2, Diast. A and B), 4.81–4.61 (4H, m, H-31, Diast. A and B), 4.38–4.30 (2H, m, H-1, Diast. A and B), 4.21–4.13 (2H, m, H-1', Diast. A and B), 3.83–3.58 (8H, m, H-3, H-29, H-30, Diast. A and B), 2.32–2.26 (8H, m, H-5, H-21, Diast. A and B), 1.66–1.56 (8H, m, H-6, H-22, Diast. A and B), 1.34–1.23 (64H, m, H-7 to H-18 and H-23 to H-26, Diast. A and B),

1.21–1.16 (24H, m, 2×C(29)CH₃, 2×C(30)CH₃, Diast. A and B), 0.91–0.84 (12H, m, H-19, H-27, Diast. A and B); ³¹P NMR (162 MHz, CDCl₃) δ_P 148.8 (P-28, Diast. A), 148.7 (P-28, Diast. B); LRMS *m/z* (ESI⁺) 694.575 ([M+H]⁺, 62%); HRMS *m/z* (ESI⁺) found 694.5164 [M+H]⁺ (C₄₀H₇₃NO₆P requires 694.5170 [M+H]⁺).

(+)-(7*R*)-4-(Benzyloxy)-2-methyl-10-oxo-3-(propan-2-yl)-5,9-dioxo-3-aza-4-phosphoheptadecan-7-yl hexadecanoate (+)-S17




To a solution of benzyloxy-bis(*N,N*-diisopropylamino) phosphine **33** (558 mg, 1.65 mmol, 2.5 eq) in anhydrous CH₂Cl₂

(7 mL) was added 1*H*-tetrazole (4.40 mL, 1.98 mmol, 3.0 eq, 0.45 M in MeCN). The solution was stirred for 10 min, after which, a solution of alcohol (–)-**S15** (300 mg, 0.657 mmol, 1.0 eq) in anhydrous CH₂Cl₂ (18 mL) was added dropwise. The reaction mixture was stirred at RT for 18 h, then diluted with CH₂Cl₂ (10 mL), and was then quenched by the addition of a saturated aqueous solution of NaHCO₃ (10 mL). The organic phase was extracted with CH₂Cl₂ (3 × 10 mL). The combined organic layers were washed with brine (30 mL), dried over MgSO₄, filtered, and then concentrated *in vacuo*. The residue obtained was purified by column chromatography over silica gel (hexane:EtOAc:Et₃N, 85:10:5) to give phosphoramidite (+)-**S17** (420 mg, 92%) as a colorless viscous oil, containing a mixture of two diastereoisomers. Due to its unstable nature, this phosphoramidite was synthesized fresh before each use and used without further characterization: *R_f* 0.75 (petroleum ether:EtOAc:Et₃N, 85:10:5); [α]_D²⁵ +6.9 (c 1.0, CHCl₃); ν_{max} (thin film)/cm⁻¹ 2963, 2926, 2855, 1743, 1457, 976; ¹H NMR (400 MHz, CDCl₃) δ_H 7.39–7.22 (10H, m, H-33, H-34, H-35, H-36, H-37, Diast. A and B), 5.24–5.15 (2H, m, H-2, Diast. A and B), 4.81–4.61 (4H, m, H-31, Diast. A and B), 4.36 (1H, dd, *J* 8.5, 3.8, H-1' Diast. A), 4.33 (1H, dd, *J* 8.5, 3.8, H-1', Diast. B), 4.19 (1H, dd, *J* 6.3, 5.0, H-1'' Diast. A), 4.16 (1H, dd, *J* 6.3, 5.0, H-1'' Diast. B), 3.83–3.58 (8H, m, H-3, H-29, H-30, Diast. A and B), 2.33–2.26 (8H, m, H-5, H-21, Diast. A and B), 1.66–1.55 (8H, m, H-6, H-14, Diast. A and B), 1.35–1.23 (64H, m, H-7 to H-10 and H-15

to H-26, Diast. A and B), 1.21–1.16 (24H, m, 2×C(29)CH₃, 2×C(30)CH₃), 0.92–0.84 (12H, m, H-11, H-28, Diast. A and B). ³¹P NMR (162 MHz, CDCl₃) δ_P 148.8 (P-28, Diast. A), 148.7 (P-28, Diast. B); LRMS *m/z* (ESI⁺) 694.549 ([M+H]⁺, 86%).

(+)-(2*R*)-3-[[[(Benzyloxy){(3*aR*,4*S*,5*R*,6*S*,7*R*,7*aR*)-5,7-bis(benzyloxy)-6-[(3-oxo-1,5-dihydro-3*H*-2,4,3^λ5-benzodioxaphosphepin-3-yl)oxy]hexahydrospiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl]oxy]phosphoryl]oxy}-2-(octanoyloxy)propyl hexadecanoate (+)-S18




To a solution of phosphoramidite **(+)-S16** (270 mg, 0.387 mmol, 3.0 eq) in anhydrous CH₂Cl₂ (6 mL) was added 1*H*-tetrazole (0.86 mL, 0.39 mmol, 3.0 eq, 0.45 M in

MeCN). After 10 min, protected inositol **(+)-S6** (78 mg, 0.13 mmol, 1 eq) was added as a single batch to the cloudy reaction mixture, and the mixture was stirred at RT for a further 18 h. The reaction mixture was then cooled to –78 °C and *m*CPBA (66 mg, 0.39 mmol, 3.0 eq, 77%) was added in one portion. The reaction mixture was stirred for 1 h, warmed to RT, stirred for a further 3 h, and then quenched by the addition of an aqueous solution of Na₂S₂O₃ (10% w/v, 6 mL). After stirring for 15 min, the aqueous phase was extracted with CH₂Cl₂ (4 × 5 mL) and the combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, filtered, and then concentrated *in vacuo*. Purification by column chromatography over silica gel (petroleum ether:EtOAc, 10:0 to 5:5) yielded **(+)-S18** (128 mg, 81%) as a colorless, amorphous solid containing a mixture of two diastereoisomers: *R_f* 0.34 (petroleum ether:EtOAc, 5:5); [α]_D^{25.6} +2.48 (*c* 1.0, CHCl₃); ν_{max} (thin film)/cm⁻¹ 2954, 2925, 2854, 1743, 1338, 1013, 735, 698; ¹H NMR (600 MHz, CD₂Cl₂) δ_H 7.43–7.25 (32H, m, H-9 to H-13, H-16 to H-20, H-38 to H-42, H-30 and H-31 Diast. A and B), 7.23–7.20 (4H, m, H-29 and H-32 Diast. A and B), 5.20–5.15 (1H, m, H-44 Diast. A), 5.12–4.93 (13H, m, H-44 Diast. B, H-27, H-34, H-36 Diast. A and B), 4.86–4.81 (4H, m, H-7, H-14 Diast. A and B), 4.76–4.71 (4H, m, H-7', H-14' Diast. A and B), 4.71–4.66 (2H, m, H-1 Diast.

A and B), 4.63–4.57 (2H, m, H-5 Diast. A and B), 4.49 (1H, dd, J 6.3, 3.7, H-2 Diast. A), 4.47 (1H, dd, J 6.3, 3.7, H-2 Diast. B), 4.27–4.22 (3H, m, H-3 Diast. A and B, H-45 Diast. A), 4.19–4.04 (7H, m, H-45' Diast. A, H-45 Diast. B, H-43 Diast. A and B, H-43' Diast. A, H-6 Diast. A and B), 4.01 (1H, ddd, J 11.0, 6.5, 4.2, H-43' Diast. B), 3.95 (1H, dd, J 12.0, 6.0, H-45' Diast. B), 3.91–3.87 (2H, m, H-4 Diast. A and B), 2.31–2.20 (8H, m, H-47, H-55 Diast. A and B), 2.01–1.89 (4H, m, H-22, H-25 Diast. A and B), 1.76–1.50 (20H, m, H-22', H-25' Diast. A and B, H-23, H-24, H-48, H-56 Diast. A and B), 1.32–1.22 (64H, m, H-49 to H-52, H-57 to H-68 Diast. A and B), 0.88 (6H, t, J 7.0, H-53 or H-69 Diast. A and B), 0.87 (6H, t, J 7.0, H-53 or H-69 Diast. A and B); ^{13}C NMR (151 MHz, CD_2Cl_2) δ_{C} 173.42, 173.38 (C-54 Diast. A and B), 173.1, 173.0 (C-46 Diast. A and B), 138.5, 138.40, 138.35 (C-8, C-15 Diast. A and B), 136.27 (d, J 7.8, C-37 Diast. A), 136.21 (d, J 7.6, C-37 Diast. B), 135.84, 135.79 (C-28, C-33 Diast. A and B), 129.38, 129.36, 129.1, 128.99, 128.96, 128.93, 128.9, 128.7, 128.6, 128.38, 128.35, 128.32, 128.27, 128.1, 128.06 (t, J 2.8) (C-9 to C-13, C-16 to C-20, C-29 to C-32, C-38 to C-42 Diast. A and B), 120.5 (C-21 Diast. A and B), 80.49, 80.45 (C-5 Diast. A and B), 79.59, 79.57 (C-4 Diast. A and B), 78.69–78.45 (mp, C-6 Diast. A and B), 77.7 (C-3 Diast. A and B), 75.64 (t, J 5.8, C-1 Diast. A and B), 74.6 (C-2, C-7 Diast. A and B), 73.5 (C-14 Diast. A and B), 69.89 (d, J 2.7, C-36 Diast. A), 69.86 (d, J 2.7, C-36 Diast. B), 69.68 (t, J 7.3, C-44 Diast. A and B), 68.73, 68.68 (C-27 and C-34 Diast. A and B), 66.07 (d, J 5.3, C-43 Diast. A), 65.94 (d, J 5.3, C-43 Diast. B), 62.0 (C-45 Diast. A), 61.9 (C-45 Diast. B), 36.9, 36.80, 36.77 (C-22, C-25 Diast. A and B), 34.5, 34.4, 34.34, 34.32 (C-47, C-55 Diast. A and B), 32.3, 32.1, 30.12, 30.10, 30.07, 29.9, 29.8, 29.7, 29.5, 29.44, 29.42, 29.4 (C-49, C-50, C-57 to C-66 Diast. A and B), 25.3, 25.23, 25.20 (C-48, C-56 Diast. A and B), 24.25, 24.22, 23.6 (C-23, C-24 Diast. A and B), 23.1, 23.0 (C-52, C-68 Diast. A and B), 14.29, 14.25 (C-53, C-69 Diast. A and B). ^{31}P NMR (243 MHz, CD_2Cl_2) δ_{P} -0.9 (P-26), -1.8 (P-35 Diast. A), -1.9 (P-35 Diast. B); LRMS m/z (ESI $^+$) 1217.63 ([M+H] $^+$, 100%); HRMS m/z (ESI $^+$) found 1239.5873 [M+Na] $^+$ ($\text{C}_{67}\text{H}_{94}\text{O}_{16}\text{P}_2\text{Na}$ requires 1239.5909 [M+Na] $^+$); NP-HPLC t_{R} = 4.66 min (Diast. A), 5.19 (Diast. B.), 99.7% @ 254 nm, 99.0% @ 220 nm.

(+)-(6R)-3-({(3aR,4S,5R,6S,7R,7aR)-5,7-Bis(benzyloxy)-6-[(3-oxo-1,5-dihydro-3H-2,4,3^λ5-benzodioxaphosphepin-3-yl)oxy]hexahydrospiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl}oxy)-3,9-dioxo-1-phenyl-2,4,8-trioxo-3^λ5-phosphahexadecan-6-yl hexadecanoate (+)-S19




To a solution of phosphoramidite **(+)-S17** (270 mg, 0.387 mmol, 3.0 eq) in anhydrous CH₂Cl₂ (6 mL) was added 1*H*-tetrazole (0.86 mL, 0.39 mmol, 3.0 eq, 0.45 M in MeCN). After 10 min, inositol

(+)-S6 (78 mg, 0.13 mmol, 1.0 eq) was added as a single batch to the cloudy reaction mixture, and the mixture was stirred at RT for a further 18 h. The reaction mixture was then cooled to -78 °C and *m*CPBA (66 mg, 0.39 mmol, 3.0 eq, >77%) was added in one portion. The reaction mixture was stirred for 1 h, warmed to RT, stirred for a further 3 h, and then quenched by the addition of an aqueous solution of Na₂S₂O₃ (10% w/v, 5 mL). After stirring for 15 min, the aqueous phase was extracted with CH₂Cl₂ (4 × 5 mL) and the combined organic layers were washed with brine (15 mL), dried over Na₂SO₄, filtered, and then concentrated *in vacuo*. Purification by column chromatography over silica gel (petroleum ether:EtOAc, 10:0 to 5:5) yielded **(+)-S19** (137 mg, 88%) as a colorless, amorphous solid containing a mixture of two diastereoisomers: *R_f* 0.34 (petroleum ether:EtOAc, 5:5); $[\alpha]_D^{25} +2.09$ (c 1.0, CHCl₃); ν_{\max} (thin film)/cm⁻¹ 2925, 2854, 1743, 1338, 1014, 735, 698; ¹H NMR (600 MHz, CD₂Cl₂) δ_H 7.45–7.24 (34H, m, H-9 to H-13, H-16 to H-20, H-38 to H-42, H-30 and H-31 Diast. A and B), 7.24–7.19 (4H, m, H-29 and H-32 Diast. A and B), 5.20–5.15 (1H, m, H-44 Diast. A), 5.12–4.92 (13H, m, H-44 Diast. B, H-27, H-34, H-36 Diast. A and B), 4.86–4.81 (4H, m, H-7, H-14 Diast. A and B), 4.76–4.71 (4H, m, H-7', H-14' Diast. A and B), 4.71–4.66 (2H, m, H-1 Diast. A and B), 4.63–4.57 (2H, m, H-5 Diast. A and B), 4.49 (1H, dd, *J* 6.4, 3.8, H-2 Diast. A), 4.47 (1H, dd, *J* 6.3, 3.7, H-2 Diast. B), 4.27–4.22 (3H, m, H-3 Diast.

A and B, H-45 Diast. A), 4.19–4.05 (7H, m, H-45' Diast. A, H-45 Diast. B, H-43 Diast. A and B, H-43' Diast. A, H-6 Diast. A and B), 4.01 (1H, ddd, J 10.9, 6.5, 4.1, H-43' Diast. B), 3.95 (1H, dd, J 12.0, 6.0, H-45' Diast B), 3.89 (2H, ddd, J 7.3, 6.0, 2.8, H-4 Diast. A and B), 2.31–2.20 (8H, m, H-47, H-63 Diast. A and B), 2.00–1.89 (4H, m, H-22, H-25 Diast. A and B), 1.76–1.50 (20H, m, H-22', H-25' Diast. A and B, H-23, H-24, H-48, H-64 Diast. A and B), 1.40–1.21 (64H, m, H-49 to H-60, H-65 to H-68 Diast. A and B), 0.88 (12H, t, J 6.8, H-61, H-69 Diast. A and B); ^{13}C NMR (151 MHz, CD_2Cl_2) δ_{C} 173.41, 173.36 (C-62 Diast. A and B), 173.1, 173.0 (C-46 Diast. A and B), 138.5, 138.4, 138.3 (C-8, C-15 Diast. A and B), 136.25 (d_{p} , J_{p} 7.1, C-37 Diast. A), 136.18 (d_{p} , J_{p} 7.1, C-37 Diast. B), 135.82, 135.77 (C-28, C-33 Diast. A and B), 129.4, 129.3, 129.1, 128.97, 128.95, 128.92, 128.86, 128.7, 128.6, 128.4, 128.34, 128.30, 128.25, 128.1, 128.05 (t_{p} , J_{p} 2.9) (C-9 to C-13, C-16 to C-20, C-29 to C-32, C-38 to C-42 Diast. A and B), 120.4 (C-21 Diast. A and B), 80.45, 80.41 (C-5 Diast. A and B), 79.56, 79.54 (C-4 Diast. A and B), 78.6–78.4 (m_{p} , C-6 Diast. A and B), 77.6 (C-3 Diast. A and B), 75.6 (t_{p} , J_{p} 5.5, C-1 Diast. A and B) 74.64, 74.61, 74.60, 74.58, (C-2, C-7 Diast. A and B) 73.48, 73.47 (C-14 Diast. A and B), 69.87 (d_{p} , J_{p} 2.9, C-36 Diast. A), 69.83 (d_{p} , J_{p} 2.9, C-36 Diast. B), 69.73–69.57 (m_{p} , C-44 Diast. A and B), 68.75–68.61 (m_{p} , C-27 and C-34 Diast. A and B), 66.05 (d_{p} , J_{p} 5.3, C-43 Diast. A), 65.92 (d_{p} , J_{p} 5.2, C-43 Diast. B), 62.0 (C-45 Diast. A), 61.9 (C-45 Diast. B), 36.9, 36.79, 36.76 (C-22, C-25 Diast. A and B), 34.47, 34.42, 34.32, 34.29 (C-47, C-63 Diast. A and B), 32.3 (C-59 Diast. A and B), 32.1 (C-67 Diast. A and B), 30.11, 30.09, 30.06, 29.9, 29.8, 29.7, 29.49, 29.47, 29.46, 29.3 (C-49 to C-58, C-65, C-66 Diast. A and B), 25.23, 25.22, 25.20 (C-48, C-64 Diast. A and B), 24.23, 24.20, 23.6 (C-23, C-24 Diast. A and B), 23.1, 23.0 (C-60, C-68 Diast. A and B), 14.3, 14.2 (C-61, C-69 Diast. A and B); ^{31}P NMR (162 MHz, CD_2Cl_2) δ_{P} -0.9 (P-26), -1.8 (P-35 Diast. A), -1.9 (P-35 Diast. B); LRMS m/z (ESI $^{+}$) 1217.67 ([M+H] $^{+}$, 100%); HRMS m/z (ESI $^{+}$) found 1239.5879 [M+Na] $^{+}$ ($\text{C}_{67}\text{H}_{94}\text{O}_{16}\text{P}_2\text{Na}$ requires 1239.5909 [M+Na] $^{+}$); NP-HPLC t_{R} = 4.74 min (Diast. A), 5.19 min (Diast B.), 99.6% @ 254 nm, 99.5% @ 220 nm.


(+)-(2R)-3-[(Hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,4,6-tetrahydroxy-5-(phosphonoxy)cyclohexyl]oxy}phosphoryl)oxy]-2-(octanoyloxy)propyl hexadecanoate (+)-7



To a solution of protected PI(5)P **(+)-18** (36 mg, 0.030 mmol, 1.0 eq) in a mixture of *t*BuOH (1.36 mL) and H₂O (0.24 mL) was added palladium black (64 mg, 0.60 mmol, 20 eq). The flask was purged with Ar_(g), before being placed under vacuum. H_{2(g)} was then bubbled through the solution, and the reaction mixture was stirred vigorously at RT under an atmosphere of H_{2(g)} for 17 h. The flask was then purged with Ar_(g) and NaHCO₃ (8 mg, 0.09 mmol, 3.0 eq) was then added in one portion to the reaction mixture. The mixture was stirred for a further 2 h under an atmosphere of H_{2(g)}, with freshly added palladium black (32 mg, 0.30 mmol, 10 eq) to ensure complete deprotection. The reaction mixture was finally purged with Ar_(g) and filtered through a PTFE syringe filter. The remaining palladium was further washed with milliQ H₂O (3 × 5 mL), which again, was passed through the same syringe filter. The combined filtrates were lyophilized to give **(+)-7** (15 mg, 60%) as a fluffy, colorless solid. The compound was stored at -80 °C as the sodium salt: ν_{\max} (solid)/cm⁻¹ 2922, 2853, 1737, 1068, 975, 864, 816, 721; ¹H NMR (600 MHz, MeOD) δ_{H} 5.28–5.22 (1H, m, H-10), 4.43* (1H, m, H-11') 4.20 (1H, dd, *J* 12.2, 7.6, H-11''), 4.16 (1H, dd, *J* 2.8, 2.8, H-2), 4.08–3.97 (3H, m, H-1 and H-9), 3.87–3.73 (3H, m, H-4, H-5 and H-6), 3.51 (1H, dd, *J* 9.6, 2.8, H-3), 2.37–2.28 (4H, m, H-13 and H-21), 1.65–1.52 (4H, m, H-14 and H-22), 1.36–1.21 (32H, m, H-15 to H-19 and H-23 to H-34), 0.87 (3H, t, *J* 7.0, H-19 or H-35), 0.87 (3H, t, *J* 7.0, H-19 or H-35); ³¹P NMR (243 MHz, MeOD) δ_{P} 4.32 (P-7), 0.10 (P-8); ¹³C NMR (151 MHz, MeOD) δ_{C} 175.2, 174.9 (C-12, C-20), 79.1 (C-5), 77.0 (C-1), 72.9 (C-4), 72.1 (C-2), 72.0 (C-6), 71.8 (C-3), 71.44–71.38 (m, C-10), 64.4 (C-9), 63.7 (C-11), 34.9, 34.8 (C-13, C-

21), 32.6, 32.4, 30.32, 30.28, 30.19, 30.0, 29.8, 29.72, 29.68, 25.61, 25.56, 23.31, 23.28 (C-14 to C-18 and C-22 to C-34), 14.5 (C-19 and C-35); LRMS m/z (ESI⁻) 777.3 ([M-H]⁻, 100%); HRMS m/z (ESI⁻) found 777.3592 [M-H]⁻ (C₃₃H₆₃O₁₆P₂ requires 777.3597 [M-H]⁻).*obscured by H₂O peak, observed in HSQC.

(2R)-1-[(Hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,4,6-tetrahydroxy-5-(phosphonooxy)cyclohexyl]oxy}phosphoryl)oxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (+)-8




To a solution of protected PI(5)P **(+)-S19** (40 mg, 0.033 mmol, 1.0 eq) in a mixture of ^tBuOH (1.36 mL) and H₂O (0.24 mL) was added palladium black (70 mg, 0.66 mmol, 20

eq). The flask was purged with Ar_(g), before being placed under vacuum. H_{2(g)} was then bubbled through the solution, and the reaction mixture was stirred vigorously at RT under an atmosphere of H_{2(g)} for 17 h. The flask was then purged with Ar_(g) and NaHCO₃ (8 mg, 0.09 mmol, 3.0 eq) was then added in one portion to the reaction mixture. The mixture was stirred for a further 2 h under an atmosphere of H_{2(g)}, with freshly added palladium black (35 mg, 0.33 mmol, 10 eq) to ensure complete deprotection. The reaction mixture was finally purged with Ar_(g) and filtered through a PTFE syringe filter. The remaining palladium was further washed with milliQ H₂O (3 × 5 mL), which again, was passed through the same syringe filter. The combined filtrates were lyophilized to give **(+)-8** (21 mg, 75%) as a fluffy, colorless solid. The compound was stored at -80 °C as the sodium salt: ν_{\max} (solid)/cm⁻¹ 2922, 2853, 1739, 1225, 1068, 978, 866, 833, 709; ¹H NMR (600 MHz, MeOD) δ_{H} 5.27–5.22 (1H, m, H-10), 4.42* (1H, m, H-11'), 4.19 (1H, dd, J 12.2, 7.5, H-11''), 4.16 (1H, dd, J 2.9, 2.9, H-2), 4.08–3.92 (3H, m, H-1 and H-9), 3.88–3.73 (3H, m, H-4, H-5 and H-6), 3.51 (1H, dd, J 9.7, 2.9, H-3), 2.36–2.28 (4H, m, H-13 and H-29), 1.64–1.53 (4H, m, H-14 and H-30), 1.35–1.20 (32H, m, H-15 to H-26 and H-31 to H-34), 0.87 (3H, t, J 7.1, H-27 or H-35),

0.87 (4H, t, J 7.1, H-27 or H-35); ^{31}P NMR (243 MHz, MeOD) δ_{P} 3.72 (P-7), 0.07 (P-8); ^{13}C NMR (151 MHz, MeOD) δ_{C} 175.2, 174.9 (C-12, C-28), 78.9 (C-5), 77.0 (C-1), 72.9 (C-4), 72.1 (C-2), 71.9 (C-6), 71.8 (C-3), 71.3 (C-10), 64.4 (C-9), 63.7 (C-11), 34.9, 34.8 (C-13 and C-29), 32.6, 32.4 (C-25 and C-33), 30.35, 30.32, 30.28, 30.24, 30.1, 30.0, 29.80, 29.76, 29.6 (C-15 to C-24 and C-31 to C-32), 25.6, 25.5 (C-14 and C-30), 23.30, 23.25 (C-26 and C-34), 14.50, 14.47 (C-27 and C-35); LRMS m/z (ESI $^{-}$) 777.3 ([M-H] $^{-}$, 100%); HRMS m/z (ESI $^{-}$) found 777.3586 [M-H] $^{-}$ (C $_{33}$ H $_{63}$ O $_{16}$ P $_2$ requires 777.3597 [M-H] $^{-}$). *obscured by H $_2$ O peak, observed in HSQC.

(+)-(2R)-3-[[[(2S)-2-Methoxy-2-phenylacetyl]oxy]-2-(octanoyloxy)propyl hexadecanoate (+)-S20



(S)-(+)- α -Methoxyphenylacetic acid (5 mg,

0.03 mmol, 2.0 eq), N,N' -

dicyclohexylcarbodiimide (10 mg,

0.049 mmol, 2.7 eq) and 4-DMAP (1 mg, 0.008 mmol, 0.5 eq) were added to a solution of alcohol

(-)-**S14** (7 mg, 0.02 mmol, 1.0 eq) in CH $_2$ Cl $_2$ (0.5 mL). After stirring at RT for 4 h, the reaction

mixture was diluted with CH $_2$ Cl $_2$ (5 mL), and the organic layer was washed with a saturated

aqueous solution of NaHCO $_3$ (2 \times 3 mL), and brine (3 mL), then dried over MgSO $_4$, filtered, and

concentrated *in vacuo*. Purification by column chromatography over silica gel (petroleum

ether:Et $_2$ O, 10:0 to 7:3) gave **(+)-S20** (10 mg, 83%) as a colorless film: R_f 0.77 (petroleum

ether:EtOAc, 6:4); $[\alpha]_D^{25} +18.4$ (c 0.83, CHCl $_3$); ν_{max} (thin film)/cm $^{-1}$ 2921, 2851, 1745, 1463, 1163,

1114, 727; ^1H NMR (600 MHz, CDCl $_3$) δ_{H} 7.44–7.31 (5H, m, H-32 to H-36), 5.20–5.16 (1H, m, H-

2), 4.77 (1H, s, H-29), 4.36 (1H, dd, J 11.9, 4.3, H-3'), 4.20 (1H, dd, J 11.9, 5.6, H-3''), 4.18 (1H,


dd, J 11.9, 4.5, H-1'), 3.97 (1H, dd, J 11.9, 5.9, H-1''), 3.41 (3H, s, H-30), 2.28–2.24 (2H, m, H-5),

2.23–2.13 (2H, m, H-21), 1.61–1.50 (4H, m, H-6 and H-22), 1.33–1.21 (32H, m, H-7 to H-18 and

H-23 to H-26), 0.89 (3H, t, J 7.0, H-19 or H-27), 0.88 (3H, t, J 7.0, H-19 or H-27); ^{13}C NMR (151

MHz, CDCl₃) δ_C 173.3 (C-4), 172.8 (C-20), 170.3 (C-28), 136.1 (C-31), 129.0 (C-34), 128.8 (C-32 and C-36), 127.3 (C-33 and C-35), 82.5 (C-29), 68.8 (C-2), 62.7 (C-3), 61.9 (C-1), 57.5 (C-30), 34.2 (C-21), 34.1 (C-5), 32.1, 31.8 (C-17, C-25), 29.85, 29.81, 29.77, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1 (C-7 to C-16, C-23, C-24) 24.98, 24.89 (C-6, C-22), 22.84, 22.76 (C-18, C-26), 14.3, 14.2 (C-19, C-27); LRMS *m/z* (ESI⁺) 627.4 ([M+Na]⁺, 100%); HRMS *m/z* (ESI⁺) found 627.4227 [M+Na]⁺ (C₃₆H₆₀O₇Na requires 627.4231 [M+Na]⁺).


(-)-(2R)-3-[[(2R)-2-Methoxy-2-phenylacetyl]oxy]-2-(octanoyloxy)propyl hexadecanoate (-)-S21



(*R*)-(-)- α -Methoxyphenylacetic acid (5 mg, 0.0310 mmol, 2.0 eq), *N,N'*-dicyclohexylcarbodiimide (10 mg, 0.049 mmol, 2.7 eq) and 4-DMAP (1 mg, 0.008 mmol, 0.5 eq) were added to a solution of (-)-**S14** (7 mg, 0.016 mmol, 1.0 eq) in CH₂Cl₂ (0.5 mL). After stirring at RT for 4 h, the reaction mixture was diluted with CH₂Cl₂ (5 mL), and the organic layer was washed with a saturated aqueous solution of NaHCO₃ (2 × 3 mL), and brine (3 mL), then dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification by column chromatography over silica gel (petroleum ether:Et₂O, 10:0 to 7:3) gave (-)-**S21** (7 mg, 75%) as a colorless film: *R_f* 0.77 (petroleum ether:EtOAc, 6:4); [α]_D²⁵ -27.9 (c 0.58, CHCl₃); ν_{max} (thin film)/cm⁻¹ 2923, 2853, 1744, 1495, 1164, 1114, 727; ¹H NMR (600 MHz, CDCl₃) δ_H 7.44–7.31 (5H, m, H-32 to H-36), 5.24–5.20 (1H, m, H-2), 4.77 (1H, s, H-29), 4.34 (1H, dd, *J* 11.9, 4.0, H-3'), 4.19 (1H, dd, *J* 11.9, 6.3, H-3''), 4.16 (1H, dd, *J* 11.9, 4.5, H-1'), 4.04 (1H, dd, *J* 11.9, 5.8, H-1''), 3.41 (3H, s, H-30), 2.26 (2H, t, *J* 7.6, H-5), 2.23–2.12 (2H, m, H-21), 1.60–1.51 (4H, m, H-6 and H-22), 1.33–1.21 (32H, m, H-7 to H-18 and H-23 to H-26), 0.89 (3H, t, *J* 7.0, H-19 or H-27), 0.88 (3H, t, *J* 7.1, H-19 or H-27); ¹³C NMR (151 MHz, CDCl₃) δ_C 173.3 (C-4), 172.9 (C-20), 170.4 (C-28), 136.1 (C-31), 129.0 (C-34), 128.8 (C-32

and C-36), 127.3 (C-33 and C-35), 82.5 (C-29), 68.7 (C-2), 63.0 (C-3), 61.9 (C-1), 57.5 (C-30), 34.2 (C-21), 34.1 (C-5), 32.1, 31.8 (C-17, C-25), 29.84, 29.83, 29.80, 29.76, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1 (C-7 to C-16, C-23, C-24), 24.97, 24.90 (C-6, C-22), 22.83, 22.75 (C-18, C-26), 14.3, 14.2 (C-19, C-27); LRMS m/z (ESI⁺) 627.4 ([M+Na]⁺, 100%); HRMS m/z (ESI⁺ found 627.4229 [M+Na]⁺ (C₃₆H₆₀O₇Na requires 627.4231 [M+Na]⁺).


(+)-(2R)-1-[[[(2S)-2-Methoxy-2-phenylacetyl]oxy]-3-(octanoyloxy)propan-2-yl]hexadecanoate (+)-S22



(S)-(+)- α -Methoxyphenylacetic acid (5 mg, 0.03 mmol, 2.0 eq), *N,N'*-dicyclohexylcarbodiimide (10 mg, 0.049 mmol, 2.7 eq) and 4-DMAP (1 mg, 0.008 mmol, 0.5 eq) were added to a solution of (–)-**S15** (7 mg, 0.02 mmol, 1.0 eq) in CH₂Cl₂ (0.5 mL). After stirring at RT for 4 h, the reaction mixture was diluted with CH₂Cl₂ (5 mL) and the organic layer was washed with a saturated aqueous solution of NaHCO₃ (2 × 3 mL), brine (3 mL), and then dried over MgSO₄, before being filtered, and concentrated *in vacuo*. Purification by silica gel column chromatography (petroleum ether:Et₂O, 10:0 to 7:3) resulted in **(+)-S22** (7 mg, 75%) as a colorless film: R_f 0.77 (petroleum ether:EtOAc, 6:4); $[\alpha]_D^{25}$ +35.5 (*c* 0.58, CHCl₃); ν_{\max} (thin film)/cm⁻¹ 2924, 2854, 1744, 1495, 1165, 1114, 728; ¹H NMR (600 MHz, CDCl₃) δ_H 7.44–7.31 (5H, m, H-32 to H-36), 5.20–5.15 (1H, m, H-2), 4.77 (1H, s, H-29), 4.35 (1H, dd, *J* 11.9, 4.3, H-3'), 4.22–4.16 (2H, m, H-3'' and H-1'), 3.97 (1H, dd, *J* 11.9, 5.8, H-1''), 3.41 (3H, s, H-30), 2.26 (2H, td, *J* 7.4, 0.9, H-5 or H-13), 2.18 (2H, td, *J* 7.6, 4.1, H-5 or H-13), 1.61–1.50 (4H, m, H-6 and H-14), 1.32–1.22 (32H, m, H-7 to H-10 and H-16 to H-26), 0.88 (6H, t, *J* 6.9, H-11 and H-27); ¹³C NMR (151 MHz, CDCl₃) δ_C 173.3 (C-4), 172.8 (C-12), 170.3 (C-28), 136.1 (C-31), 129.0 (C-34), 128.8 (C-32 and C-36), 127.3 (C-33 and C-35), 82.5 (C-29), 68.8 (C-2), 62.7 (C-3), 61.9 (C-1), 57.5 (C-30), 34.2, 34.1 (C-5 and C-13), 32.1, 31.8 (C-9 and C-25),

29.84, 29.81, 29.80, 29.78, 29.6, 29.5, 29.4, 29.21, 29.19, 29.0 (C-7, C-8 and C-15 to C-24), 25.0, 24.9 (C-6, C-14), 22.8, 22.7 (C-10, C-26), 14.3, 14.2 (C-27, C-11); LRMS m/z (ESI⁺) 627.4 ([M+Na]⁺, 100%); HRMS m/z (ESI⁺) found 627.4229 [M+Na]⁺ (C₃₆H₆₀O₇Na requires 627.4231 [M+Na]⁺).

(-)-(2R)-1-[[[(2R)-2-Methoxy-2-phenylacetyl]oxy]-3-(octanoyloxy)propan-2-yl]hexadecanoate (-)-S23



(R)-(-)- α -Methoxyphenylacetic acid (5 mg,

0.03 mmol, 2.0 eq), *N,N'*-

dicyclohexylcarbodiimide (10 mg, 0.049 mmol,

2.7 eq) and 4-DMAP (1 mg, 0.008 mmol, 0.5 eq) were added to a solution of (-)-**S15** (7.0 mg,

0.016 mmol, 1.0 eq) in CH₂Cl₂ (0.5 mL). After stirring at RT for 4 h, the reaction mixture was

diluted with CH₂Cl₂ (5 mL), and the organic layer was washed with a saturated aqueous solution

of NaHCO₃ (2 × 3 mL) and brine (3 mL), and then dried over MgSO₄, filtered, and concentrated

in vacuo. Purification by silica gel column chromatography (petroleum ether:Et₂O, 10:0 to 7:3)

gave (-)-**S23** (8 mg, 81%) as a colorless film: R_f 0.77 (petroleum ether:EtOAc, 6:4); $[\alpha]_D^{25}$ -31.8 (c

0.67, CHCl₃); ν_{\max} (thin film)/cm⁻¹ 2925, 2854, 1745, 1457, 1165, 1115, 728; ¹H NMR (600 MHz,

CDCl₃) δ_H 7.44–7.31 (5H, m, H-32 to H-36), 5.24–5.20 (1H, m, H-2), 4.77 (1H, s, H-29), 4.34 (1H,

dd, J 11.9, 4.0, H-3'), 4.21–4.15 (2H, m, H-3'' and H-1'), 4.04 (1H, dd, J 11.9, 5.8, H-1''), 3.41 (3H,

s, H-30), 2.26 (2H, t, J 7.6, H-5 or H-13), 2.22–2.12 (2H, m, H-5 or H-13), 1.62–1.50 (4H, m, H-6

and H-14), 1.32–1.23 (32H, m, H-7 to H-10 and H-16 to H-26), 0.88 (6H, t, J 6.9, H-11 and H-27);

¹³C NMR (151 MHz, CDCl₃) δ_C 173.3 (C-4), 172.9 (C-12), 170.4 (C-28), 136.1 (C-31), 129.0 (C-


34), 128.8 (C-32 and C-36), 127.3 (C-33 and C-35), 82.5 (C-29), 68.7 (C-2), 63.0 (C-3), 61.9 (C-

1), 57.5 (C-30), 34.2, 34.1 (C-5, C-13), 32.1, 31.8 (C-9, C-25), 29.84, 29.81, 29.80, 29.78, 29.6,

29.5, 29.4, 29.22, 29.19, 29.0 (C-7, C-8 and C-15 to C-24), 25.0, 24.9 (C-6, C-14), 22.8, 22.7 (C-

10, C-26), 14.3, 14.2 (C-11, C-27); LRMS m/z (ESI⁺) 627.4 ([M+Na]⁺, 100%); HRMS m/z (ESI⁺) found 627.4228 [M+Na]⁺ (C₃₆H₆₀O₇Na requires 627.4231 [M+Na]⁺).

(+)-(S)-3-(Bis(4-methoxyphenyl)(phenyl)methoxy)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)propyl palmitate S24




To a solution of alcohol **S10** (684 mg, 1.08 mmol, 1.0 eq) in CH₂Cl₂ (6 mL) was added DCC (446 mg, 2.16 mmol, 2.0 eq), 4-DMAP (8 mg, 0.1 mmol, 0.06 eq) and

diazirine **27** (300 mg, 1.08 mmol, 1.0 eq). The solution was stirred at RT for 18 h, after which the reaction mixture was diluted with hexane (20 mL). The suspension was filtered through celite, and the celite subsequently was washed with hexane (3 × 10 mL). The combined filtrates were concentrated *in vacuo* at RT and the resulting residue was purified by column chromatography over silica gel (petroleum ether:Et₂O, 10:0 to 8:2) which yielded (+)-**S24** (400 mg, 41%) as a colorless oil with a slight impurity corresponding to the migration product: R_f 0.49 (petroleum ether:EtOAc, 9:1); $[\alpha]_D^{25} +10.66$ (c 1.0, CHCl₃); ν_{\max} (thin film)/cm⁻¹ 3309, 2925, 2854, 1742, 1608, 1509, 1251, 1177, 1037, 829; ¹H NMR (600 MHz, CDCl₃) δ_H 7.43–7.38 (2 H, m, H-38, H-42), 7.31–7.26 (6 H, m, H-39, H-41, H-44, H-48, H-51, H-55), 7.23–7.19 (1 H, m, H-40), 6.84–6.80 (4 H, m, H-45, H-47, H-52, H-54), 5.27–5.21 (1 H, m, H-2), 4.34 (1 H, dd, J 11.9, 3.6, H-1'), 4.22 (1 H, dd, J 11.9, 6.6, H-1''), 3.79 (6 H, s, H-49, H-56), 3.22 (2 H, dd, J 5.0, 2.5, H-3), 2.24 (2 H, t, J 7.6, H-5), 2.17 (2 H, td, J 7.1, 2.6, H-33), 2.12 (2 H, td, J 7.6, 2.8, H-21 or H-22), 1.93 (1 H, t, J 2.6, H-35), 1.75–1.70 (2 H, m, H-21 or H-22), 1.56–1.49 (4 H, m, H-6 and H-32), 1.40–1.35 (4 H, m, H-24, H-31), 1.33–1.18 (34 H, m, H-30 to H-26 and H-18 to H-7), 1.10–1.03 (2 H, m, H-25), 0.88 (3 H, t, J 7.0, H-19); ¹³C NMR (151 MHz, CDCl₃) δ_C 173.6 (C-4), 171.7 (C-20), 158.7 (C-46 and C-53), 144.7 (C-37), 135.83, 135.81 (C-43, C-50), 130.13, 130.12 (C-44, C-48, C-51, C-55), 128.2, 128.0 (C-38, C-39, C-41, C-42), 127.0 (C-40), 113.3 (C-52, C-54, C-45 and C-47), 86.3 (C-36), 84.9 (C-34), 71.2 (C-2), 68.2 (C-35), 62.9 (C-1), 62.0 (C-3), 55.3 (C-56 and C-49), 34.2 (C-5),

32.9 (C-24), 32.1, 29.85, 29.81, 29.80, 29.78, 29.64, 29.60, 29.56, 29.55, 29.50, 29.43, 29.42, 29.31, 29.28, 29.22, 29.20, 28.9 (C-7 to C-17, C-20, C-26 to C-31) 28.8, 28.6, 28.4 (C-21, C-22, C-32), 28.3 (C-23), 25.0 (C-6), 24.0 (C-25), 22.8 (C-18), 18.5 (C-33), 14.3 (C-19); LRMS m/z (ESI⁺) 915.6 ([M+Na]⁺, 100%); HRMS m/z (ESI⁺) found 915.5853 [M+Na]⁺ (C₅₆H₈₀O₇N₂Na) requires 915.5858 [M+Na]⁺.

(R)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-((S)-2-methoxy-2-phenylacetoxy)propyl palmitate (+)-S25




(S)-(+)- α -Methoxyphenylacetic acid (6 mg, 0.04 mmol, 2.2 eq), *N,N'*-dicyclohexylcarbodiimide (10 mg, 0.046 mmol, 2.7 eq) and 4-DMAP (1 mg, 0.008 mmol, 0.5

eq) were added to a solution of alcohol **32** (10 mg, 0.017 mmol, 1 eq) in CH₂Cl₂ (0.5 mL). After stirring at RT for 16 h, the reaction mixture was diluted with CH₂Cl₂ (5 mL), the organic layer was washed with 1 M HCl_(aq) (5 mL), then a saturated aqueous solution of NaHCO₃ (5 mL) and then brine (5 mL), and then dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Purification by silica gel column chromatography (petroleum ether:Et₂O, 10:0 to 7:3) gave **(+)-25** (8 mg, 65%) as a colorless film: R_f 0.63 (petroleum ether:Et₂O, 6:4); $[\alpha]_D^{25} +33.1$ (c 0.8, CHCl₃); ν_{\max} (thin film)/cm⁻¹ 3313, 2928, 2855, 1748, 1466, 1171; ¹H NMR (600 MHz, CDCl₃) δ_H 7.47–7.31 (5 H, m, H-40 to H-44), 5.19–5.11 (1 H, m, H-2), 4.78 (1 H, s, H-37), 4.37 (1 H, dd, J 12.0, 4.1, m, H-3'), 4.22–4.16 (2 H, m, H-3'', H-1'), 3.96 (1 H, dd, J 12.0, 5.8, H-1''), 3.40 (3 H, s, H-38), 2.27 (2 H, t, J 7.6, H-5), 2.17 (2 H, td, J 7.2, 2.7, H-33), 1.98–1.92 (3 H, m, H-21, H-35), 1.66–1.61 (2 H, m, H-22), 1.60–1.54 (2 H, m, H-6), 1.54–1.49 (2 H, m, H-32), 1.41–1.33 (4 H, m, H-24, H-31), 1.32–1.18 (34 H, m, H-7 to H-18 and H-26 to H-30), 1.10–1.02 (2 H, m, H-25), 0.88 (3 H, t, J 7.0, H-19); ¹³C NMR (151 MHz, CDCl₃) δ_C 173.3 (C-4), 171.4 (C-20), 170.3 (C-36), 136.1 (C-39), 129.1 (C-42), 128.9,

127.3 (C-40, C-41, C-43, C-44), 84.9 (C-34), 82.4 (C-37), 69.3 (C-2), 68.2 (C-35), 62.5 (C-3), 61.8 (C-1), 57.5 (C-38), 34.1 (C-5), 32.8 (C-24), 32.1, 29.9, 29.84, 29.81, 29.77, 29.62, 29.56, 29.53, 29.51, 29.4, 29.3, 29.3, 29.2, 28.9, 28.6 (C-7 to C-17 and C-25 to C-32), 28.5 (C-21), 28.2 (C-23), 28.1 (C-22), 25.0 (C-6), 23.9 (C-29), 22.8 (C-18), 18.5 (C-33), 14.3 (C-19); HRMS m/z (ESI⁺) found 761.5106 [M+Na]⁺ (C₄₄H₇₀O₇N₂Na) requires 761.5075[M+Na]⁺.

(R)-2-((3-(3-(Dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-((R)-2-methoxy-2-phenylacetoxy)propyl palmitate (-)-S26



(R)-(-)- α -Methoxyphenylacetic acid (6 mg, 0.04 mmol, 2.2 eq), *N,N'*-dicyclohexylcarbodiimide (10 mg, 0.046

mmol, 2.7 eq) and 4-DMAP (1 mg, 0.008 mmol, 0.5 eq) were added to a solution of alcohol **32** (10 mg, 0.017 mmol, 1.0 eq) in CH₂Cl₂ (0.5 mL). After stirring at RT for 16 h, the reaction mixture was diluted with CH₂Cl₂ (5 mL), and the organic layer was washed with 1 M HCl_(aq) (5 mL), a saturated aqueous solution of NaHCO₃ (5 mL), then brine (5 mL), and then dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Purification using silica gel column chromatography (petroleum ether:Et₂O, 10:0 to 7:3) gave **(-)-S26** (10 mg, 82%) as a colorless film: R_f 0.63 (petroleum ether:Et₂O, 6:4); $[\alpha]_D^{25}$ -24.0 (c 1.0, CHCl₃); ν_{\max} (thin film)/cm⁻¹ 3312, 2928, 2855, 1749, 1466, 1171; ¹H NMR (600 MHz, CDCl₃) δ_H 7.44–7.32 (5 H, m, H-40 to H-44), 5.22–5.18 (1 H, m, H-2), 4.77 (1 H, s, H-37), 4.33 (1 H, dd, J 11.9, 4.0, H-3'), 4.19 (1 H, dd, J 11.5, 5.8, H-3''), 4.16 (1 H, dd, J 11.5, 4.0, H-1'), 4.03 (1 H, dd, J 11.9, 5.8, H-1''), 3.41 (3 H, s, H-38), 2.26 (2 H, t, J 7.6, H-5), 2.18 (2 H, td, J 7.2, 2.7, H-33), 2.00–1.88 (3 H, m, H-35 and H-21), 1.69–1.60 (2 H, m, H-22), 1.61–1.53 (2 H, m, H-6), 1.56–1.48 (2 H, m, H-32), 1.42–1.32 (4 H, m, H-24 and H-31), 1.30–1.19 (34 H, m, H-7 to H-18 and H-26 to H-30), 1.09–1.03 (2 H, m, H-25), 0.88 (3 H, t, J 7.0, H-19); ¹³C NMR (151 MHz, CDCl₃) δ_C 173.3 (C-4), 171.4 (C-20), 170.4 (C-36), 136.1 (C-39), 129.1

(C-42), 128.9, 127.3 (C-40, C-41, C-43, C-44), 84.9 (C-34), 82.4 (C-37), 69.3 (C-2), 68.2 (C-35), 62.8 (C-3), 61.8 (C-1), 57.6 (C-38), 34.1 (C-5), 32.8 (C-24), 32.1, 29.9, 29.84, 29.81, 29.77, 29.62, 29.57, 29.5, 29.4, 29.32, 29.25, 29.21, 28.9, 28.6 (C-7 to C-17 and C-25 to C-32), 28.5 (C-21), 28.18 (C-23), 28.15 (C-22), 25.0 (C-6), 24.0 (C-29), 22.8 (C-18), 18.5 (C-33), 14.3 (C-19); HRMS m/z (ESI⁺) found 761.5094 [M+Na]⁺ (C₄₄H₇₀O₇N₂Na) requires 761.5075[M+Na]⁺.



NMR Spectra and Other Data

1D-1-O-Acetate-2,3-O-cyclopentylidene-4,6-di-O-(4-methoxybenzyl)-5-O-(2-oxo-5,6-benzo-1,3,2-dioxaphosphep-2-yl)-myo-inositol (-)-18 ¹H NMR

Current Data Parameters
 NAME gb653390802
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date 20220208
 Time 21.07 h
 INSTRUM Avance
 PROBHD Z159656_0020 ()
 PULPROG zg30
 TD 65536
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 11904.762 Hz
 FIDRES 0.363304 Hz
 AQ 2.7525120 sec
 RG 84.3283
 DW 42.000 usec
 DE 22.00 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 600.4230021 MHz
 NUC1 ¹H
 PC 4.00 usec
 P1 12.00 usec
 PLW1 13.51200008 W

F2 - Processing parameters
 SI 65536
 SF 600.4200137 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00





1D-1-O-Acetate-2,3-O-cyclopentylidene-4,6-di-O-(4-methoxybenzyl)-5-O-(2-oxo-5,6-benzo-1,3,2-dioxaphosphep-2-yl)-myo-inositol (-)-18 ³¹P NMR

Current Data Parameters
NAME gbr3330802
EXPNO 6
PROCNO 1

F2 - Acquisition Parameters
Date_ 20220208
Time 23.33 h
INSTRUM Avance
PROBHD Z159656_002D (1
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 16
DS 4
SWH 48943.688 Hz
FIDRES 1.481436 Hz
AQ 0.6750208 sec
RG 101
DW 10.300 usec
DE 18.00 usec
TE 298.0 K
D1 2.0000000 sec
D11 0.03000000 sec
TD0 1
SFO1 243.0423184 MHz
NUC1 31P
FO 4.00 usec
F1 12.00 usec
PLM1 39.4080000 W
SFO2 600.4224017 MHz
NUC2 1H
CDEPRG(2) Waltz16
PCPD2 80.00 usec
PLM2 13.5120000 W
PLM12 0.10124050 W
PLM13 0.13098180 W

F2 - Processing parameters
SI 32768
SF 243.0544711 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40




1D-1-O-Acetate-2,3-O-cyclopentylidene-4,6-di-O-(4-methoxybenzyl)-5-O-(2-oxo-5,6-benzo-1,3,2-dioxaphosphep-2-yl)-myo-inositol (-)-18 ¹³C NMR

```

Current Data Parameters
NAME      g053330802
EXPNO     5
PROCNO    1


F2 - Acquisition Parameters
Date_     20220208
Time      23.31 h
INSTRUM   Avance
PROBHD    z159656_002D (
PULPROG   zgpg30
TD        65536
SOLVENT   CDCl3
NS        2048
DS        4
SWE       35714.285 Hz
FIDRES    1.089913 Hz
AQ         0.9175040 sec
RG         101
DM         14.000 usec
DE         18.00 usec
TE         298.0 K
D1         2.00000000 sec
D11        0.03000000 sec
TD0        1
SFO1       150.9908267 MHz
NUC1       13C
FO         3.33 usec
F1         10.00 usec
PLM1       41.91400146 W
SFO2       600.4224017 MHz
NUC2       1H
CFDPRG(2) waltz16
PCPD2      80.00 usec
PLM2       13.51200008 W
PLM12      0.30124050 W
PLM13      0.15098180 W

F2 - Processing parameters
SI         65536
SF         150.9757084 MHz
WDW        EM
SSB        0
LB         1.00 Hz
GB         0
PC         1.40
    
```




170.13
159.35
159.34
135.49
135.45
130.32
130.23
129.81
129.63
129.07
129.04
128.85
120.12
113.84
113.76

80.84
80.79
78.90
78.88
77.67
77.64
77.58
73.95
73.71
72.85
70.47
68.46
68.44
68.42
68.40
55.41
36.85
36.66
24.10
23.46
21.21



1D-1-O-Acetate-2,3-O-cyclopentylidene-4,6-di-O-(4-methoxybenzyl)-5-O-(2-oxo-5,6-benzo-1,3,2-dioxaphosph-2-yl)-myo-inositol (-)-18 HRMS





1D-2,3-O-Cyclopentylidene-4,6-di-O-(4-methoxybenzyl)-5-O-(2-oxo-5,6-benzo-1,3,2-dioxaphosphep-2-yl)-myo-inositol (+)-19 ¹H NMR

Current Data Parameters
 NAME gb654340103
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date 20220301
 Time 18.10 h
 INSTRUM Avance
 PROBHD Z159656_0020 (Z159656)
 PULPROG zg30
 TD 65536
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 11904.762 Hz
 FIDRES 0.363304 Hz
 AQ 2.7525120 sec
 RG 76.1298
 DW 42.000 usec
 DE 22.00 usec
 TE 298.0 K
 D1 1.00000000 sec
 TDO 1
 SFO1 600.4230021 MHz
 NUC1 1H
 PO 4.00 usec
 P1 12.00 usec
 PLW1 13.51200008 W

F2 - Processing parameters
 SI 65536
 SF 600.4200137 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00




1D-2,3-O-Cyclopentylidene-4,6-di-O-(4-methoxybenzyl)-5-O-(2-oxo-5,6-benzo-1,3,2-dioxaphosphep-2-yl)-myo-inositol (+)-19 ¹³C NMR

```

Current Data Parameters
NAME          g0534340103
EXPNO         5
PROCNO        1


F2 - Acquisition Parameters
Date_         20220301
Time          19.44 h
INSTRUM       Avance
PROBHD        z159656_0020 (
PULPROG       zgpg30
TD            65536
SOLVENT       CDCl3
NS            1024
DS            4
SHE          35714.285 Hz
FIDRES        1.089913 Hz
AQ            0.9175040 sec
RG            101
DM            14.000 usec
DE            18.00 usec
TE            298.0 K
D1            2.0000000 sec
D11           0.0300000 sec
TD0           1
SFO1          150.9908267 MHz
NUC1          13C
FO            3.33 usec
F1            10.00 usec
PLM1          41.91400146 W
SFO2          600.4224017 MHz
NUC2          1H
CFDPRG[2]    waltz16
PCPD2         80.00 usec
PLM2          13.51200008 W
PLM12         0.30124050 W
PLM13         0.15098180 W

F2 - Processing parameters
SI            65536
SF            150.9757098 MHz
WDW           EM
SSB           0
LB            1.00 Hz
GB            0
PC            1.40
    
```




1D-2,3-O-Cyclopentylidene-4,6-di-O-(4-methoxybenzyl)-5-O-(2-oxo-5,6-benzo-1,3,2-dioxaphosph-2-yl)-*myo*-inositol (+)-19 HRMS

Expanded Spectrum RT 0.10, NL 2842247, Peak [1], Target Mass 669.2459



Theoretical Spectrum for C₃₅H₄₂O₁₁P, Minimum Abundance 0.01%




Measured Mass	Calculated Mass	Error (mDa)	Error (ppm)	Formula [M+H] ⁺	Response
669.2479	669.2459	1.97	2.94	C ₃₅ H ₄₂ O ₁₁ P	2534295


13-{{tetrahydropyran-2'-yl)oxy}tridecan-1-yne 22 ¹H NMR

Current Data Parameters
NAME Aug05-2021-24-GB-099 (12-tridec
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20210805
Time 9.47 h
INSTRUM avh400
PROBHD Z108618_0873 (
PULPROG zg80
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 8012.820 Hz
FIDRES 0.244532 Hz
AQ 4.0894465 sec
RG 44.06
DW 62.400 usec
DE 6.50 usec
TE 300.8 K
D1 1.00000000 sec
TD0 1
SFO1 400.1324008 MHz
NUC1 ¹H
P1 14.00 usec
PLW1 14.36999988 W



F2 - Processing parameters
SI 32768
SF 400.1300101 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00



13-{{(tetrahydropyran-2'-yl)oxy}}tridecan-1-yne 22 ¹³C NMR



Current Data Parameters
 NAME Aug05-2021-24-08-099 (12-tridecyn-1-ol THP ether)
 EXPNO 2
 PROCNO 1

F2 - Acquisition Parameters

Date_ 20210806
 Time 1.58 h
 INSTRUM av9400
 PROBHD Z108618_0873 (4
 PULPROG zgpg30
 TD 32768
 SOLVENT CDCl3
 NS 512
 DS 4
 SWH 26041.666 Hz
 FIDRES 1.589457 Hz
 AQ 0.6291456 sec
 RG 197.18
 DM 19.200 usec
 DE 6.50 usec
 TE 303.1 K
 D1 1.00000000 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 100.6228298 MHz
 NUC1 13C
 PO 3.33 usec
 P1 10.00 usec
 PLM1 47.86100000 W
 SFO2 400.1316005 MHz
 NUC2 1H
 CTEPRG(2) waltz16
 ECPD2 90.00 usec
 PLM2 14.36999989 W
 PLM12 0.34772000 W
 PLM13 0.17490000 W


F2 - Processing parameters

SI 32768
 SF 100.6127533 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40




13-((tetrahydropyran-2'-yl)oxy)tridecan-1-yne 22 HRMS

Expanded Spectrum RT 0.10, NL 760738, Peak [1], Target Mass 303.2295



Theoretical Spectrum for C₁₈H₃₂O₂Na, Minimum Abundance 0.01%






Measured Mass	Calculated Mass	Error (mDa)	Error (ppm)	Formula [M+Na] ⁺	Response
303.2299	303.2295	0.44	1.47	C ₁₈ H ₃₂ O ₂ Na	314088

ethyl 4-oxohexadec-15-ynoate ¹H NMR

Current Data Parameters
NAME gb636740309
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date 20210906
Time 4.44 h
INSTRUM Avance
PROBHD Z159656_0020 (Z159656)
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 11904.762 Hz
FIDRES 0.363304 Hz
AQ 2.7525120 sec
RG 73.1775
DW 42.000 usec
DE 22.00 usec
TE 298.0 K
D1 1.0000000 sec
TDO 1
SFO1 600.4230021 MHz
NUC1 1H
P0 4.00 usec
P1 12.00 usec
PLW1 13.51200008 W



F2 - Processing parameters
SI 65536
SF 600.4200138 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00




ethyl 4-oxohexadec-15-ynoate 25 ¹³C NMR

```

Current Data Parameters
NAME      g0636740309
EXENO     5
PROCNO    1
F2 - Acquisition Parameters
Date_     20210906
Time      5.31 h
INSTRUM   Avance
PROBHD    Z159656_0020 (
PULPROG   zgpg30
TD        65536
SOLVENT   CDCl3
NS         512
DS         4
SWH        35714.285 Hz
FIDRES     1.089913 Hz
AQ         0.9175040 sec
RG         101
DM         14.000 usec
DE         18.00 usec
TE         298.0 K
D1         2.0000000 sec
D11        0.03000000 sec
TDO        1
SFO1       150.9908267 MHz
NUC1       13C
PC         3.33 usec
P1         10.00 usec
PLM1       41.91400146 W
SFO2       600.4224017 MHz
NUC2       1H
CPDPRG2   waltz16
PCPD2      80.00 usec
PLM2       13.51200008 W
PLM12      0.30124050 W
PLM13      0.15098180 W
F2 - Processing parameters
SI         65536
SF         150.9757082 MHz
WDW        EM
SSB        0
LB         1.00 Hz
GB         0
PC         1.40
    
```



ethyl 4-oxohexadec-15-ynoate 25 HMRS





4-oxohexadec-15-ynoic acid 26 ¹H NMR

Current Data Parameters
NAME gb636950609
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date 20210907
Time 5.20 h
INSTRUM Avance
PROBHD Z159656_0020 (Z159656)
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 11904.762 Hz
FIDRES 0.363304 Hz
AQ 2.7525120 sec
RG 77.4444
DW 42.000 usec
DE 22.00 usec
TE 298.0 K
D1 1.0000000 sec
TDO 1
SFO1 600.4230021 MHz
NUC1 1H
P0 4.00 usec
P1 12.00 usec
PLW1 13.51200008 W

F2 - Processing parameters
SI 65536
SF 600.4200145 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00





4-oxohexadec-15-ynoic acid 26 ¹³C NMR

```


Current Data Parameters
NAME      qb63695009
EXENO     5
PROCNO    1

F2 - Acquisition Parameters
Date_     20210907
Time      6.28 h
INSTRUM   Avance
PROBHD    Z159656_0020 (
PULPROG   zgpg30
TD        65536
SOLVENT   CDCl3
NS         512
DS         4
SWH       35714.285 Hz
FIDRES    1.089913 Hz
AQ         0.9175040 sec
RG         101
DM         14.000 usec
DE         18.000 usec
TE         298.0 K
D1         2.00000000 sec
D11        0.03000000 sec
TDO        1
SFO1      150.9908267 MHz
NUC1       13C
PC         3.33 usec
P1         10.00 usec
PLM1      41.91400146 W
SFO2      600.4224017 MHz
NUC2       1H
CPDPRG2   waltz16
PCPD2     80.00 usec
PLM2      13.51200008 W
PLM12     0.30124050 W
PLM13     0.15098180 W

F2 - Processing parameters
SI         65536
SF         150.9757062 MHz
WDW        EM
SSB        0
LB         1.00 Hz
GB         0
PC         1.40
    
```



4-oxohexadec-15-ynoic acid 26 HRMS






3-[3-(dodec-11-yn-1-yl)diazirin-3-yl]propanoic acid 27 ¹H NMR

Current Data Parameters
NAME gb664210305 (C16 Diaz Acid)
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20220504
Time 1.15 h
INSTRUM Avance
PROBHD Z159656_0020 (
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 11904.762 Hz
FIDRES 0.363304 Hz
AQ 2.7525120 sec
RG 75.0793
DW 42.000 usec
DE 22.00 usec
TE 298.0 K
D1 1.0000000 sec
TD0 1
SFO1 600.4230021 MHz
NUC1 1H
P0 4.00 usec
P1 12.00 usec
PLW1 13.51200008 W

F2 - Processing parameters
SI 65536
SF 600.4200145 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00




3-[3-(dodec-11-yn-1-yl)diazirin-3-yl]propanoic acid 27 ¹³C NMR

Current Data Parameters
 NAME gp664210305 (C16 Diaz Acid)
 EXPNO 3
 PROCNO 1



F2 - Acquisition Parameters
 Date_ 20220504
 Time 2.24 h
 INSTRUM Avance
 PFGPBD 2159456_0020 (1
 PULPROG zgpg30
 TD 65536
 SOLVENT cdc13
 NS 512
 DS 4
 SWH 35714.285 Hz
 FIDRES 1.089913 Hz
 AQ 0.9175040 sec
 RG 101
 DW 14.000 usec
 DE 18.00 usec
 TE 298.0 K
 D1 2.00000000 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 150.9923364 MHz
 NUC1 13C
 FO 3.33 usec
 F1 10.00 usec
 FLM1 41.91400146 W
 SFO2 600.4224017 MHz
 NUC2 1H
 CPDPRG2 waltz16
 PCPD2 80.00 usec
 FLM2 13.51200008 W
 FLM12 0.30124030 W
 FLM13 0.15098180 W

F2 - Processing parameters
 SI 65536
 SF 150.9923364 MHz
 WDM EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40



3-[3-(dodec-11-yn-1-yl)diazirin-3-yl]propanoic acid 27 HRMS

\\mass-exact\Xcalibur\data\2021\09 Sep\ESI90492.raw 29/09/2021 10:53 am





Peak Mass Display...	Delta [p...	Combin...	RDB	Theo. m...	Rank	Combin...	# Match...	# Misse...	MS Cov...	Pattern...	MSMS...	
277.1919	C ₁₆ H ₂₅ ...	2.90	23.059...	5.50	277.19...	1	84.796...	4	0	88.226...	98.455...	(Collec...

(+)-(R)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-((triethylsilyl)oxy)propyl palmitate 31 ¹H NMR

Current Data Parameters
 NAME gb64510405 (C16, C16 Diaz-OTES)
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20220505
 Time 1.04 h
 INSTRUM Avance
 PROBHD Z159656_0020 (zg30)
 PULPROG zg30
 TD 65536
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 11904.762 Hz
 FIDRES 0.363304 Hz
 AQ 2.7525120 sec
 RG 70.8784
 DW 42.000 usec
 DE 22.00 usec
 TE 298.0 K
 D1 1.0000000 sec
 TDO 1
 SFO1 600.4230021 MHz
 NUC1 1H
 RO 4.00 usec
 P1 12.00 usec
 PLW1 13.51200008 W

F2 - Processing parameters
 SI 65536
 SF 600.4200144 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



(+)-(R)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-((triethylsilyl)oxy)propyl palmitate 31 ¹³C NMR

Current Data Parameters
 NAME gb664510405 (C16, C16 Diaz -OTES)
 EXPNO 5
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20220505
 Time 2.38 h
 INSTRUM Avance
 PROBHD Z199656_0020 (1
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 1024
 DS 4
 SWH 35714.283 Hz
 FIDRES 1.089913 Hz
 AQ 0.9175040 sec
 RG 101
 DM 14.000 usec
 DE 18.00 usec
 TE 298.0 K
 D1 2.0000000 sec
 D11 0.0300000 sec
 TD0 1
 SFO1 150.9923364 MHz
 NUC1 13C
 PO 3.33 usec
 P1 10.00 usec
 PLM1 41.91400146 M
 SFO2 600.4224017 MHz
 NUC2 1H
 CPDPRG2 waltz16
 PCPD2 80.00 usec
 PLM2 13.51200008 M
 PLM12 0.30124000 M
 PLM13 0.15098180 M

F2 - Processing parameters
 SI 65536
 SF 150.9757073 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

173.62
171.79

84.91

72.43

68.19

62.42

61.23

34.29

32.85

32.08

29.85

29.81

29.79

29.64

29.56

29.56

29.51

29.45

29.32

29.29

29.21

28.88

28.79

28.63

28.40

28.25

25.06

23.95



22.84

18.54


14.26

6.79

4.44



(+)-(R)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-((triethylsilyl)oxy)propyl palmitate 31 HRMS





(S)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-hydroxypropyl palmitate 32 ¹H NMR

Current Data Parameters
NAME gb66641005 (C16, C16 Diaz -OH)
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20220511
Time 13.23 h
INSTRUM Avance
PROBHD Z199666.0020 (zg30)
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 11904.762 Hz
FIDRES 0.363304 Hz
AQ 2.7525120 sec
RG 74.9728
DW 42.000 usec
DE 22.00 usec
TE 298.0 K
D1 1.00000000 sec
TDO 1
SFO1 600.4230021 MHz
NUC1 1H
PO 4.00 usec
P1 12.00 usec
PLW1 13.51200008 W

F2 - Processing parameters
SI 65536
SF 600.4200139 MHz
WDW EM
SSB 0
LB 0.33 Hz
GB 0
PC 1.00



(S)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-hydroxypropyl palmitate ¹³C NMR

Current Data Parameters
 NAME gb66341005 (C16, C16 Diaz -OH)
 EXPNO 5
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20220511
 Time 14:57 h
 INSTRUM Avance
 PROBHD Z199656_0020 (rpgq90
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 1024
 DS 4
 SWH 35714.285 Hz
 FIDRES 1.089913 Hz
 AQ 0.9175040 sec
 RG 101
 DM 14.000 usec
 DE 18.00 usec
 TE 298.0 K
 D1 2.0000000 sec
 D11 0.0300000 sec
 TD0 1
 SFO1 150.9923364 MHz
 NUC1 13C
 PC 3.33 usec
 P1 10.00 usec
 PLM1 41.91400146 W
 SFO2 600.4224017 MHz
 NUC2 1H
 CDEPRG(2) waltz16
 ECPD2 80.00 usec
 PLM2 13.51200008 W
 PLM12 0.30124000 W
 PLM13 0.15098180 W

F2 - Processing parameters
 SI 65536
 SF 150.9797072 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

173.90
171.96

84.92

72.88

68.19

62.00

61.56

34.23

32.80

29.84

29.83

29.80

29.76

29.62

29.55

29.54

29.51

29.48

29.41

29.29

29.27

29.20

28.87

28.62

28.41



28.32

25.03



22.84

18.54

14.26



(S)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-hydroxypropyl palmitate 32
HRMS



Peak Mass Display...	Combin...	RDB	Delta [p...	Theo. m...	Rank	Combin...	# Match...	# Misse...	MS Cov...	Pattern...	MSMS...	
613.4553	C...H...	22388	550	0.77	613.45	1	89849	4	1	92597	92248	/Coller

(2R)-3-(((benzyloxy)(diisopropylamino)phosphaneyl)oxy)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)propyl palmitate 34 ¹H NMR



Current Data Parameters
NAME Dec08-2021-22-GB-161 C16 Diaz
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters

Date_ 20211208
Time_ 15.30 h
INSTRUM avh400
PROBHD Z108618_0873 (PULPROG zg60
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 8012.820 Hz
FIDRES 0.244532 Hz
AQ 4.0894465 sec
RG 88.17
DW 62.400 usec
DE 6.50 usec
TE 298.5 K
D1 1.00000000 sec
TD0 1
SFO1 400.1324008 MHz
NUC1 1H
P1 14.00 usec
PLW1 14.36989888 W

F2 - Processing parameters

SI 32768
SF 400.1300100 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00





(2R)-3-(((benzyloxy)(diisopropylamino)phosphanyl)oxy)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)propyl palmitate 34 ³¹P NMR

```



Current Data Parameters
NAME      Dec08-2021-22-GB-161  C16 Diaz Phosphoramidite
EXPNO    2
PROCNO   1

F2 - Acquisition Parameters
Date_    20211209
Time     23.14 h
INSTRUM  avn400
PROBHD   z108618_0873  i
PULPROG  zgpg30
TD       131072
SOLVENT  CDCl3
NS       16
DS       4
SWH      64102.562 Hz
FIDRES   0.978127 Hz
AQ       1.023616 sec
RG       197.18
DW       7.800 usec
DE       6.50 usec
TE       299.7 K
D1       2.0000000 sec
D11      0.0300000 sec
TDS      1
SFO1     161.9755930 MHz
NUC1     31P
FO       5.00 usec
F1       15.00 usec
PLW1     13.93799973 W
SFO2     400.1316005 MHz
NUC2     1H
CPDPRG2  waltz16
PCPDG    90.00 usec
PLW2     14.36999989 W
PLW12    0.34772000 W
PLW13    0.17480000 W

F2 - Processing parameters
SI       65536
SF       161.9755930 MHz
WDW      EM
SSB      0
LB       1.00 Hz
GB       0
PC       1.40
    
```



(2R)-3-(((benzyloxy)(diisopropylamino)phosphaneyl)oxy)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)propyl palmitate 34 HRMS





Peak Mass Display...	Combin...	RDB	Delta [p...	Theo. m...	Rank	Combin...	# Match...	# Misse...	MS Cov...	Pattern...	MSMS...		
828.6007	C...	50	519	9.50	0.84	828.60	1	96.848	4	1	99.477	99.779	1/1

(+)-(2R)-3-(((Benzyloxy)(((3aR,4R,5S,6R,7S,7aR)-4,6-bis((4-methoxybenzyl)oxy)-5-((3-oxido-1,5-dihydrobenzo[e][1,3,2]dioxaphosphepin-3-yl)oxy)hexahydrospiro[benzo[d][1,3]dioxole-2,1'-cyclopentan]-7-yl)oxy)phosphoryl)oxy)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)propyl palmitate (+)-35 ¹H NMR

Current Data Parameters
 NAME g1666672005 (ProtectedC16 Diaz inositol)
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20220523
 Time 19:28 h
 INSTRUM Avance
 PROBHD Z169656_0020 (PULPROB
 PULPROB zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 11904.762 Hz
 FIDRES 0.363304 Hz
 AQ 2.7525120 sec
 RG 41.4305
 DW 42.000 usec
 DE 22.00 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 600.4230021 MHz
 NUC1 1H
 PD 4.00 usec
 P1 12.00 usec
 PLW1 13.51200000 W

F2 - Processing parameters
 SI 65536
 SF 600.4230148 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00




(+)-(2R)-3-(((Benzyloxy)(((3aR,4R,5S,6R,7S,7aR)-4,6-bis((4-methoxybenzyl)oxy)-5-((3-oxido-1,5-dihydrobenzo[e][1,3,2]dioxaphosphepin-3-yl)oxy)hexahydrospiro[benzo[d][1,3]dioxole-2,1'-cyclopentan]-7-yl)oxy)phosphoryl)oxy)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)propyl palmitate (+)-35 ³¹P NMR

Current Data Parameters
 NAME gb666672005 (Protected C16 Diaz inositol)
 EXPNO 6
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20220523
 Time 19.39 h
 INSTRUM Avance
 PROBHD z159e56_0020 (1
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 16
 DS 4
 SWH 48543.688 Hz
 FIDRES 1.481436 Hz
 AQ 0.6750208 sec
 RG 101
 DW 10.300 usec
 DE 18.00 usec
 TE 298.0 K
 D1 2.0000000 sec
 D11 0.0300000 sec
 TD0 1
 SFO1 243.0423184 MHz
 NUC1 31P
 FO 4.00 usec
 F1 12.00 usec
 FLM1 39.40800000 M
 SFO2 600.4224017 MHz
 NUC2 1H
 CTDPRG2 waltz16
 PCPD2 80.00 usec
 PLM2 13.51200008 M
 PLM12 0.30124050 M
 PLM13 0.15098180 M

F2 - Processing parameters
 SI 32768
 SF 243.0544711 MHz
 NH 64
 SEB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

-0.64
 -0.67
 -1.86
 -1.97





(+)-(2R)-3-(((Benzyloxy)(((3aR,4R,5S,6R,7S,7aR)-4,6-bis((4-methoxybenzyl)oxy)-5-((3-oxido-1,5-dihydrobenzo[e][1,3,2]dioxaphosphepin-3-yl)oxy)hexahydrospiro[benzo[d][1,3]dioxole-2,1'-cyclopentan]-7-yl)oxy)phosphoryl)oxy)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)propyl palmitate (+)-35 ¹³C NMR

Current Data Parameters
 NAME gb66672005 (Protected C16 Diast inositol)
 EXPNO 5
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 15 03 2020
 Time 14.37
 INSTRUM spect
 PROCNO 5
 PULPROG zgpg30
 TE 300.2


SOLVENT 1
 NS 212
 DS 4
 SWH 35714.285 Hz
 FIDRES 1.089913 Hz
 AQ 0.9175040 sec
 RG 101
 DM 14.000 usec
 DE 18.00 usec
 TE 298.0 K
 D1 2.0000000 sec
 D11 0.0300000 sec
 TDO 1
 SFO1 150.9923364 MHz
 NUC1 13C
 PD 3.33 usec
 P1 10.00 usec
 PLM1 41.91400146 W
 SFO2 600.4224017 MHz
 NUC2 1H
 CDEPRG(2) waltz16
 ECPD2 80.00 usec
 PLM2 13.51200008 W
 PLM12 0.30124050 W
 PLM13 0.15098180 W

F2 - Processing parameters
 SI 65536
 SF 150.9757085 MHz
 WHW 8M
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40



(+)-(2*R*)-3-(((Benzyloxy)(((3*aR*,4*R*,5*S*,6*R*,7*S*,7*aR*)-4,6-bis((4-methoxybenzyl)oxy)-5-((3-oxido-1,5-dihydrobenzo[*e*][1,3,2]dioxaphosphepin-3-yl)oxy)hexahydrospiro[benzo[*d*][1,3]dioxole-2,1'-cyclopentan]-7-yl)oxy)phosphoryl)oxy)-2-((3-(3-(dodec-11-yn-1-yl)-3*H*-diazirin-3-yl)propanoyl)oxy)propyl palmitate (+)-35


HPLC 280nm



Time	Height	Area	Area %
3.277	875.6	4,641.7	0.03
3.536	3,577.9	31,004.7	0.17
3.634	1,172.9	6,234.2	0.03
5.162	546.7	3,752.2	0.02
5.722	2,163.9	10,848.1	0.06
8.419	419.9	25,820.5	0.14
11.278	222,879.7	9,439,156.3	51.54
12.202	199,256.7	8,792,337.5	48.01
Total		18,313,795.1	100.00

(+)-(2*R*)-3-(((Benzyloxy)(((3*aR*,4*R*,5*S*,6*R*,7*S*,7*aR*)-4,6-bis((4-methoxybenzyl)oxy)-5-((3-oxido-1,5-dihydrobenzo[*e*][1,3,2]dioxaphosphepin-3-yl)oxy)hexahydrospiro[benzo[*d*][1,3]dioxole-2,1'-cyclopentan]-7-yl)oxy)phosphoryl)oxy)-2-((3-(3-(dodec-11-yn-1-yl)-3*H*-diazirin-3-yl)propanoyl)oxy)propyl palmitate (+)-35

HPLC 254nm





Time	Height	Area	Area %
3.266	2,471.9	29,013.9	0.30
3.473	4,153.9	30,649.7	0.32
3.586	3,855.9	30,122.2	0.32
4.194	245.7	9,503.5	0.10
5.241	236.7	1,224.2	0.01
5.765	2,005.5	11,704.4	0.12
8.112	231.2	7,705.9	0.08
11.008	116,975.3	4,977,390.4	52.24
11.969	102,803.8	4,430,765.5	46.50
Total		9,528,079.6	100.00

(+)-(2R)-3-(((Benzyloxy)(((3aR,4R,5S,6R,7S,7aR)-4,6-bis((4-methoxybenzyl)oxy)-5-((3-oxido-1,5-dihydrobenzo[e][1,3,2]dioxaphosphepin-3-yl)oxy)hexahydrospiro[benzo[d][1,3]dioxole-2,1'-cyclopentan]-7-yl)oxy)phosphoryl)oxy)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)propyl palmitate (+)-35 HRMS

Z:\data\2022\02 (Feb)\ESI92955.raw

21/02/2022 4:02 pm





Peak Mass Display...	Combin...	RDB	Delta (p...	Theo. m...	Rank	Combin...	# Match...	# Misse...	MS Cov...	Pattern...	MSMS...	
1411.7	C...H...	50.588	25.50	-3.12	1411.7	1	94.616	7	0	97.062	99.917	IColler

Ammonium (1S,2R,3R,4R,5R,6R)-3-(((R)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-(palmitoyloxy)propoxy)oxidophosphoryl)oxy)-2,4,5,6-tetrahydroxycyclohexyl phosphate 9 ¹H NMR

Current Data Parameters
 NAME gb669431406 (C16 Diaz inositol)
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date 20220614
 Time 10.18 h
 INSTRUM Avance
 PROBHD Z159856 0020 (zq30)
 PULPROG zg30
 TD 65536
 SOLVENT MeOD
 NS 16
 DS 2
 SWH 11904.762 Hz
 FIDRES 0.363304 Hz
 AQ 2.7525120 sec
 RG 85.9444
 DW 42.000 usec
 DE 22.00 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 600.4230021 MHz
 NUC1 ¹H
 P0 4.00 usec
 P1 12.00 usec
 PLW1 13.51200008 W

F2 - Processing parameters
 SI 65536
 SF 600.4200117 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00





Ammonium (1S,2R,3R,4R,5R,6R)-3-(((R)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-(palmitoyloxy)propoxy)oxidophosphoryl)oxy)-2,4,5,6-tetrahydroxycyclohexyl phosphate 9 ³¹P NMR

Current Data Parameters
 NAME gbb69431406 (C16 Diaz inositol)
 EXPNO 9
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20220614
 Time 17.14 h
 INSTRUM Avance
 PROBHD 219656_0020 (zpg30)
 PULPROG zgpg30
 TD 65536
 SOLVENT MeOD
 NS 64
 DS 4
 SWH 48543.688 Hz
 FIDRES 1.481436 Hz
 AQ 0.6750208 sec
 RG 101
 DM 10.300 usec
 DE 18.00 usec
 TE 298.0 K
 D1 2.0000000 sec
 D11 0.0300000 sec
 TD0 1
 SFO1 243.0423184 MHz
 NUC1 ³¹P
 FO 4.00 usec
 FI 12.00 usec
 PLM1 39.4080095 W
 SFO2 600.4224017 MHz
 NUC2 ¹H
 CDFPR2 waltz16
 PCPD2 80.00 usec
 PLM2 13.5120008 W
 PLM12 0.30124050 W
 PLM13 0.15068180 W

F2 - Processing parameters
 SI 32768
 SF 243.0544711 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40




Ammonium (1S,2R,3R,4R,5R,6R)-3-(((R)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-(palmitoyloxy)propoxy)oxidophosphoryl)oxy)-2,4,5,6-tetrahydroxycyclohexyl phosphate 9 ¹³C NMR

Current Data Parameters
 NAME g0669431406 (C16 Diaz inositol)
 EXPNO 7
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20220614
 Time 17.02 h
 INSTRUM Avance
 PROBHD z159e56_0020 (zpgpg30)
 PULPROG zgpg30
 TD 65536
 SOLVENT H₂O
 NS 4195
 DS 4
 SWH 35714.283 Hz
 FIDRES 1.089913 Hz
 AQ 0.9175040 sec
 RG 101
 DM 14.000 usec
 DE 18.00 usec
 TE 298.0 K
 D1 2.0000000 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 150.9923364 MHz
 NUC1 13C
 FO 3.33 usec
 F1 10.00 usec
 PLM1 41.91400146 W
 SFO2 600.4224017 MHz
 NUC2 1H
 CDEPRG(2) Waltz16
 PCDE2 80.00 usec
 PLM2 13.51200008 W
 PLM12 0.30124050 W
 PLM13 0.15098180 W

F2 - Processing Parameters
 SI 131072
 SF 150.9756054 MHz
 MDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 PC 1.40



Ammonium (1S,2R,3R,4R,5R,6R)-3-((((R)-2-(((3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-(palmitoyloxy)propoxy)oxidophosphoryl)oxy)-2,4,5,6-tetrahydrocyclohexyl phosphate 9 ¹H to ¹³C HSQC NMR

Current Data Parameters
 NAME gb669431406 (C16 Diaz inositol)
 EXPNO 2
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20220914
 Time 10:41 h
 INSTRUM Avance
 PROBHD Z130859 0020 (1
 PULPROG zgpg30
 TD 2048

SOLVENT MeOD
 NS 4
 DS 16
 SWH 7142.857 Hz
 FIDRES 0.875448 Hz
 AQ 0.143390 sec
 RG 101
 DW 70.000 usec
 DE 22.000 usec
 TE 295.0 K
 CNST2 145.0000000
 D0 0.0000000 sec
 D1 1.0000000 sec
 D4 0.00172414 sec
 D11 0.0000000 sec
 D18 0.00010000 sec
 D21 0.00000000 sec
 INO 0.0000000 sec



TDav 1
 ZGPGTNS
 SFO1 600.4200021 MHz
 NUC1 1H
 P1 12.00 usec
 R2 24.00 usec
 PLW1 13.51200008 W
 SFO2 130.857071 MHz
 NUC2 13C
 CPDPRG2 garp
 P3 10.00 usec
 P14 500.00 usec
 P31 1730.00 usec
 PCPD2 55.00 usec
 PLW0 0 W
 PLW2 41.81400149 W
 PLW12 1.38558897 W
 SPNAM[3] Crp90.0.5.20.1
 SFOA L3 0.300
 SFOFFS3 0 Hz
 SPW3 6.400000051 W
 SPNAM[18] Crp90_xfilt2
 SFOA L18 0.300
 SFOFFS18 0 Hz
 SPW18 1.880000005 W
 GPNAM[1] SMSG10.100
 GZ1 80.00 %
 GPNAM[2] SMSG10.100
 GZ2 20.10 %
 P18 1000.00 usec

===== F1 INDIRECT DIMENSION =====
 td1 256
 sw_F1 184.066352

F1 - Acquisition parameters
 TD 256
 SFO1 150.8578 MHz
 FIDRES 18.843417 Hz
 SW 185.000 ppm
 FaMODE Echo-Antiecho

F2 - Processing parameters
 SI 2048
 SF 600.4200000 MHz
 WDW CSINE
 SSB 2
 LB 0 Hz
 GB 0
 RC 1.00



F1 - Processing parameters
 SI 1024
 MC2 echo-antiecho
 SF 150.857291 MHz
 WDW CSINE
 SSB 2
 LB 0 Hz
 GB 0



Ammonium (1S,2R,3R,4R,5R,6R)-3-(((R)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-(palmitoyloxy)propoxy)oxidophosphoryl)oxy)-2,4,5,6-tetrahydrocyclohexyl phosphate 9 HRMS

Z:\data\2022\03 (Mar)\ESI93132.raw

02/03/2022 5:32 pm





Peak Mass Display...	Combin...	RDB	Delta [p...	Theo. m...	Rank	Combin...	# Match...	# Misse...	MS Cov...	Pattern...	MSMS...	
911.4425	C...H...	19.749	7.50	-1.69	911.44	1	86.181	5	0	89.899	89.392	ifCellar

(+)-(2S)-3-[bis(4-methoxyphenyl)(phenyl)methoxy]-2-hydroxypropyl hexadecanoate (+)-S10 ¹H NMR


Current Data Parameters
NAME Apr01-2021-42-GB-043
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date 20210401
Time 8.45 h
INSTRUM avq400
PROBHD Z108618_0816 (
PULPROG zg60
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 8012.820 Hz
FIDRES 0.244532 Hz
AQ 4.0894465 sec
RG 35.2
DW 62.400 usec
DE 6.50 usec
TE 298.1 K
D1 1.00000000 sec
TDO 1
SFO1 400.2024012 MHz
NUC1 1H
P1 14.00 usec
PLW1 14.0000000 W

F2 - Processing parameters
SI 32768
SF 400.2000094 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00



(+)-(2S)-3-[bis(4-methoxyphenyl)(phenyl)methoxy]-2-hydroxypropyl hexadecanoate (+)-S10
HRMS





(+)-(2S)-3-[bis(4-methoxyphenyl)(phenyl)methoxy]-2-hydroxypropyl octanoate (+)-S11 ¹H NMR

Current Data Parameters
NAME Apr05-2021-2-GB-044
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20210405
Time 9.29 h
INSTRUM avq400
PROBHD Z108618.0816 ()
PULPROG zg60
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 8012.820 Hz
FIDRES 0.244532 Hz
AQ 4.0894465 sec
RG 91.39
DW 62.400 usec
DE 6.50 usec
TE 297.7 K
D1 1.0000000 sec
TD0 1
SFO1 400.2024012 MHz
NUC1 1H
P1 14.00 usec
PLW1 14.0000000 W

F2 - Processing parameters
SI 32768
SF 400.2000094 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00





(+)-(2S)-3-[bis(4-methoxyphenyl)(phenyl)methoxy]-2-hydroxypropyl octanoate (+)-S11 ¹³C NMR


Current Data Parameters
NAME Apr05-2021-2-08-044
EXPNO 2
PROCNO 1

F2 - Acquisition Parameters
Date_ 20210405
Time 10:11 h
INSTRUM avq400
PROBHD Z108618_0816 (r
PULPROG zgpg30
TD 32768
SOLVENT CDCl3
NS 512
DS 4
SWH 26041.666 Hz
FIDRES 1.589457 Hz
AQ 0.6291456 sec
RG 206.87
DM 19.200 usec
DE 6.20 usec
TE 298.8 K
D1 1.0000000 sec
D11 0.0300000 sec
TD0 1
SFO1 100.6404331 MHz
NUC1 13C
FO 3.33 usec
P1 10.00 usec
PLM1 56.0000000 M
SFO2 400.2016008 MHz
NUC2 1H
CPDPRG2 waltz16
PCPD2 30.00 usec
PLM2 14.0000000 M
PLM12 0.33877000 M
PLM13 0.17039999 M

F2 - Processing parameters
SI 32768
SF 100.6303577 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40



(+)-(2S)-3-[bis(4-methoxyphenyl)(phenyl)methoxy]-2-hydroxypropyl octanoate (+)-S11 HRMS






(+)-(2S)-3-[bis(4-methoxyphenyl)(phenyl)methoxy]-2-(octanoyloxy)propyl hexadecanoate (+)-S12 ¹H NMR

Current Data Parameters
NAME Apr05-2021-3-GB-045
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date 20210405
Time 9.34 h
INSTRUM avq400
PROBHD Z108618_0816 ()
PULPROG zg60
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 8012.820 Hz
FIDRES 0.244532 Hz
AQ 4.0894465 sec
RG 39.24
DW 62.400 usec
DE 6.50 usec
TE 297.7 K
D1 1.00000000 sec
TDO 1
SFO1 400.2024012 MHz
NUC1 1H
P1 14.00 usec
PLW1 14.00000000 W

F2 - Processing parameters
SI 32768
SF 400.2000099 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00




(+)-(2S)-3-[bis(4-methoxyphenyl)(phenyl)methoxy]-2-(octanoyloxy)propyl hexadecanoate (+)-S12 ¹³C NMR


Current Data Parameters
NAME Apr05-2021-3-08-045
EXPNO 2
PROCNO 1

F2 - Acquisition Parameters
Date_ 20210405
Time 10.29 h
INSTRUM avq400
PROBHD Z108618_0816 ()
PULPROG zgpg30
TD 22768
SOLVENT CDCl3
NS 512
DS 4
SMH 26041.666 Hz
FIDRES 1.589457 Hz
AQ 0.6291436 sec
RG 206.87
DM 19.200 usec
DE 6.50 usec
TE 298.8 K
D1 1.0000000 sec
D11 0.0300000 sec
TDO 1
SFO1 100.6404331 MHz
NUC1 13C
PO 3.33 usec
P1 10.00 usec
PLM1 56.0000000 W
SFO2 400.2016008 MHz
NUC2 1H
CPDPRG2 waltz16
PCPD2 90.00 usec
PLM2 14.0000000 W
PLM12 0.33877000 W
PLM13 0.17039999 W

F2 - Processing parameters
SI 32768
SF 100.6303989 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40



(+)-(2S)-3-[bis(4-methoxyphenyl)(phenyl)methoxy]-2-(octanoyloxy)propyl hexadecanoate (+)-S12 HRMS






(+)-(2S)-1-[bis(4-methoxyphenyl)(phenyl)methoxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (+)-S13 ¹H NMR

Current Data Parameters
NAME Apr07-2021-20-GB-046
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date 20210407
Time 10.13 h
INSTRUM avq400
PROBHD Z108618_0816 ()
PULPROG zg60
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 8012.820 Hz
FIDRES 0.244532 Hz
AQ 4.0894465 sec
RG 22.48
DW 62.400 usec
DE 6.50 usec
TE 296.3 K
D1 1.00000000 sec
TDO 1
SFO1 400.2024012 MHz
NUC1 1H
P1 14.00 usec
PLW1 14.0000000 W

F2 - Processing parameters
SI 32768
SF 400.2000095 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00





(+)-(2S)-1-[bis(4-methoxyphenyl)(phenyl)methoxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (+)-S13 ¹³C NMR


Current Data Parameters
 NAME Apr07-2021-20-08-046
 EXPNO 2
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20210407
 Time 11:05 h
 INSTRUM avq400
 PROBEID Z108618_0816 ()
 PULPROG zgpg30
 TD 32768
 SOLVENT CDCl3
 NS 512
 DS 4
 SMH 26041.666 Hz
 FIDRES 1.589457 Hz
 AQ 0.6291436 sec
 RG 206.87
 DM 19.200 usec
 DE 6.50 usec
 TE 297.4 K
 D1 1.0000000 sec
 D11 0.0300000 sec
 TDO 1
 SFO1 100.6404331 MHz
 NUC1 13C
 PO 3.33 usec
 P1 10.00 usec
 PLM1 36.0000000 W
 SFO2 400.2016008 MHz
 NUC2 1H
 CPDPRG2 waltz16
 FPCP2 90.00 usec
 PLM2 14.0000000 W
 PLM12 0.33877000 W
 PLM13 0.17039999 W

173.52
 173.15
 158.64
 144.69
 135.89
 135.86
 130.13
 130.11
 128.21
 127.94
 126.94
 113.23
 86.18
 70.60
 63.06
 62.16
 55.29
 34.54
 34.24
 32.05
 31.79
 29.82
 29.78
 29.62
 29.49
 29.46
 29.29
 29.19
 29.04
 25.10
 24.98
 22.81
 22.73
 14.24
 14.19



(+)-(2S)-1-[bis(4-methoxyphenyl)(phenyl)methoxy]-3-(octanoyloxy)propan-2-yl hexadecanoate
(+)-S13 HMRS





(-)-(2S)-3-hydroxy-2-(octanoyloxy)propyl hexadecanoate (-)-S14 ¹H NMR

Current Data Parameters
NAME gb710731807 (C16, C8 -OH)
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date 20230718
Time 20.43 h
INSTRUM Avance
PROBHD Z159656_0020 (zg30)
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 11904.762 Hz
FIDRES 0.363304 Hz
AQ 2.7525120 sec
RG 64
DW 42.000 usec
DE 22.00 usec
TE 298.0 K
D1 1.00000000 sec
TDO 1
SFO1 600.4230021 MHz
NUC1 1H
P0 4.00 usec
P1 12.00 usec
PLW1 13.51200008 W

F2 - Processing parameters
SI 65536
SF 600.4200137 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00




(-)-(2S)-3-hydroxy-2-(octanoyloxy)propyl hexadecanoate (-)-S14 ¹³C NMR

Current Data Parameters
 NAME qb710731807 (C16, C8 -OH)
 EXPNO 5
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20230719
 Time 0.08 h
 INSTRUM Avance
 PROBHD Z199656_0020 (1
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 2048
 DS 4
 SWH 35714.283 Hz
 FIDRES 1.089913 Hz
 AQ 0.9175040 sec
 RG 101
 DM 14.000 usec
 DE 18.00 usec
 TE 298.0 K
 D1 3.0000000 sec
 D11 0.0300000 sec
 ED0 1
 SFO1 150.9923364 MHz
 NUC1 13C
 PO 3.33 usec
 P1 10.00 usec
 PLM1 41.91400146 M
 SFO2 600.4224017 MHz
 NUC2 1H
 CPDPRG2 waltz16
 PCPD2 70.00 usec
 PLM2 13.51200008 M
 PLM12 0.39708999 M
 PLM13 0.19972999 M



F2 - Processing parameters
 SI 65536
 SF 150.9757081 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

173.93
173.57




72.27
62.15
61.72

34.43
34.26
32.07
31.79
29.83
29.82
29.79
29.75
29.61
29.50
29.41
29.27
29.18
29.06
25.08
25.04
22.83
22.74
14.25
14.19



(-)-(2S)-3-hydroxy-2-(octanoyloxy)propyl hexadecanoate (-)-S14 HRMS





(2S)-1-hydroxy-3-(octanoyloxy)propan-2-yl hexadecanoate (-)-S15 ¹H NMR

Current Data Parameters
NAME Apr08-2021-6-GB-050
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date 20210408
Time 9.49 h
INSTRUM avq400
PROBHD Z108618_0816 ()
PULPROG zg60
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 8012.820 Hz
FIDRES 0.244532 Hz
AQ 4.0894465 sec
RG 91.39
DW 62.400 usec
DE 6.50 usec
TE 297.3 K
D1 1.00000000 sec
TDO 1
SFO1 400.2024012 MHz
NUC1 1H
P1 14.00 usec
PLW1 14.00000000 W

F2 - Processing parameters
SI 32768
SF 400.2000098 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00



(2S)-1-hydroxy-3-(octanoyloxy)propan-2-yl hexadecanoate (-)-S15 ¹³C NMR

Current Data Parameters
NAME Apr08-2021-6-08-050
EXPNO 2
PROCNO 1

F2 - Acquisition Parameters
Date_ 20210408
Time 21.52 h
INSTRUM avq400
PROBHD Z108618_0816 ()
PULPROG zgpg30
TD 32768
SOLVENT CDCl3
NS 512
DS 4
SMH 26041.666 Hz
FIDRES 1.589457 Hz
AQ 0.6291456 sec
RG 206.87
DM 19.200 usec
DE 6.50 usec
TE 299.2 K
D1 1.0000000 sec
D11 0.0300000 sec
TDO 1
SFO1 100.6404331 MHz
NUC1 13C
PC 3.33 usec
P1 10.00 usec
PLM1 56.0000000 W
SFO2 400.2016008 MHz
NUC2 1H
CPDPRG2 waltz16
PCPD2 90.00 usec
PLM2 14.0000000 W
PLM12 0.33877000 W
PLM13 0.17039999 W




F2 - Processing parameters
SI 32768
SF 100.6303559 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40

173.92
173.57

72.26




62.14
61.73

34.44
34.25
32.07
31.79
29.83
29.80
29.76
29.62
29.50
29.41
29.24
29.21
29.05
25.09
25.03
22.83
22.74
14.25
14.19



(2S)-1-hydroxy-3-(octanoyloxy)propan-2-yl hexadecanoate (-)-S15 HRMS

Z:\data\2021\05 May\ESI88218.raw 17/05/2021 7:08 pm
 NL: 9.28E5
 ESI88218 #14-33 RT: 0.16-0.39 AV: 10 NL:
 3.42E+006
 T: FTMS [1.1] + p ESI Full lock ms
 [80.00-1600.00]





NL: 7.34E5
 C27H52O5Na1 Chrg 1 R: 36167 Res.
 Pwr. @FWHM

Theoretical Spectrum

Peak Mass Display...	Combin...	RDB	Delta (p...	Theo. m...	Rank	Combin...	# Match...	# Misse...	MS Cov...	Pattern...	MSMS...
479.3706	1	1	0.00	479.37	1	1	1	0	100.00	100.00	100.00

(+)-(2R)-3-((benzyloxy)[di(propan-2-yl)amino]phosphanyl)oxy)-2-(octanoyloxy)propyl hexadecanoate (+)-S16 ¹H NMR

Current Data Parameters
 NAME: Apr09-2021-215-BB-0491-3 (D6-C8 phosphoramidite)
 EXPNO: 1
 PROCNO: 1
 F2 - Acquisition Parameters
 Date_: 20210409
 Time: 15:45
 INSTRUM: av400
 PROBHD: z100113 01771
 PULPROG: zgpg
 TD: 65536
 SOLVENT: CDCl3
 NS: 10
 DS: 2
 SFO1: 805.220 MHz
 FIDRES: 0.244532 Hz
 AQ: 4.0164405 sec
 RG: 50.45
 DDF: 60.400 usec
 DE: 6.50 usec
 TE: 293.5 K
 D1: 1.0000000 sec
 TSD: 1
 SFO2: 400.1324008 MHz
 NUC1: 1H
 P1: 14.00 usec
 PL1: 14.2000000 W
 F2 - Processing parameters
 SI: 32768
 SF: 400.1320099 MHz
 WDW: EM
 GB: 0
 LB: 0.20 Hz
 GB: 0
 PC: 1.00





(+)-(2R)-3-(((benzyloxy)[di(propan-2-yl)amino]phosphanyl)oxy)-2-(octanoyloxy)propyl hexadecanoate (+)-S16 ³¹P NMR

```

Current Data Parameters
NAME      Apr09-2021-26-09-0481-3 (C16-C8 phosphoramidite)
EXPNO     2
PROCNO    1
F2 - Acquisition Parameters
Date_     20210410
Time      1.22 h
INSTRUM   av400
PROCNO    2100618_0079 (
PULPROG   zgpg30
TD         131072
SOLVENT   CDCl3
NS         16
DS         4
SFO       64102.562 Hz
FIDRES    0.976127 Hz
AQ         1.0227616 sec
RG         197.18
DM         7.500 usec
DE         6.50 usec
TE         299.2 K
D1         2.00000000 sec
D11        0.03000000 sec
ZD0        1
SFO1       161.9755500 MHz
NUC1       31P
FO         5.00 usec
P1         15.00 usec
PLM1       13.2079973 W
SFO2       400.1216005 MHz
NUC2       1H
CPDPRG2   waltz16
PCPD2     90.00 usec
PLM2       14.0699989 W
PLM12     0.2472000 W
PLM13     0.17490000 W
F2 - Processing parameters
SI         65536
SF         161.9755500 MHz
WDW        EM
SSB        0
LB         1.00 Hz
GB         0
PC         1.40
    
```

150.00
149.00
148.00





150 100 50 0 -50 -100 -150 ppm

(+)-(2R)-3-((benzyloxy)[di(propan-2-yl)amino]phosphanyl)oxy)-2-(octanoyloxy)propyl hexadecanoate (+)-S16 HRMS

Z:\data\2021\05 May\ESI88245.raw



18/05/2021 2:14 pm



Peak Mass	Display...	Combin...	RDB	Delta [p...	Theo. m...	Rank	Combin...	# Match...	# Misse...	MS Cov...	Pattern...	MSMS...		
694.5164	C...H...	60	5.50	-0.82	694.51	1	42	216	2	0	41	302	100	Collor

(+)-(7R)-4-(benzyloxy)-2-methyl-10-oxo-3-(propan-2-yl)-5,9-dioxa-3-aza-4-phosphaheptadecan-7-yl hexadecanoate (+)-S17 ¹H NMR



Current Data Parameters
 NAME Apr22-2021-05-G-B-052 (C1-C16 phosphoramidite)
 EXPNO 1
 PROCNO 1
 F2 - Acquisition Parameters
 Date_ 20210322
 Time 10:22 h
 INSTRUM av640
 PROBHD Z101815_0116 (1
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 2
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.244532 Hz
 AQ 4.0164405 sec
 RG 32.24
 DW 62.400 usec
 DE 6.30 usec
 TE 297.5 K
 DI 1.00000000 sec
 TDD 1
 SFO1 400.2024012 MHz
 NUC1 1H
 P1 14.00 usec
 PLW1 14.00000000 W
 F2 - Processing parameters
 SI 32768
 SF 400.2024012 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



(+)-(7R)-4-(benzyloxy)-2-methyl-10-oxo-3-(propan-2-yl)-5,9-dioxa-3-aza-4-phosphaheptadecan-7-yl hexadecanoate (+)-S17 ³¹P NMR

Current Data Parameters
NAME Apr22-2021-26-QB-052 (08-c16 phosphoramidite)
EXPNO 2
PROCNO 1

F2 - Acquisition Parameters
Date_ 20210422
Time 10.25 h
INSTRUM avq400
PROCNO 2108618_0816 (4 0 0 3
PULPROG zgpg30 1 4 0 0 0 7
TD 131072
SOLVENT cdc13
MS 16
DE 4
SWH 64102.562 Hz
FIDRES 0.978127 Hz
AQ 1.0231616 sec
RG 206.87
DW 7.800 usec
DE 6.50 usec
TE 298.0 K
D1 2.0000000 sec
D11 0.0300000 sec
TDS 1
SFO1 162.0039295 MHz
NUC1 31P
FO 5.00 usec
PI 15.00 usec
PLW1 13.0000000 W
SFO2 400.2016008 MHz
NUC2 1H
CPDPRG2 waltz16
PCPD 90.00 usec
PLW2 14.0000000 W
PLW12 0.33877000 W
PLW13 0.11039999 W
F2 - Processing parameters
SI 65536
SF 162.0039295 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40





(+)-(2R)-3-[[[(benzyloxy)((3aR,4S,5R,6S,7R,7aR)-5,7-bis(benzyloxy)-6-[(3-oxo-1,5-dihydro-3H-2,4,3λ5-benzodioxaphosphepin-3-yl)oxy]hexahydrospiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl)oxy)phosphoryl]oxy]-2-(octanoyloxy)propyl hexadecanoate (+)-S18 ¹H NMR

Current Data Parameters
 NAME g062201809 (c16-C8 protected Inositol)
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20210520
 Time 13:44 h
 INSTRUM Avance
 PROBHD z19009 0120 (PULPROG zg30
 TD 65536
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 11804.762 Hz
 FIDRES 0.363304 Hz
 AQ 2.7529120 sec
 RG 66.8698
 DW 42.000 usec
 DE 22.000 usec
 TE 298.0 K
 D1 1.0000000 sec
 TDO 1
 SFO1 600.4230021 MHz
 NUC1 1H
 P0 4.00 usec
 P1 12.00 usec
 PLW1 13.9120006 W

F2 - Processing parameters
 SI 65536
 SF 600.4230021 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



(+)-(2R)-3-[[[(benzyloxy)((3aR,4S,5R,6S,7R,7aR)-5,7-bis(benzyloxy)-6-[(3-oxo-1,5-dihydro-3H-2,4,3λ5-benzodioxaphosphepin-3-yl)oxy]hexahydrospiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl)oxy)phosphoryl]oxy]-2-(octanoyloxy)propyl hexadecanoate (+)-S18 ³¹P NMR

Current Data Parameters
 NAME g962261905 (C16-C8 protected inositol)
 EXPNO 5
 PROCNO 1


F2 - Acquisition Parameters

Date_ 20210520
 Time 14.45 h
 INSTRUM Avance
 PROBHD Z159656_0020 (1
 PULPROG zgpg30
 TD 65536
 SOLVENT CD2Cl2
 NS 512
 DS 4
 SWH 48943.688 Hz
 FIDRES 1.481436 Hz
 AQ 0.6750208 sec
 RG 101
 DW 10.500 usec
 DE 18.00 usec
 TE 298.0 K
 D1 2.0000000 sec
 D11 0.0300000 sec
 TD0 1
 SFO1 243.0423184 MHz
 NUC1 ³¹P
 PD 4.00 usec
 F1 12.00 usec
 PL1 39.4080000 W
 SFO2 600.4224017 MHz
 NUC2 ¹H
 CDEPRG(2) Waltz16
 ECPD2 80.00 usec
 PLM2 13.5120000 W
 PLM12 0.30124050 W
 PLM13 0.13098180 W


F2 - Processing parameters

SI 32768
 SF 243.0544711 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40


1.091
 1.80
 1.96



(+)-(2R)-3-[(benzyloxy)((3aR,4S,5R,6S,7R,7aR)-5,7-bis(benzyloxy)-6-[(3-oxo-1,5-dihydro-3H-2,4,3λ5-benzodioxaphosphepin-3-yl)oxy]hexahydrospiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl)oxy]phosphoryl]oxy}-2-(octanoyloxy)propyl hexadecanoate (+)-S18 ¹³C NMR




(+)-(2R)-3-[[[(benzyloxy){(3aR,4S,5R,6S,7R,7aR)-5,7-bis(benzyloxy)-6-[(3-oxo-1,5-dihydro-3H-2,4,3λ5-benzodioxaphosphepin-3-yl)oxy]hexahydrospiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl)oxy]phosphoryl]oxy}-2-(octanoyloxy)propyl hexadecanoate (+)-S18 HPLC 254nm



Time	Height	Area	Area %
4.278	477.3	2,996.1	0.24
4.656	44,957.3	649,405.9	51.36
5.189	21,603.0	610,963.4	48.32
7.115	164.2	432.9	0.03
10.910	231.5	683.8	0.05
Total		1,264,482.1	100.00

(+)-(2R)-3-[[[(benzyloxy){(3aR,4S,5R,6S,7R,7aR)-5,7-bis(benzyloxy)-6-[(3-oxo-1,5-dihydro-3H-2,4,3λ5-benzodioxaphosphepin-3-yl)oxy]hexahydrospiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl}oxy]phosphoryl]oxy]-2-(octanoyloxy)propyl hexadecanoate (+)-S18 HPLC 220nm





Time	Height	Area	Area %
4.355	6,102.3	45,838.7	0.34
4.753	361,524.5	6,326,487.7	47.36
5.335	194,836.1	6,893,991.7	51.61
6.636	5,553.0	91,593.1	0.69
Total		13,357,911.2	100.00

(+)-(2R)-3-[[[(benzyloxy){(3aR,4S,5R,6S,7R,7aR)-5,7-bis(benzyloxy)-6-[(3-oxo-1,5-dihydro-3H-2,4,3λ5-benzodioxaphosphepin-3-yl)oxy]hexahydrospiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl}oxy)phosphoryl]oxy}-2-(octanoyloxy)propyl hexadecanoate (+)-S18 HRMS

Z:\data\2021\05\May\ESI88203.raw

17/05/2021 6:47 pm





Peak Mass Display...	Combin...	RDB	Delta [p...	Theo. m...	Rank	Combin...	# Match...	# Misse...	MS Cov...	Pattern...	MSMS...
1239.5	C...H...	58.787	21.50	1239.5	1	94.329	6	0	96.304	100	Collar

(+)-(6R)-3-((3aR,4S,5R,6S,7R,7aR)-5,7-bis(benzyloxy)-6-[(3-oxo-1,5-dihydro-3H-2,4,3λ5-benzodioxaphosphepin-3-yl)oxy]hexahydrospiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl)oxy)-3,9-dioxo-1-phenyl-2,4,8-trioxa-3λ5-phosphahexadecan-6-yl hexadecanoate (+)-S19 ¹H NMR

Current Data Parameters
 NAME g16c0773009 (c9-C16 protected Inositol)
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20210309
 Time 11:42 h
 INSTRUM Avance
 PROBHD 21mmQNP 1300 (1
 PULPROG zg30
 TD 65536
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 11804.762 Hz
 FIDRES 0.36304 Hz
 AQ 2.729120 sec
 RG 47.4347
 DW 42.000 usec
 DE 23.00 usec
 TE 298.0 K
 D1 1.0000000 sec
 TDO 1
 SFO1 600.4230021 MHz
 NUC1 1H
 P0 4.00 usec
 P1 12.00 usec
 PLW1 13.2120000 W

F2 - Processing parameters
 SI 65536
 SF 600.4230000 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



(+)-(6R)-3-((3aR,4S,5R,6S,7R,7aR)-5,7-bis(benzyloxy)-6-[(3-oxo-1,5-dihydro-3H-2,4,3λ5-benzodioxaphosphepin-3-yl)oxy]hexahydrospiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl)oxy)-3,9-dioxo-1-phenyl-2,4,8-trioxa-3λ5-phosphahexadecan-6-yl hexadecanoate (+)-S19 ³¹P NMR




```

Current Data Parameters
NAME      gms20770605 (C8-C16 protected inositol)
EXPNO    7
PROCNO   1


F2 - Acquisition Parameters
Date_    20210503
Time     12.26 h
INSTRUM  avq400
PROBHD   Z108618_0816 (
PULPROG  zgpg30
TD       131072
SOLVENT  CD2CL2
NS       16
DS       4
SWH      64102.562 Hz
FIDRES   0.978127 Hz
AQ       1.0223616 sec
RG       206.87
DM       7.800 usec
DE       6.50 usec
TE       298.1 K
D1       2.0000000 sec
D11      0.0300000 sec
TD0      1
SFO1     162.0039295 MHz
NUC1     31P
PD       5.00 usec
P1       15.00 usec
PLA1     13.0000000 W
SFO2     400.2016008 MHz
NUC2     1H
CDEPRG2  waltz16
ECPD2    90.00 usec
PLM2     14.0000000 W
PLM12    0.33877050 W
PLM13    0.17639999 W

F2 - Processing parameters
SI       65536
SF       162.0039295 MHz
WDW      EM
SSB      0
LB       1.00 Hz
GB       0
PC       1.40
    
```


-0.91
 -1.80
 -1.94



(+)-(6R)-3-((3aR,4S,5R,6S,7R,7aR)-5,7-bis(benzyloxy)-6-[(3-oxo-1,5-dihydro-3H-2,4,3λ5-benzodioxaphosphepin-3-yl)oxy]hexahydrospiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl)oxy)-3,9-dioxo-1-phenyl-2,4,8-trioxa-3λ5-phosphahexadecan-6-yl hexadecanoate (+)-S19 ¹³C NMR




(+)-(6R)-3-((3aR,4S,5R,6S,7R,7aR)-5,7-bis(benzyloxy)-6-[(3-oxo-1,5-dihydro-3H-2,4,3λ5-benzodioxaphosphepin-3-yl)oxy]hexahydrospiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl)oxy)-3,9-dioxo-1-phenyl-2,4,8-trioxa-3λ5-phosphahexadecan-6-yl hexadecanoate (+)-S19 HPLC 254 nm



Time	Height	Area	Area %
4.362	691.6	5,588.2	0.44
4.742	42,578.5	568,610.9	44.87
5.185	25,163.5	693,050.8	54.69
Total		1,267,249.9	100.00

(+)-(6R)-3-((3aR,4S,5R,6S,7R,7aR)-5,7-bis(benzyloxy)-6-[(3-oxo-1,5-dihydro-3H-2,4,3λ5-benzodioxaphosphepin-3-yl)oxy]hexahydrospiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl)oxy)-3,9-dioxo-1-phenyl-2,4,8-trioxa-3λ5-phosphahexadecan-6-yl hexadecanoate (+)-S19 HPLC 220 nm





Time	Height	Area	Area %
4.347	7,433.2	57,182.2	0.44
4.748	344,882.0	5,605,897.8	43.22
5.268	215,370.0	7,308,067.4	56.34
Total		12,971,147.4	100.00

(+)-(6R)-3-((3aR,4S,5R,6S,7R,7aR)-5,7-bis(benzyloxy)-6-[(3-oxo-1,5-dihydro-3H-2,4,3λ5-benzodioxaphosphepin-3-yl)oxy]hexahydrospiro[1,3-benzodioxole-2,1'-cyclopentan]-4-yl)oxy)-3,9-dioxo-1-phenyl-2,4,8-trioxa-3λ5-phosphahexadecan-6-yl hexadecanoate (+)-S19 HRMS

Z:\data\2021\051 May\ESI87799.raw

05/05/2021 11:39 am





Peak Mass Display...	Combin...	RDB	Delta (p...	Theo. m...	Rank	Combin...	# Match...	# Misse...	MS Cov...	Pattern...	MSMS...	
1239.5	C...	67.931	21.50	-2.46	1239.5	1	94.892	6	0	96.390	100	ICollor

(+)-(2R)-3-[(hydroxy[[[(1R,2R,3R,4R,5S,6R)-2,3,4,6-tetrahydroxy-5-(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy]-2-(octanoyloxy)propyl hexadecanoate (+)-7 ¹H NMR

Current Data Parameters
 NAME gb624001006 (C16-C8 PI5P)
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20210610
 Time 9.23 h
 INSTRUM Avance
 PROBHD Z159656_0020 (PULPROG zg30)
 TD 65536
 SOLVENT MeOD
 NS 16
 DS 2
 SWH 11904.762 Hz
 FIDRES 0.363304 Hz
 AQ 2.7525120 sec
 RG 89.2706
 DW 42.000 usec
 DE 22.00 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 600.4230021 MHz
 NUC1 1H
 P0 4.00 usec
 P1 12.00 usec
 PLW1 13.51200008 W

F2 - Processing parameters
 SI 65536
 SF 600.4200117 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00




(+)-(2R)-3-[(hydroxy[[[(1R,2R,3R,4R,5S,6R)-2,3,4,6-tetrahydroxy-5-(phosphonoxy)cyclohexyl]oxy}phosphoryl]oxy]-2-(octanoyloxy)propyl hexadecanoate (+)-7 ³¹P NMR

Current Data Parameters
 NAME g9624001006 (C16-C8 P1SP)
 EKFN0 2
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20210610
 Time 9.25 h
 INSTRUM Avance
 PROBHD Z199656_002D ((
 PULPROG zgpg30
 TD 65536
 SOLVENT MeOD
 NS 16
 DS 4
 SWH 48543.688 Hz
 FIDRES 1.481436 Hz
 AQ 0.6750208 sec
 RG 101
 DW 10.300 usec
 DE 18.00 usec
 TE 298.0 K
 D1 2.0000000 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 243.0423184 MHz
 NUC1 ³¹P
 PD 4.00 usec
 P1 12.00 usec
 PL1 39.40800000 W
 SFO2 600.4224017 MHz
 NUC2 ¹H
 CDEPRG(2) malt16
 PCPD2 80.00 usec
 PLM2 13.51200008 W
 PLM12 0.20124050 W
 PLM13 0.13098180 W

F2 - Processing parameters
 SI 22768
 SF 243.0544711 MHz
 MEW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40




(+)-(2R)-3-[(hydroxy[[[(1R,2R,3R,4R,5S,6R)-2,3,4,6-tetrahydroxy-5-(phosphonoxy)cyclohexyl]oxy}phosphoryl]oxy]-2-(octanoyloxy)propyl hexadecanoate (+)-7 ¹³C NMR

```

Current Data Parameters
NAME      gbc2400106 (c16-C8 P15P)
EXPNO    4
PROCNO   1

F2 - Acquisition Parameters
Date_    20210610
Time     12.48 h
INSTRUM  Avance
PROBHD   ZL59656_0020 (
PULPROG  zgpg30
TD       65536
SOLVENT  MeOD
NS       3072
DS       4
SWH      35714.285 Hz
FIDRES   1.089913 Hz
AQ       0.9175040 sec
RG       101
DM       14.000 usec
DE       18.00 usec
TE       298.0 K
D1       2.0000000 sec
D11      0.0300000 sec
TD0      1
SFO1     150.9908267 MHz
NUC1     13C
PD       3.33 usec
P1       10.00 usec
PLM1     41.91400146 W
SFO2     600.4224017 MHz
NUC2     1H
CPCPRG2  waltz16
PCPD2    80.00 usec
PLW2     13.51200008 W
PLW12    0.30124050 W
PLW13    0.15058180 W

F2 - Processing parameters
SI       32768
SF       150.9756068 MHz
WDW      EM
SSB      0
LB       2.00 Hz
GB       0
PC       1.40
    
```



(+)-(2R)-3-[(hydroxy[[[(1R,2R,3R,4R,5S,6R)-2,3,4,6-tetrahydroxy-5-(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy]-2-(octanoyloxy)propyl hexadecanoate (+)-7 ¹H to ¹³C HSQC NMR

Current Data Parameters
 NAME gb624001006 (C16-C8 PISP)
 EXPNO 9
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20210810
 Time_ 13:29 h
 INSTRUM Avance
 PROBHD Z150000000 (C16-C8 PISP)
 PULPROG hsqc2d16
 TD 2048
 SOLVENT MeOD

NS 8
 DS 32
 SWH 7142.857 Hz
 FIDRES 0.1433600 usec
 AQ 0.1433600 usec
 RG 101
 DW 70.000 usec
 DE 22.000 usec
 TE 289.0 K
 CNST2 145.0000000
 D0 0.0000000 usec
 D1 1.0000000 usec
 D4 0.00172414 usec
 D11 0.03000000 usec
 D19 0.00010000 usec
 D21 0.00380000 usec
 INO 0.0000000 usec
 TDAV 1


ZGPGTNS
 SFO1 600.4228220 MHz
 NUC1 1H
 P1 12.00 usec
 P2 24.00 usec
 PLW1 13.51200008 W
 SFO2 150.8752071 MHz
 NUC2 13C
 CPDPRG2 garp
 P3 10.00 usec
 P14 500.00 usec
 P31 1730.00 usec
 RC PD2 55.00 usec
 PLW0 0 W
 PLW2 41.01400149 W
 PLW12 1.35538887 W
 SPNA M[3] C rp80,0.5,20.1
 SFOAL3 0.300
 SROFFS3 0 Hz
 SPW3 6.40300081 W
 SPNA M[18] C rp80,0.5,20.1
 SFOAL18 0.300
 SROFFS18 0 Hz
 SPW18 1.35538887 W
 GPNA M[1] SMSQ10,100
 GPZ1 20.10 %
 GPNA M[2] SMSQ10,100
 GPZ2 20.10 %
 P16 1000.00 usec

===== F1 INDIRECT DIMENSION =====
 td1 259
 sw_f1 164.868332



F1 - Acquisition parameters
 TD 259
 SFO1 150.8752071 MHz
 FIDRES 0.1433600 usec
 SW 165.000 ppp
 FMODE Echo-Antiecho

F2 - Processing parameters
 SI 1024
 SF 600.4200000 MHz
 WDW COSINE
 SSB 2
 LB 0 Hz
 GB 0
 RC 1.40

F1 - Processing parameters
 SI 1024
 MC2 echo-antiecho
 SF 150.8752071 MHz
 WDW COSINE
 SSB 2
 LB 0 Hz
 GB 0



(+)-(2R)-3-[(hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,4,6-tetrahydroxy-5-(phosphonoxy)cyclohexyl]oxy}phosphoryl)oxy]-2-(octanoyloxy)propyl hexadecanoate (+)-7 HRMS




Peak Mass Display...	Combin...	RDB	Delta [p...	Theo. m...	Rank	Combin...	# Match...	# Misse...	MS Cov...	Pattern...	MSMS...	
777.3592	C...H...	43.254	3.50	-0.61	777.35	1	92.963	5	0	95.724	99.793	/Collar

(2R)-1-[(hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,4,6-tetrahydroxy-5-(phosphonoxy)cyclohexyl]oxy}phosphoryl)oxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (+)-8 ¹H NMR

Current Data Parameters
 NAME gb624011506 (C8-C16 PI5P)
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date 20210615
 Time 9.21 h
 INSTRUM Avance
 PROBHD Z159656_0020 (zq30)
 PULPROG zg30
 TD 65536
 SOLVENT MeOD
 NS 16
 DS 2
 SWH 11904.762 Hz
 FIDRES 0.363304 Hz
 AQ 2.7525120 sec
 RG 85.5505
 DW 42.000 usec
 DE 22.00 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 600.4230021 MHz
 NUC1 ¹H
 P0 4.00 usec
 P1 12.00 usec
 PLW1 13.51200008 W

F2 - Processing parameters
 SI 65536
 SF 600.4200119 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00





(2R)-1-[(hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,4,6-tetrahydroxy-5-(phosphonoxy)cyclohexyl]oxy}phosphoryl)oxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (+)-8 ³¹P NMR

Current Data Parameters
 NAME gpc24011506 (C8-C16 P15P)
 EXPNO 2
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20210615
 Time 9.45 h
 INSTRUM Avance
 PROBHD z159e56_0020 (zpgpg30)
 PULPROG zgpg30
 TD 65536
 SOLVENT MeCO
 NS 512
 DS 4
 SWE 48543.688 Hz
 FIDRES 1.481436 Hz
 AQ 0.6750208 sec
 RG 101
 DM 10.300 usec
 DE 18.00 usec
 TE 298.0 K
 D1 2.0000000 sec
 D11 0.0300000 sec
 TD0 1
 SFO1 243.0423184 MHz
 NUC1 31P
 FO 4.00 usec
 F1 12.00 usec
 PLM1 39.4080000 W
 SFO2 600.4224017 MHz
 NUC2 1H
 CFCF2P2 waltz16
 PFCF2 80.00 usec
 PLM2 13.5120000 W
 PLM12 0.30124050 W
 PLM13 0.15058180 W

F2 - Processing Parameters
 SI 32768
 SF 243.0544711 MHz
 MDW no
 SSB 0
 LB 0 Hz
 GB 0
 PC 1.40

3.72
0.07



(2R)-1-[(hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,4,6-tetrahydroxy-5-(phosphonoxy)cyclohexyl]oxy}phosphoryl)oxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (+)-8 ¹³C NMR

Current Data Parameters
 NAME gb24011506 (c8-c16 P15P)
 EXPNO 4
 PROCNO 1



F2 - Acquisition Parameters
 Date_ 20210615
 Time 13.43 h
 INSTRUM Brance
 PROBHD E159656_0020 (zpg30)
 PULPROG zgpg30
 TD 65536
 SOLVENT MeD2
 NS 4096
 DS 4
 SWH 35714.289 Hz
 FIDRES 1.089913 Hz
 AQ 0.9175040 sec
 RG 101
 DW 14.000 usec
 DE 18.00 usec
 TE 298.0 K
 D1 2.0000000 sec
 D11 0.0300000 sec
 TD0 1
 SFO1 150.9908267 MHz
 NUC1 13C
 PO 3.33 usec
 P1 10.00 usec
 PLM1 41.91400146 W
 SFO2 600.4224017 MHz
 NUC2 1H
 CDFPR2 Waltz16
 PCPD2 80.00 usec
 PLM2 13.51200008 W
 PLM12 0.30124050 W
 PLM13 0.15098180 W

F2 - Processing parameters
 SI 85536
 SF 150.9756112 MHz
 MDW EM
 SSB 0
 LB 2.00 Hz
 GB 0
 PC 1.40

175.18
174.91

76.95
72.91
72.09
71.92
71.79
71.54
64.38
63.73

34.92
34.78
32.57
32.36
30.34
30.32
30.28
30.24
30.07
29.98
29.79
29.75
29.62
25.83
25.51
23.50
23.25
14.50
14.47



(2R)-1-[(hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,4,6-tetrahydroxy-5-(phosphonoxy)cyclohexyl]oxy}phosphoryl)oxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (+)-8 ¹H to ¹³C HSQC NMR

Current Data Parameters
 NAME gb624011506 (C3-C18 PISP)
 EXPNO 9
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20210815
 Time_ 18.37 h
 INSTRUM Avance
 PROBHD Z130P30 2020 (1
 PULPROG hsqcedtq.psp.3
 TD 2048

SOLVENT MeOD
 NS 32
 DS 16
 SWH 7142.857 Hz
 FIDRES 0.875448 Hz
 AQ 0.143390 sec
 RG 101
 DW 70.000 usec
 DE 22.000 usec
 TE 289.0 K
 CNST2 145.000000
 D0 0.0000300 sec
 D1 1.0000000 sec
 D4 0.0017244 sec
 D11 0.0300000 sec
 D18 0.0001000 sec
 D21 0.0038000 sec
 INO 0.0003309 sec


TDav 1
 ZGPGTNS
 SFO1 800.4230021 MHz
 NUC1 1H
 P1 12.00 usec
 P2 24.00 usec
 PLW1 13.5120000 W
 SFO2 150.8752371 MHz
 NUC2 13C
 CPDPRG2 gamp
 P3 10.00 usec
 P14 500.00 usec
 P31 1730.00 usec
 PCPD2 55.00 usec
 PLW0 0 W
 PLW2 41.81400148 W
 PLW12 1.38550087 W
 SPNAM[3] C rp80.0.5.20.1
 SPOAL3 0.500
 SPROFFS3 0 Hz
 SPW3 8.40300051 W
 SPNAM[18] C rp80_xfhit2
 SPOAL18 0.500
 SPROFFS18 0 Hz
 SPW18 1.85000005 W
 GPNAM[1] SIMSQ10.100
 GPZ1 80.00 %
 GPNAM[2] SIMSQ10.100
 GPZ2 20.10 %
 P18 1000.00 usec

===== F1 INDIRECT DIMENSION =====
 td1 298
 sw_f1 164.86352

F1 - Acquisition parameters
 TD 298
 SFO1 150.87578 MHz
 FIDRES 184.843417 Hz
 SW 185.000 ppm
 FaMODE Echo-Antiecho

F2 - Processing parameters
 SI 2048
 SF 800.4200000 MHz
 WDW QSINE
 SSB 2
 LB 0 Hz
 GB 0
 PC 1.40

F1 - Processing parameters
 SI 1024
 MC2 echo-antiecho
 SF 150.8752371 MHz
 WDW QSINE
 SSB 2
 LB 0 Hz
 GB 0




(2R)-1-[(hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,4,6-tetrahydroxy-5-(phosphonoxy)cyclohexyl]oxy}phosphoryl)oxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (+)-8 HRMS


Z:\data\2021\051 May\ESI88421.raw

25/05/2021 3:37 pm

NL: 3.27E3
 ESI88421 #14-27 RT: 0.16-0.32 AV: 7 NL:
 2.92E5
 T: FTMS (1.2) - p ESI Full ms
 [80.00-1600.00]



NL: 6.70E5
 C33H63O16P2 Chrg -1 R: 27979 Res.
 Pwr. @FWHM





Peak Mass Display...	Combin...	RDB	Delta (p...	Theo. m...	Rank	Combin...	# Match...	# Misse...	MS Cov...	Pattern...	MSMS...
----------------------	-----------	-----	-------------	------------	------	-----------	------------	------------	-----------	------------	---------

(+)-(2R)-3-[[[(2S)-2-methoxy-2-phenylacetyl]oxy]-2-(octanoyloxy)propyl hexadecanoate (+)-S20 ¹H NMR

Current Data Parameters
NAME gb534271208 (C16, C-8 S MPA)
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20210813
Time 16.56 h
INSTRUM Avance
PROBHD Z159856 0020 (PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 11904.762 Hz
FIDRES 0.363304 Hz
AQ 2.7525120 sec
RG 52.7314
DW 42.900 usec
DE 22.00 usec
TE 298.0 K
D1 1.00000000 sec
TD0 1
SFO1 600.4230021 MHz
NUC1 1H
P0 4.00 usec
P1 12.00 usec
PLW1 13.51200008 W

F2 - Processing parameters
SI 65536
SF 600.4200136 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00






(+)-(2R)-3-[[[(2S)-2-methoxy-2-phenylacetyl]oxy]-2-(octanoyloxy)propyl hexadecanoate (+)-S20 ¹³C NMR

Current Data Parameters
 NAME gb634271208 (C16, C-8 S MPA)
 EXPNO 5
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20210813
 Time 19.04 h
 INSTRUM Avance
 PROBHD Z199656_0020 (1
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 512
 DS 4
 SWH 35714.283 Hz
 FIDRES 1.089913 Hz
 AQ 0.9175040 sec
 RG 101
 DM 14.000 usec
 DE 18.00 usec
 TE 298.0 K
 D1 2.0000000 sec
 D11 0.0300000 sec
 TD0 1
 SFO1 150.9908267 MHz
 NUC1 13C
 PO 3.33 usec
 P1 10.00 usec
 PLM1 41.91400146 M
 SFO2 600.4224017 MHz
 NUC2 1H
 CPDPRG2 waltz16
 PCPD2 80.00 usec
 PLM2 13.51200008 M
 PLM12 0.30124000 M
 PLM13 0.15098180 M

F2 - Processing parameters
 SI 65536
 SF 150.9757075 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40



173.31
 172.83
 170.34
 136.08
 129.00
 128.83
 127.31
 82.50
 68.78
 62.72
 61.93
 57.53
 34.18
 34.14
 32.07
 31.81
 29.85
 29.81
 29.77
 29.62
 29.51
 29.41
 29.25
 29.15
 29.05
 24.97
 24.89
 22.84
 22.76
 14.26
 14.20



(+)-(2R)-3-[[[(2S)-2-methoxy-2-phenylacetyl]oxy]-2-(octanoyloxy)propyl hexadecanoate (+)-S20
HRMS

Z:\data\2021\05 May\ESI88527.raw

01/06/2021 12:19 pm





Peak Mass Display...	Combin...	RDB	Delta [p...	Theo. m...	Rank	Combin...	# Match...	# Misse...	MS Cov...	Pattern...	MSMS...	
627.4227	C...H...	73.449	6.50	-0.63	627.42	1	98.551	5	0	99.945	100	1/0/0/0

(-)-(2R)-3-[[(2R)-2-methoxy-2-phenylacetyl]oxy]-2-(octanoyloxy)propyl hexadecanoate (-)-S21 ¹H NMR

Current Data Parameters
NAME gb64281208 (C16, C8 R MPA)
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20210813
Time 18.12 h
INSTRUM Avance
PROBHD Z159856_0020 (PULPROG zg30)
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 11904.762 Hz
FIDRES 0.365304 Hz
AQ 2.7525120 sec
RG 58.3812
DW 42.000 usec
DE 22.00 usec
TE 298.0 K
D1 1.00000000 sec
TDO 1
SFO1 600.4230021 MHz
NUC1 1H
P0 4.00 usec
P1 12.00 usec
PLW1 13.51200008 W

F2 - Processing parameters
SI 65536
SF 600.4200138 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00




(-)-(2R)-3-[[(2R)-2-methoxy-2-phenylacetyl]oxy]-2-(octanoyloxy)propyl hexadecanoate (-)-S21 ¹³C NMR


Current Data Parameters
 NAME gb634281208 (C16, C8 R MPA)
 EXPNO 5
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20210813
 Time 18:59 h
 INSTRUM Avance
 PROBHD z139636_002D (zpg30)
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 512
 DS 4
 SWH 35714.285 Hz
 FIDRES 1.089913 Hz
 AQ 0.9175040 sec
 RG 101
 DM 14.000 usec
 DE 18.00 usec
 TE 298.0 K
 D1 2.0000000 sec
 D11 0.0300000 sec
 ZD 1
 SFO1 150.9808267 MHz
 NUC1 13C
 PC 3.33 usec
 P1 10.00 usec
 PLM1 41.91400146 M
 SFO2 600.4224017 MHz
 NUC2 1H
 CDEPRG[2] waltz16
 PCPD2 80.00 usec
 PLM2 13.51200008 M
 PLM12 0.30124050 M
 PLM13 0.1508180 M

F2 - Processing parameters
 SI 65536
 SF 150.9757081 MHz
 WMW EM
 GSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40



(-)-(2R)-3-[[2-(2-methoxy-2-phenylacetyl)oxy]-2-(octanoyloxy)propyl hexadecanoate (-)-S21
HRMS





(+)-(2R)-1-[[[(2S)-2-methoxy-2-phenylacetyl]oxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (+)-S22 ¹H NMR

Current Data Parameters
 NAME gb634291208 (C8, C16 S MPA)
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20210813
 Time 19:07 h
 INSTRUM Avance
 PROBHD Z158656.0020 ()
 PULPROG zg30
 TD 65536
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 11904.762 Hz
 FIDRES 0.363304 Hz
 AQ 2.7525120 sec
 RG 74.5948
 DW 42.000 usec
 DE 22.00 usec
 TE 298.0 K
 D1 1.00000000 sec
 TD0 1
 SFO1 600.4230021 MHz
 NUC1 1H
 P0 4.00 usec
 P1 12.00 usec
 PLW1 13.51200008 W

F2 - Processing parameters
 SI 65536
 SF 600.4200145 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00






(+)-(2R)-1-[[2(S)-2-methoxy-2-phenylacetyl]oxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (+)-S22 ¹³C NMR


Current Data Parameters
 NAME g634291208 (3, C16 S MPA)
 EXPNO 5
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20210813
 Time 19.55 h
 INSTRUM Avance
 PROBHD z159656_0020 ((
 PULPROG zgpg30
 TD 65336
 SOLVENT CDCl3
 NS 512
 DS 4
 SWE 35714.285 Hz
 FIDRES 1.089913 Hz
 AQ 0.9175040 sec
 RG 101
 DM 14.000 usec
 DE 18.00 usec
 TE 298.0 K
 D1 2.00000000 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 150.9908267 MHz
 NUC1 13C
 FO 3.33 usec
 FI 10.00 usec
 FLM1 41.91400146 W
 SFO2 600.4224017 MHz
 NUC2 1H
 CPDPRG2 waltz16
 PCPD2 80.00 usec
 PLM2 13.51200008 W
 PLM12 0.30124050 W
 PLM13 0.15098180 W

173.40
 172.94
 170.43
 136.18
 129.10
 128.92
 127.40
 82.60
 68.87
 62.82
 62.02
 57.62
 34.28
 34.23
 32.16
 31.89
 29.94
 29.91
 29.90
 29.88
 29.73
 29.60
 29.51
 29.31
 29.28
 29.14
 25.06
 24.99
 22.93
 22.83
 14.35
 14.29



(+)-(2R)-1-[[[(2S)-2-methoxy-2-phenylacetyl]oxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (+)-S22 HRMS





(-)-(2R)-1-[[[(2R)-2-methoxy-2-phenylacetyl]oxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (-)-S23 ¹H NMR

Current Data Parameters
NAME gb54301208 (C8, C16 R MPA)
EXPNO 6
PROCNO 1

F2 - Acquisition Parameters
Date_ 20210817
Time 13.10 h
INSTRUM Avance
PROBHD Z159856_0020 (PULPROG zg30)
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 11904.762 Hz
FIDRES 0.365304 Hz
AQ 2.7525120 sec
RG 77.9052
DW 42.000 usec
DE 22.00 usec
TE 298.0 K
D1 1.00000000 sec
TD0 1
SFO1 600.4230021 MHz
NUC1 1H
P0 4.00 usec
P1 12.00 usec
PLW1 13.51200008 W

F2 - Processing parameters
SI 65536
SF 600.420145 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00




(-)-(2R)-1-[[[(2R)-2-methoxy-2-phenylacetyl]oxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (-)-S23 ¹³C NMR



Current Data Parameters
 NAME gb634301208 (C8, C16 R MPA)
 EXPNO 5
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20210813
 Time 20:30 h
 INSTRUM Avance
 PROBHD z159656_002D (4
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 512
 DS 4
 SWH 35714.285 Hz
 FIDRES 1.089913 Hz
 AQ 0.9175040 sec
 RG 191
 DM 14.000 usec
 DE 18.000 usec
 TE 298.0 K
 D1 2.00000000 sec
 D11 0.03000000 sec
 TD0 1
 SFO1 150.998267 MHz
 NUC1 13C
 PO 3.33 usec
 P1 10.00 usec
 PLM1 41.91400146 M
 SFO2 600.4224017 MHz
 NUC2 1H
 CPDPRG2 waltz16
 PCPD2 80.00 usec
 PLM2 13.51200008 M
 PLM12 0.30124050 M
 PLM13 0.15098180 M

F2 - Processing parameters
 SI 65536
 SF 150.9757084 MHz
 MHZ EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40



(-)-(2R)-1-[[[(2R)-2-methoxy-2-phenylacetyl]oxy]-3-(octanoyloxy)propan-2-yl hexadecanoate (-)-S23 HRMS





Peak Mass Display...	Combin...	RDB	Delta [p...	Theo. m...	Rank	Combin...	# Match...	# Misse...	MS Cov...	Pattern...	MSMS...	
627.4228	C...H...	42.899	6.50	-0.53	627.42	1	97.047	4	1	100	99.877	1/Cellar

(+)-(S)-3-(bis(4-methoxyphenyl)(phenyl)methoxy)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)propyl palmitate S24 ¹H NMR

Current Data Parameters
 NAME gb645232311
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20211123
 Time 9.59 h
 INSTRUM Avance
 PROBHD Z159656_0020 (zg30)
 PULPROG zg30
 TD 65536
 SOLVENT CDCl3
 NS 16
 DS 2
 SWH 11904.762 Hz
 FIDRES 0.363304 Hz
 AQ 2.7525120 sec
 RG 44.1803
 DW 42.000 usec
 DE 22.00 usec
 TE 298.0 K
 D1 1.0000000 sec
 TD0 1
 SFO1 600.4230021 MHz
 NUC1 ¹H
 PO 4.00 usec
 P1 12.00 usec
 PLW1 13.5120008 W

F2 - Processing parameters
 SI 65536
 SF 600.4200154 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00




(+)-(S)-3-(bis(4-methoxyphenyl)(phenyl)methoxy)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)propyl palmitate S24 ¹³C NMR

```

Current Data Parameters
NAME      gb645232311
EXPNO    5
PROCNO   1

F2 - Acquisition Parameters
Date_    20211123
Time     11:07 h
INSTRUM  Avance
PROBHD   Z199656_0020 (
PULPROG  zgpg30
TD       65536
SOLVENT  CDCl3
NS       512
DS       4
SWH      35714.283 Hz
FIDRES   1.089913 Hz
AQ       0.9175040 sec
RG       101
DM       14.000 usec
DE       18.00 usec
TE       298.0 K
D1       2.0000000 sec
D11      0.0300000 sec
EDU      1
SFO1     150.9908267 MHz
NUC1     13C
PC       3.33 usec
P1       10.00 usec
PLM1     41.91400146 M
SFO2     600.4224017 MHz
NUC2     1H
CPDPRG2  waltz16
PCPD2    80.00 usec
PLM2     13.51200008 M
PLM12    0.30124000 M
PLM13    0.15098180 M


F2 - Processing parameters
SI       65536
SF       150.9757097 MHz
WDW      EM
SSB      0
LB       1.00 Hz
GB       0
PC       1.40
    
```




(+)-(S)-3-(bis(4-methoxyphenyl)(phenyl)methoxy)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)propyl palmitate S24 HRMS

Z:\data\2021\10\ Oct\ESI90914.raw

14/10/2021 1:48 pm



NL: 1.53E6
ESI90914 #11 RT: 0.12 AV: 1 NL:
3.76E+007
T: FTMS (1,1) + p ESI Full lock ms
[80.00-1600.00]



NL: 5.29E5
C56H80O7N2Na1 Chrg 1 R: 27100 Res.
Pwr. @FWHM



Peak Mass Display...	Combin...	RDB	Delta [p...	Theo. m...	Rank	Combin...	# Match...	# Misse...	MS Cov...	Pattern...	MSMS...
915.5853	...	17.50	0.09	915.58	1	97.510	4	1	100	99.580	1/1000

(R)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-((S)-2-methoxy-2-phenylacetoxy)propyl palmitate (+)-S25 ¹H NMR

Current Data Parameters
NAME gb716170509 (R, R)
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date 20230905
Time 5.43 h
INSTRUM av600
PROBHD Z130037_0008 (zg30)
PULPROG 65536
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 12019.230 Hz
FIDRES 0.366798 Hz
AQ 2.7262976 sec
RG 50.94
DW 41.600 usec
DE 10.00 usec
TE 298.0 K
D1 1.0000000 sec
TD0 1
SFO1 600.1830009 MHz
NUC1 ¹H
PO 4.00 usec
P1 12.00 usec
PLW1 26.5459953 W

F2 - Processing parameters
SI 65536
SF 600.1800146 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00




(R)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-((S)-2-methoxy-2-phenylacetoxy)propyl palmitate (+)-S25 ¹³C NMR

```

Current Data Parameters
NAME      qb716170509 (R, R)
EXPNO     5
PROCNO    1


F2 - Acquisition Parameters
Date_     20230905
Time      7.22 h
INSTRUM   av600
PROBHD    Z130037_0008 (
PULPROG   zgpg30
TD        65536
SOLVENT   CDCl3
NS        1024
DS        4
SWH       36057.691 Hz
FIDRES    1.100393 Hz
AQ        0.9087659 sec
RG        197.67
DM        13.867 usec
DE        18.00 usec
TE        298.0 K
D1        2.0000000 sec
D11       0.0300000 sec
TD0       1
SFO1      150.9304719 MHz
NUC1      13C
PO        3.33 usec
P1        10.00 usec
PLM1      64.0000000 M
SFO2      600.1824007 MHz
NUC2      1H
CFDPRG[2] waltz16
PCPD2     70.00 usec
PLM2      26.5459953 M
PLM12     0.79013003 M
PLM13     0.39240000 M

F2 - Processing parameters
SI        32768
SF        150.9153606 MHz
WDW       EM
SSB       0
LB        1.00 Hz
GB        0
PC        1.40
    
```




(R)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-((S)-2-methoxy-2-phenylacetoxy)propyl palmitate (+)-S25 HRMS

Expanded Spectrum RT 0.09, NL 1248267, Peak [1], Target Mass 761.5075



Theoretical Spectrum for C₄₄H₇₀N₂O₇Na, Minimum Abundance 0.01%





Measured Mass	Calculated Mass	Error (mDa)	Error (ppm)	Formula [M+Na] ⁺	Response
761.5094	761.5075	1.87	2.46	C ₄₄ H ₇₀ N ₂ O ₇ Na	348746

(R)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-((R)-2-methoxy-2-phenylacetoxy)propyl palmitate (-)-S26 ¹H NMR

Current Data Parameters
NAME gb716180509 (R, S)
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20230905
Time 7.29 h
INSTRUM av600
PROBHD Z130037_0008 (PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 12019.230 Hz
FIDRES 0.366798 Hz
AQ 2.7262976 sec
RG 60.94
DW 41.600 usec
DE 10.00 usec
TE 298.0 K
D1 1.00000000 sec
TD0 1
SFO1 600.1830009 MHz
NUC1 1H
PO 4.00 usec
P1 12.00 usec
PLW1 26.54589953 W

F2 - Processing parameters
SI 65536
SF 600.1800147 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00



(R)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-((R)-2-methoxy-2-phenylacetoxy)propyl palmitate (-)-S26 ¹³C NMR

```

Current Data Parameters
NAME      gb716180509 (R, S)
EXPNO     5
PROCNO    1

F2 - Acquisition Parameters
Date_     20230905
Time      20:25 h
INSTRUM   av600
PROBHD    E130037_0008 (
PULPROG   zgpg30
TD         65536
SOLVENT   CDCl3
NS         1024
DS         4
SWH        36057.691 Hz
FIDRES     1.100393 Hz
AQ         0.9087659 sec
RG         197.67
DM         13.867 usec
DE         18.00 usec
TE         298.0 K
D1         2.0000000 sec
D11        0.0300000 sec
TD0        1
SFO1       150.9304719 MHz
NUC1       13C
PC         3.33 usec
P1         10.00 usec
PLM1       64.0000000 W
SFO2       600.1824007 MHz
NUC2       1H
CPDPRG2    waltz16
PCPD2      70.00 usec
PLM2       26.5459953 W
PLM12      0.78013003 W
PLM13      0.39240000 W




F2 - Processing parameters
SI         32768
SF         150.9153610 MHz
WDW        EM
SSB        0
LB         1.00 Hz
GB         0
PC         1.40
    
```

173.32
171.36
170.33

136.05
129.06
128.85
127.30


84.92
82.44

69.32
68.119
62.54
61.74
57.52
34.10
32.81
32.07
29.84
29.80
29.76
29.62
29.55
29.51
29.40
29.31
29.24
29.20
28.87
28.62
28.49
28.18
28.13
24.95
23.94
22.83
18.53
14.27




(R)-2-((3-(3-(dodec-11-yn-1-yl)-3H-diazirin-3-yl)propanoyl)oxy)-3-((R)-2-methoxy-2-phenylacetoxy)propyl palmitate (-)-S26 HRMS

Expanded Spectrum RT 0.09, NL 1347099, Peak [1], Target Mass 761.5075



Theoretical Spectrum for C₄₄H₇₀N₂O₇Na, Minimum Abundance 0.01%



Measured Mass	Calculated Mass	Error (mDa)	Error (ppm)	Formula [M+Na] ⁺	Response
761.5106	761.5075	3.07	4.03	C ₄₄ H ₇₀ N ₂ O ₇ Na	375493

References

- (1) Seco, J. M.; Quiñoá, E.; Riguera, R. The Assignment of Absolute Configuration by NMR. *Chem. Rev.* **2004**, *104* (1), 17–118. <https://doi.org/10.1021/cr000665j>.
- (2) Mandal, P.; Eswara, K.; Yerkesh, Z.; Kharchenko, V.; Zandarashvili, L.; Szczepski, K.; Bensaddek, D.; Jaremko, Ł.; Black, B. E.; Fischle, W. Molecular Basis of hUHRF1 Allosteric Activation for Synergistic Histone Modification Binding by PI5P. *Sci. Adv.* **2022**, *8* (34), eabl9461. <https://doi.org/10.1126/sciadv.abl9461>.
- (3) MacKinnon, A. L.; Taunton, J. Target Identification by Diazirine Photo-Cross-Linking and Click Chemistry. *Curr. Protoc. Chem. Biol.* **2009**, *1* (1), 55–73. <https://doi.org/10.1002/9780470559277.ch090167>.
- (4) Fulmer, G. R.; Miller, A. J. M.; Sherden, N. H.; Gottlieb, H. E.; Nudelman, A.; Stoltz, B. M.; Bercaw, J. E.; Goldberg, K. I. NMR Chemical Shifts of Trace Impurities: Common Laboratory Solvents, Organics, and Gases in Deuterated Solvents Relevant to the Organometallic Chemist. *Organometallics* **2010**, *29* (9), 2176–2179. <https://doi.org/10.1021/om100106e>.
- (5) M. Joffrin, A.; M. Saunders, A.; Barneda, D.; Flemington, V.; L. Thompson, A.; J. Sanganee, H.; J. Conway, S. Development of Isotope-Enriched Phosphatidylinositol-4- and 5-Phosphate Cellular Mass Spectrometry Probes. *Chem. Sci.* **2021**. <https://doi.org/10.1039/D0SC06219G>.
- (6) Descôteaux, C.; Leblanc, V.; Bélanger, G.; Parent, S.; Asselin, É.; Bérubé, G. Improved Synthesis of Unique Estradiol-Linked Platinum(II) Complexes Showing Potent Cytocidal Activity and Affinity for the Estrogen Receptor Alpha and Beta. *Steroids* **2008**, *73* (11), 1077–1089. <https://doi.org/10.1016/j.steroids.2008.04.009>.
- (7) Schill, G.; Schweickert, N.; Fritz, H.; Vetter, W. Synthese von [2]-Catenanen aus [2]-Rotaxanen. *Chem. Ber.* **1988**, *121* (5), 961–970. <https://doi.org/10.1002/cber.19881210522>.
- (8) Oppolzer, W.; Radinov, R. N.; El-Sayed, E. Catalytic Asymmetric Synthesis of Macrocyclic (E)-Allylic Alcohols from ω -Alkynals via Intramolecular 1-Alkenylzinc/Aldehyde Additions. *J. Org. Chem.* **2001**, *66* (14), 4766–4770. <https://doi.org/10.1021/jo000463n>.
- (9) Mori, K. Pheromone Synthesis. Part 253: Synthesis of the Racemates and Enantiomers of Triglycerides of Male *Drosophila* Fruit Flies with Special Emphasis on the Preparation of Enantiomerically Pure 1-Monoglycerides. *Tetrahedron* **2012**, *68* (40), 8441–8449. <https://doi.org/10.1016/j.tet.2012.07.086>.
- (10) Nadler, A.; Reither, G.; Feng, S.; Stein, F.; Reither, S.; Müller, R.; Schultz, C. The Fatty Acid Composition of Diacylglycerols Determines Local Signaling Patterns. *Angew. Chem. Int. Ed.* **2013**, *52* (24), 6330–6334. <https://doi.org/10.1002/anie.201301716>.
- (11) Forget, S. M.; Jee, A.; Smithen, D. A.; Jagdhane, R.; Anjum, S.; Beaton, S. A.; Palmer, D. R. J.; Syvitski, R. T.; Jakeman, D. L. Kinetic Evaluation of Glucose 1-Phosphate Analogues with a Thymidyltransferase Using a Continuous Coupled Enzyme Assay. *Org. Biomol. Chem.* **2014**, *13* (3), 866–875. <https://doi.org/10.1039/C4OB02057J>.
- (12) Laumen, K.; Ghisalba, O. Preparative-Scale Chemo-Enzymatic Synthesis of Optically Pure d-Myo-Inositol-1-Phosphate. *Biosci. Biotechnol. Biochem.* **1994**, *58* (11), 2046–2049. <https://doi.org/10.1271/bbb.58.2046>.